

Books, Book Chapters

1. Byrne RA, Kastrati A. Drug-Eluting Stent: Weighing costs and benefits. In: De Luca G, Lansky Coughlan JJ, Byrne RA, Alfonso F, Kastrati A. Treatment of In-Stent Restenosis. In Bhatt DL, ed. Cardiovascular Intervention: A Companion to Braunwald's Heart Disease: 2 ed. Philadelphia: Saunders Elsevier, 2023.
https://books.google.de/books?id=YW66zwEACAAJ&hl=de&source=gbs_book_other_versions
2. Ndrepepa G, Byrne RA, Kastrati A. Percutaneous coronary interventions in acute ST-segment elevation myocardial infarction. In: Topol EJ, Teirstein PS, ed. Textbook of interventional cardiology. 8 ed. Philadelphia: Saunders Elsevier, 2020:338-383.
https://books.google.de/books?id=8JKqDwAAQBAJ&printsec=frontcover&hl=de&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false
3. Schüpke S, Massberg M, Kastrati A. The role of bivalirudin in percutaneous coronary interventions. In: Redwood S, Curzen N, Banning A, eds. 2 ed. Oxford Textbook of Interventional Cardiology. Oxford University Press, 2018:401-416.
https://www.google.de/books/edition/Oxford_Textbook_of_Interventional_Cardio/XkY36mo8XcQC?hl=de&gbpv=1&dq=Oxford+Textbook+of+Interventional+Cardiology.+Oxford+University+Press&printsec=frontcover
4. Byrne RA, Joner M, Alfonso F, Kastrati A. Treatment of In-Stent Restenosis. In Bhatt DL, ed. Cardiovascular Intervention: A Companion to Braunwald's Heart Disease: Philadelphia: Saunders Elsevier, 2016: 209-222.
<https://books.google.de/books?id=XGKGBwAAQBAJ&printsec=frontcover&hl=de#v=onepage&q&f=false>
5. Ndrepepa G, Byrne RA, Schömig A, Kastrati A. Percutaneous coronary interventions in acute ST-segment elevation myocardial infarction. In: Topol EJ, Teirstein PS, ed. Textbook of interventional cardiology. 7 ed. Philadelphia: Saunders Elsevier, 2015:329-367.
https://www.google.de/books/edition/Textbook_of_Interventional_Cardiology_E/d2tqCgAAQBAJ?hl=de&gbpv=1&dq=Textbook+of+Interventional+Cardiology&printsec=frontcover
6. Garg P, Kastrati A, Mauri L. Clinical Trial Design in Interventional Cardiology. In: Eeckhout E, Serruys PW, Wijns W, Vahanian A, van Sambeek M, eds. Percutaneous interventional cardiovascular medicine. The PCR-EAPCI textbook. Europa Edition; 2012 (V4): 53-71.
<https://textbooks.pconline.com/the-pcr-eapci-textbook>
7. Schömig A, Ndrepepa G, Byrne RA, Kastrati A. Percutaneous coronary interventions in acute ST-segment elevation myocardial infarction. In: Topol EJ, Teirstein PS, ed. Textbook of interventional cardiology. 6 ed. Philadelphia: Saunders Elsevier, 2012:237-262.
https://books.google.de/books?id=2QNpS8kliMAC&printsec=frontcover&hl=de&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false

8. A, eds. Mechanical Reperfusion for STEMI: From Randomized Trials to Clinical Practice. Informa healthcare, 2010:114-122. <https://doi.org/10.3109/9781841847467>
9. Byrne RA, Kastrati A. Primary Percutaneous Coronary Intervention: Role of Stenting versus Balloon Angioplasty and Drug-Eluting Stents versus Bare Metal Stents. Trial Evidence and Current Concepts. In: Brecker S, Rothman M, eds. Clinical Guide to Primary Angioplasty. Informa healthcare, 2010:65-77. <https://doi.org/10.3109/9781841847351>
10. Byrne RA, Joner M, Massberg S, Kastrati A. Restenosis in bare metal and drug-eluting stents. In: Escaned J, Serruys PW, eds. Coronary artery stenosis. Imaging, structure and physiology. Europa Edition, 2010:475-496. https://books.google.de/books/about/Coronary_Stenosis_Imaging_Structure_and.html?id=5BmxZwEACAAJ&redir_esc=y
11. Massberg M, Mehilli J, Kastrati A. The role of bivalirudin in percutaneous coronary interventions. In: Redwood S, Curzen N, Thomas MR, eds. Oxford Textbook of Interventional Cardiology. Oxford University Press, 2010:439-454. https://www.google.de/books/edition/Oxford_Textbook_of_Interventional_Cardio/XkY36mo8XcQC?hl=de&gbpv=1&dq=Oxford+Textbook+of+Interventional+Cardiology.+Oxford+University+Press&printsec=frontcover
12. von Beckerath N, Kastrati A. Timing, closing and length of clopidogrel therapy. In: Angiolillo D, Kastrati A, Simon D, eds. Clinical guide to the use of antithrombotic drugs in coronary artery disease: Informa healthcare, 2008:53-60. <https://doi.org/10.3109/9780203091494>
13. Angiolillo D, Kastrati A, Simon D, eds. Clinical guide to the use of antithrombotic drugs in coronary artery disease. Informa healthcare, 2008 (424 pp). <https://doi.org/10.3109/9780203091494>
14. Schömig A, Ndrepepa G, Kastrati A. Percutaneous coronary interventions in acute ST-segment elevation myocardial infarction. In: Topol EJ, ed. Textbook of interventional cardiology. 5 ed. Philadelphia: Saunders Elsevier, 2008:321-347. https://books.google.de/books/about/Textbook_of_Interventional_Cardiology_E.html?id=2QNpS8kliMAC&redir_esc=y
15. Zohlnhöfer D, Kastrati A. Molekulargenetische Aspekte in der Kardiologie. In: Roskamm H, Neumann FJ, Kalusche D, Besthorn HP, eds. Herzkrankheiten. 5 ed. Berlin Heidelberg New York: Springer-Verlag, 2004:11-22. https://books.google.co.ls/books?id=NDUeBgAAQBAJ&printsec=frontcover&source=gbs_atb&hl=de&pli=1#v=onepage&q&f=false

Abstracts

1. Voll F, Koch T, Tolg R, Lenz T, Schroeter M, Lenders G, Hokken R, Cassese S, Xhepa E, Schunkert H, **Kastrati A**, Kufner S. Clinical Safety and Efficacy of New-Generation Single-Layer Polytetrafluorethylene Covered Coronary Stents. *Cardiovasc Revasc Med* 2023;**52**:30-36, 10.1016/j.carrev.2023.02.013
2. Voll F, Koch T, Lenz T, Cassese S, Xhepa E, Joner M, **Kastrati A**, Kufner S, Investigators R. Coronary artery perforation located in a coronary artery bypass graft treated with new-generation single-layer polytetrafluorethylene-covered stent: results from a multicenter Registry. *Coron Artery Dis* 2023;**34**(2):160-162, 10.1097/MCA.0000000000001210
3. Versaci F, Kufner S, Cassese S, Joner M, Mayer K, Xhepa E, Koch T, Wiebe J, Ibrahim T, Laugwitz KL, Schunkert H, **Kastrati A**, Byrne RA, Spagnoli A, Bernardi M, Spadafora L, Biondi-Zoccai G, Investigators I-T-. Very long-term outlook of acute coronary syndromes after percutaneous coronary intervention with implantation of polymer-free versus durable-polymer new-generation drug-eluting stents. *Minerva Med* 2023;**114**(5):590-600, 10.23736/S0026-4806.23.08684-6
4. Trenkwalder T, Lachmann M, Stolz L, Fortmeier V, Covarrubias HAA, Rippen E, Schurmann F, Presch A, von Scheidt M, Ruff C, Hesse A, Gercek M, Mayr NP, Ott I, Schuster T, Harmsen G, Yuasa S, Kufner S, Hoppmann P, Kupatt C, Schunkert H, **Kastrati A**, Laugwitz KL, Rudolph V, Joner M, Hausleiter J, Xhepa E. Machine learning identifies pathophysiologically and prognostically informative phenotypes among patients with mitral regurgitation undergoing transcatheter edge-to-edge repair. *Eur Heart J Cardiovasc Imaging* 2023;**24**(5):574-587, 10.1093/ehjci/jead013
5. Syryca F, Pellegrini C, Gollreiter M, Nicol P, Mayr NP, Alvarez-Covarrubias HA, Altaner N, Rheude T, Holdenrieder S, Schunkert H, **Kastrati A**, Joner M, Xhepa E, Trenkwalder T. Incidence of systemic inflammatory response syndrome and patient outcome following transcatheter edge-to-edge mitral valve repair. *Clin Res Cardiol* 2023, 10.1007/s00392-023-02316-y
6. Stahli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, Kesterke R, Nordbeck P, Witzenbichler B, Lang IM, Kessler M, Valina C, Dibra A, Rohla M, Moccetti M, Vercellino M, Gaede L, Bott-Flugel L, Jakob P, Stehli J, Candreva A, Templin C, Schindler M, Wischnewsky M, Zanda G, Quadri G, Mangner N, Toma A, Magnani G, Clemmensen P, Luscher TF, Munzel T, Schulze PC, Laugwitz KL, Rottbauer W, Huber K, Neumann FJ, Schneider S, Weidinger F, Achenbach S, Richardt G, **Kastrati A**, Ford I, Maier W, Ruschitzka F, Investigators MA. Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction. *N Engl J Med* 2023;**389**(15):1368-1379, 10.1056/NEJMoa2307823
7. Spirito A, Valgimigli M, Cao D, Baber U, Mehta SR, Gibson CM, Steg GP, Sharma SK, Goel R, Huber K, Kunadian V, Escaned J, Franzone A, Yaling H, Collier T, Kaul U, Kornowski R, Krucoff M, Moliterno D, Sartori S, Owen R, Zhang Z, Dangas GD, **Kastrati A**, Angiolillo DJ, Cohen DJ, Vranckx P, Windecker S, Pocock S, Mehran R. Biolimus-eluting vs. other limus-eluting stents in NSTEMI-ACS: A pooled analysis of GLASSY and TWILIGHT. *Int J Cardiol* 2023;**383**:24-32, 10.1016/j.ijcard.2023.04.027
8. Spirito A, **Kastrati A**, Cao D, Baber U, Sartori S, Angiolillo DJ, Briguori C, Cohen DJ, Dangas G, Dudek D, Escaned J, Gibson CM, Zhang Z, Huber K, Kaul U, Kornowski R, Kunadian V, Han YL, Mehta SR, Sardella G, Sharma S, Shlofmitz RA, Vogel B, Collier T, Pocock S, Mehran R. Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial. *Eur Heart J Cardiovasc Pharmacother* 2023;**9**(4):328-336, 10.1093/ehjcvp/pvad006
9. Spirito A, Itchhaporia D, Sartori S, Camenzind E, Chieffo A, Dangas GD, Galatius S, Jeger RV, Kandzari DE, **Kastrati A**, Kim HS, Kimura T, Leon MB, Mehta LS, Mikhail GW, Morice MC, Nicolas J, Pileggi B, Serruys PW, Smits PC, Steg PG, Stone GW, Valgimigli M, Vogel

- B, von Birgelen C, Weisz G, Wijns W, Windecker S, Mehran R. Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI. *EuroIntervention* 2023;**19**(6):493-501, 10.4244/EIJ-D-23-00086
10. Seguchi M, AYTEKIN A, Steiger L, Nicol P, Pellegrini C, Rheude T, Engel LC, Alvarez-Covarrubias HA, Xhepa E, Mayr NP, Hadamitzky M, **Kastrati A**, Schunkert H, Joner M, Lenz T. Near-infrared spectroscopy-intravascular ultrasound to improve assessment of coronary artery disease severity in patients referred for transcatheter aortic valve implantation (The IMPACTavi registry): Design and rationale. *Am Heart J* 2023;**264**:114-122, 10.1016/j.ahj.2023.06.004
 11. Scalapogna M, Kuna C, Voll F, AYTEKIN A, Lahu S, Kessler T, Kufner S, Rheude T, Sager HB, Xhepa E, Wiebe J, Joner M, Ndrepepa G, **Kastrati A**, Cassese S. Modified balloons to prepare severely calcified coronary lesions before stent implantation: a systematic review and meta-analysis of randomized trials. *Clin Res Cardiol* 2023, 10.1007/s00392-023-02324-y
 12. Scalapogna M, Abdel-Wahab M, Mashayekhi K, Fusaro M, Leistner DM, Ayoub M, Xhepa E, Joner M, **Kastrati A**, Cassese S, Rheude T. Randomized Comparison of Strategies to Prepare Severely Calcified Coronary Lesions 2: Design and Rationale of the ISAR-CALC 2 Trial. *Cardiovasc Revasc Med* 2023;**49**:22-27, 10.1016/j.carrev.2022.12.008
 13. Sandner S, **Kastrati A**, Niessner A, Boning A, Zeymer U, Conradi L, Danner B, Zimpfer D, Farber G, Manville E, Schunkert H, von Scheidt M, Ti CABI. Sex differences among patients receiving ticagrelor monotherapy or aspirin after coronary bypass surgery: A prespecified subgroup analysis of the TiCAB trial. *Int J Cardiol* 2023;**370**:129-135, 10.1016/j.ijcard.2022.10.166
 14. Rheude T, Koch T, Joner M, Lenz T, Xhepa E, Wiebe J, Coughlan JJ, AYTEKIN A, Cassese S, Laugwitz KL, Schunkert H, **Kastrati A**, Kufner S. Ten-year clinical outcomes of drug-eluting stents with different polymer coating strategies by degree of coronary calcification: a pooled analysis of the ISAR-TEST 4 and 5 randomised trials. *EuroIntervention* 2023;**18**(14):1188-1196, 10.4244/EIJ-D-22-00781
 15. Pellegrini C, Freissmuth M, Rheude T, Graas D, Mayr NP, Syryca F, Alvarez-Covarrubias HA, Fetcu A, Hubner J, Lennerz C, Schunkert H, **Kastrati A**, Xhepa E, Joner M. Implantation depth of balloon-expandable transcatheter heart valves and risks for permanent pacemaker implantation and midterm adverse events. *Catheter Cardiovasc Interv* 2023, 10.1002/ccd.30870
 16. Nicol P, Rank A, Lenz T, Schurmann F, Syryca F, Trenkwalder T, Reinhard W, Adolf R, Hadamitzky M, **Kastrati A**, Joner M, Schunkert H, Engel LC. Echocardiographic evaluation of left ventricular function using an automated analysis algorithm is feasible for beginners and experts: comparison with invasive and non-invasive methods. *J Echocardiogr* 2023;**21**(2):65-73, 10.1007/s12574-022-00590-9
 17. Ndrepepa G, **Kastrati A**. P2Y12 inhibitor intensity de-escalation in patients with acute coronary syndromes. *Eur Heart J* 2023;**44**(15):1371-1373, 10.1093/eurheartj/ehad050
 18. Ndrepepa G, **Kastrati A**. Coronary No-Reflow after Primary Percutaneous Coronary Intervention-Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy. *J Clin Med* 2023;**12**(17), 10.3390/jcm12175592
 19. Ndrepepa G, Holdenrieder S, **Kastrati A**. Prognostic value of De Ritis ratio with aspartate aminotransferase and alanine aminotransferase within the reference range. *Clin Chim Acta* 2023;**538**:46-52, 10.1016/j.cca.2022.11.005
 20. Ndrepepa G, Holdenrieder S, **Kastrati A**. De Ritis ratio and long-term major cardiovascular adverse events in patients undergoing elective percutaneous coronary intervention. *Eur J Clin Invest* 2023;**53**(5):e13942, 10.1111/eci.13942
 21. Ndrepepa G, Cassese S, Xhepa E, Joner M, Sager HB, Kufner S, Laugwitz KL, Schunkert H, **Kastrati A**. Coronary no-reflow and adverse events in patients with acute myocardial infarction after percutaneous coronary intervention with current drug-eluting stents and

- third-generation P2Y(12) inhibitors. *Clin Res Cardiol* 2023, 10.1007/s00392-023-02340-y
22. Ndrepepa G, Cassese S, Scalamogna M, Lahu S, AYTEKIN A, Xhepa E, Schunkert H, **Kastrati A**. Association of De Ritis Ratio with Prognosis in Patients with Coronary Artery Disease and Aminotransferase Activity within and outside the Healthy Values of Reference Range. *J Clin Med* 2023;**12**(9), 10.3390/jcm12093174
 23. Muller AM, Lohn-Kannengiesser L, Bradaric C, Dirschinger R, Koppara T, Bergmann K, Kehl V, Cassese S, Xhepa E, **Kastrati A**, Laugwitz KL, Ibrahim T. Outcomes of endovascular treatment for popliteal artery disease. *Vasa* 2023;**52**(6):386-393, 10.1024/0301-1526/a001096
 24. Muller AM, Bertram J, Bradaric C, Koppara T, Cassese S, Xhepa E, Heilmeyer B, Ott I, **Kastrati A**, Laugwitz KL, Ibrahim T, Dirschinger RJ. Frequency of subclavian artery stenosis in patients with mammalian artery coronary bypass and suspected coronary artery disease progression. *Clin Res Cardiol* 2023;**112**(9):1204-1211, 10.1007/s00392-022-02113-z
 25. Muller A, Bradaric C, Kafka A, Joner M, Cassese S, Xhepa E, Kufner S, **Kastrati A**, Laugwitz KL, Ibrahim T, Koppara T. Prevalence and patterns of in-stent neoatherosclerosis in lower extremity artery disease. *EuroIntervention* 2023;**18**(17):1462-1470, 10.4244/EIJ-D-22-00615
 26. Mendieta G, Mehta S, Baber U, Angiolillo DJ, Briguori C, Cohen D, Collier T, Dangas G, Dudek D, Escaned J, Gil R, Vogel B, Cao D, Spirito A, Huber K, **Kastrati A**, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Moliterno DJ, Ohman EM, Sardella G, Sartori S, Sharma S, Shlofmitz R, Steg PG, Han YL, Pocock S, Gibson CM, Mehran R. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions. *J Am Coll Cardiol* 2023;**82**(8):687-700, 10.1016/j.jacc.2023.05.062
 27. Mayer K, Ndrepepa G, Schroeter M, Emmer C, Bernlochner I, Schupke S, Gewalt S, Hilz R, Coughlan JJ, AYTEKIN A, Heyken C, Morath T, Schunkert H, Laugwitz KL, Sibbing D, **Kastrati A**. High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry. *Clin Res Cardiol* 2023;**112**(9):1231-1239, 10.1007/s00392-023-02161-z
 28. Leick J, Rheude T, Denne M, Cassese S, **Kastrati A**, Hauptmann F, Gehrig T, Kuna C, Lindner M, Lauterbach M, Werner N. Comparison of long-term outcome in patients with calcified stenosis treated with intravascular lithotripsy or with modified balloon angioplasty: a propensity score-adjusted study. *Front Cardiovasc Med* 2023;**10**:1185422, 10.3389/fcvm.2023.1185422
 29. Lahu S, Adler K, Mayer K, Hein-Rothweiler R, Bernlochner I, Ndrepepa G, Schupke S, Holdenrieder S, Bongiovanni D, Laugwitz KL, Schunkert H, Gawaz M, Massberg S, **Kastrati A**, Munch G. Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention. *Thromb Haemost* 2023, 10.1055/s-0043-1772221
 30. Kuna C, Wiedenmayer N, Bradaric C, Presch A, Voll F, Kufner S, Ibrahim T, Schunkert H, Laugwitz KL, Cassese S, **Kastrati A**, Wiebe J. Ten-year outcomes after percutaneous coronary intervention of in-stent restenosis in saphenous vein grafts. *Catheter Cardiovasc Interv* 2023;**102**(4):646-654, 10.1002/ccd.30807
 31. Koch T, Lenz T, Rheude T, Cassese S, Kazazi M, Xhepa E, Kessler T, Wiebe J, Ferenc M, Laugwitz KL, Joner M, Schunkert H, **Kastrati A**, Kufner S. Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis. *JACC Cardiovasc Interv* 2023, 10.1016/j.jcin.2023.10.031
 32. Koch T, Lahu S, Coughlan JJ, Cassese S, Voll F, Ndrepepa G, Menichelli M, Valina C, Hemetsberger R, Witzendichler B, Bernlochner I, Joner M, Xhepa E, Mayer K, Kessler T, Laugwitz KL, Richardt G, Schunkert H, Angiolillo DJ, Sibbing D, **Kastrati A**, Kufner S. Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. *Thromb Haemost* 2023;**123**(4):464-477, 10.1055/a-1988-5047

33. **Kastrati A**, Sinha N, Chanana BB, Kasturi S, Sinha SK, Vijay Kumar M, Bansal SS, Jose EJ, Gill GS, Garg R, Natarajan S, Mariappan P. Post market surveillance registry (PIONEER) of the Yukon Choice PC-Elite Coronary Stent System for percutaneous coronary intervention in Indian acute coronary syndrome population. *Indian Heart J* 2023;**75**(1):25-30, 10.1016/j.ihj.2022.12.005
34. **Kastrati A**, Seguchi M. New opportunities for bioresorbable scaffold technology. *AsiaIntervention* 2023;**9**(2):103-104, 10.4244/AIJ-E-23-00003
35. Guldener U, Kessler T, von Scheidt M, Hawe JS, Gerhard B, Maier D, Lachmann M, Laugwitz KL, Cassese S, Schomig AW, **Kastrati A**, Schunkert H. Machine Learning Identifies New Predictors on Restenosis Risk after Coronary Artery Stenting in 10,004 Patients with Surveillance Angiography. *J Clin Med* 2023;**12**(8), 10.3390/jcm12082941
36. Gagnano F, Cao D, Pironcini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, **Kastrati A**, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabro P, Pocock S, Mehran R, Valgimigli M, Collaboration P. P2Y(12) Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. *J Am Coll Cardiol* 2023;**82**(2):89-105, 10.1016/j.jacc.2023.04.051
37. Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, Wiebe J, Joner M, Hochholzer W, Laugwitz KL, Schunkert H, **Kastrati A**, Kufner S. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. *Eur Heart J* 2023;**44**(15):1343-1357, 10.1093/eurheartj/ehad026
38. Fitzgerald S, Gimenez MR, Allali A, Toelg R, Sulimov DS, Geist V, **Kastrati A**, Thiele H, Richardt G, Abdel-Wahab M. Sex-specific Inequalities in the Treatment of Severely Calcified Coronary Lesions: A Sub-analysis of the PREPARE-CALC Trial. *Interv Cardiol* 2023;**18**:e02, 10.15420/icr.2022.07
39. Coughlan JJ, Raber L, Brugaletta S, Kufner S, Maeng M, Jensen LO, Ortega-Paz L, Bar S, Laugwitz KL, Madsen M, Heg D, AYTEKIN A, Windecker S, Olesen KKW, Sabate M, **Kastrati A**, Cassese S. Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation. *Circulation* 2023;**147**(7):575-585, 10.1161/CIRCULATIONAHA.122.062049
40. Coughlan JJ, AYTEKIN A, Lahu S, Scalapogna M, Wiebe J, Piniack S, Kufner S, Xhepa E, Joner M, Kuna C, Voll F, Laugwitz KL, Schunkert H, **Kastrati A**, Cassese S. Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis. *EuroIntervention* 2023;**18**(16):e1328-e1338, 10.4244/EIJ-D-22-00860
41. Capodanno D, Mehran R, Krucoff MW, Baber U, Bhatt DL, Capranzano P, Collet JP, Cuisset T, De Luca G, De Luca L, Farb A, Franchi F, Gibson CM, Hahn JY, Hong MK, James S, **Kastrati A**, Kimura T, Lemos PA, Lopes RD, Magee A, Matsumura R, Mochizuki S, O'Donoghue ML, Pereira NL, Rao SV, Rollini F, Shirai Y, Sibbing D, Smits PC, Steg PG, Storey RF, Ten Berg J, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Serruys PW, Yeh RW, Morice MC, Angiolillo DJ. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. *Circulation* 2023;**147**(25):1933-1944, 10.1161/CIRCULATIONAHA.123.064473
42. Bongiovanni D, Schreiner N, Gosetti R, Mayer K, Angiolillo DJ, Sibbing D, Holdenrieder S, Anetsberger A, von Scheidt M, Schunkert H, Laugwitz KL, Schupke S, **Kastrati A**, Fegers-Wustrow I, Bernlochner I. Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy. *Arterioscler Thromb Vasc Biol* 2023;**43**(2):e83-e93, 10.1161/ATVBAHA.122.318614
43. Bongiovanni D, Novelli L, Condello F, Kirmes K, Han J, Wein B, Elvinger S, Viggiani G, von

- Scheidt M, Laugwitz KL, Raake PWJ, **Kastrati A**, Chiarito M, Bernlochner I. Reticulated Platelets Predict Cardiovascular Death and Adverse Events in Coronary Artery Disease: A Systematic Review and Meta-analysis. *Thromb Haemost* 2023, 10.1055/s-0043-1773763
44. Bikdeli B, Erlinge D, Valgimigli M, **Kastrati A**, Han Y, Steg PG, Stables RH, Mehran R, James SK, Frigoli E, Goldstein P, Li Y, Shahzad A, Schupke S, Mehdipour G, Chen S, Redfors B, Crowley A, Zhou Z, Stone GW. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. *Circulation* 2023;**148**(16):1207-1219, 10.1161/CIRCULATIONAHA.123.063946
 45. Behnes M, Lahu S, Ndrepepa G, Menichelli M, Mayer K, Wahrle J, Bernlochner I, Gewalt S, Witzenbichler B, Hochholzer W, Sibbing D, Cassese S, Angiolillo DJ, Hemetsberger R, Valina C, Muller A, Kufner S, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Joner M, Fusaro M, Richardt G, Laugwitz KL, Neumann FJ, Schunkert H, Schupke S, **Kastrati A**, Akin I. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. *Clin Res Cardiol* 2023;**112**(4):518-528, 10.1007/s00392-022-02040-z
 46. Banning AS, Sabate M, Orban M, Gracey J, Lopez-Sobrinho T, Massberg S, **Kastrati A**, Bogaerts K, Adriaenssens T, Berry C, Erglis A, Haine S, Myrmet T, Patel S, Buera I, Sionis A, Vilalta V, Yusuff H, Vrints C, Adlam D, Flather M, Gershlick AH. Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial. *EuroIntervention* 2023;**19**(6):482-492, 10.4244/EIJ-D-23-00204
 47. Baber U, Spirito A, Sartori S, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, **Kastrati A**, Kaul U, Kornowski R, Krucoff M, Kunadian V, Vogel B, Mehta SR, Moliterno D, Sardella G, Shlofmitz RA, Sharma S, Steg PG, Pocock S, Mehran R. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial. *Am J Cardiol* 2023;**208**:16-24, 10.1016/j.amjcard.2023.09.008
 48. Aytekin A, **Kastrati A**. Looking into the future of ACS patients through the small OCT window. *Rev Esp Cardiol (Engl Ed)* 2023;**76**(3):140-142, 10.1016/j.rec.2022.08.005
 49. Aytekin A, Coughlan JJ, Ndrepepa G, Cassese S, Lahu S, Kufner S, Mayer K, Xhepa E, Gewalt S, Joner M, Hapfelmeier A, Angiolillo DJ, Menichelli M, Richardt G, Neumann FJ, Schunkert H, **Kastrati A**. The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes. *Eur Heart J Cardiovasc Pharmacother* 2023;**9**(3):231-239, 10.1093/ehjcvp/pvac067
 50. Alvarez-Covarrubias HA, Joner M, Cassese S, Warmbrunn M, Lutz J, Trenkwalder T, Seguchi M, Aytekin A, Presch A, Pellegrini C, Rheude T, Patrick Mayr N, Kufner S, Schunkert H, **Kastrati A**, Xhepa E. Iliofemoral artery predilation prior to transfemoral transcatheter aortic valve implantation in patients with aortic valve stenosis and advanced peripheral artery disease. *Catheter Cardiovasc Interv* 2023;**101**(3):628-638, 10.1002/ccd.30576
 51. Allali A, Richardt G, Toelg R, Elbasha K, Sulimov DS, **Kastrati A**, Geist V, El-Mawardy M, Rheude T, Abdel-Wahab M. High-speed rotational atherectomy versus modified balloons for plaque preparation of severely calcified coronary lesions: two-year outcomes of the randomised PREPARE-CALC trial. *EuroIntervention* 2023;**18**(16):e1365-e1367, 10.4244/EIJ-D-22-00677
 52. Allali A, Abdel-Wahab M, Elbasha K, Mankerious N, Traboulsi H, **Kastrati A**, El-Mawardy M, Hemetsberger R, Sulimov DS, Neumann FJ, Toelg R, Richardt G. Rotational atherectomy of calcified coronary lesions: current practice and insights from two randomized trials. *Clin Res Cardiol* 2023;**112**(9):1143-1163, 10.1007/s00392-022-02013-2
 53. Zeng L, Moser S, Mirza-Schreiber N, Lamina C, Coassin S, Nelson CP, Annilo T, Franzen O, Kleber ME, Mack S, Andlauer TFM, Jiang B, Stiller B, Li L, Willenborg C, Munz M, Kessler T, **Kastrati A**, Laugwitz KL, Erdmann J, Moebus S, Nothen MM, Peters A, Strauch

- K, Muller-Nurasyid M, Gieger C, Meitinger T, Steinhagen-Thiessen E, Marz W, Metspalu A, Bjorkegren JLM, Samani NJ, Kronenberg F, Muller-Myhsok B, Schunkert H. Cis-epistasis at the LPA locus and risk of cardiovascular diseases. *Cardiovasc Res* 2022;**118**(4):1088-1102, 10.1093/cvr/cvab136
54. Wiebe J, Byrne RA, Alfonso F, Maeng M, Bradaric C, Kretov E, Cuesta J, Kuna C, Ibrahim T, Rivero F, Heugl M, Christiansen EH, Joner M, Schunkert H, Laugwitz KL, **Kastrati A**, Cassese S. Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. *EuroIntervention* 2022;**17**(16):1348-1351, 10.4244/EIJ-D-21-00653
55. Sardella G, Beerkens FJ, Dangas G, Cao D, Baber U, Sartori S, Cohen DJ, Briguori C, Gil R, Nicolas J, Zhang Z, Dudek D, Kunadian V, Kornowski R, Weisz G, Claessen B, Marx S, Escaned J, Huber K, Collier T, Moliterno DJ, Ohman EM, Krucoff MW, **Kastrati A**, Steg PG, Angiolillo DJ, Mehta S, Shlofmitz R, Sharma S, Pocock S, Gibson CM, Mehran R. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. *EuroIntervention* 2022;**18**(11):e897-e909, 10.4244/EIJ-D-22-00319
56. Sandner SE, Schunkert H, **Kastrati A**, Milojevic M, Boning A, Zimpfer D, Zellmer S, Wiedemann D, Laufer G, von Scheidt M, Ti CABI. Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease. *Ann Thorac Surg* 2022;**113**(2):554-562, 10.1016/j.athoracsur.2021.03.061
57. Sandner S, Gaudino M, **Kastrati A**. Commentary: Ticagrelor monotherapy-Not for CABG? *J Card Surg* 2022;**37**(4):1087-1089, 10.1111/jocs.16203
58. Rheude T, Fitzgerald S, Allali A, Mashayekhi K, Gori T, Cuculi F, Kufner S, Hemetsberger R, Sulimov DS, Rai H, Ayoub M, Bossard M, Xhepa E, Fusaro M, Toelg R, Joner M, Byrne RA, Richardt G, **Kastrati A**, Cassese S, Abdel-Wahab M. Rotational Atherectomy or Balloon-Based Techniques to Prepare Severely Calcified Coronary Lesions. *JACC Cardiovasc Interv* 2022;**15**(18):1864-1874, 10.1016/j.jcin.2022.07.034
59. Rai H, Harzer F, Otsuka T, Abdelwahed YS, Antuna P, Blachutzik F, Koppa T, Raber L, Leistner DM, Alfonso F, Nef H, Seguchi M, Aytakin A, Xhepa E, Kufner S, Cassese S, Laugwitz KL, Byrne RA, **Kastrati A**, Joner M. Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. *J Am Heart Assoc* 2022;**11**(9):e023493, 10.1161/JAHA.121.023493
60. Pellegrini C, Xhepa E, Ndrepepa G, Alvarez-Covarrubias H, Kufner S, Lahmann AL, Rheude T, Rai H, Mayr NP, Schunkert H, **Kastrati A**, Joner M, Cassese S. Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. A meta-analysis of randomized controlled trials. *Clin Res Cardiol* 2022;**111**(1):14-22, 10.1007/s00392-020-01791-x
61. Ndrepepa G, Neumann FJ, Menichelli M, Richardt G, Cassese S, Xhepa E, Kufner S, Lahu S, Aytakin A, Sager HB, Joner M, Ibrahim T, Muller A, Fusaro M, Hapfelmeier A, Laugwitz KL, Schunkert H, **Kastrati A**, Kasel M. Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes. *Coron Artery Dis* 2022;**33**(3):213-221, 10.1097/MCA.0000000000001120
62. Ndrepepa G, Lahu S, Aytakin A, Scalamogna M, Coughlan JJ, Gewalt S, Pellegrini C, Mayer K, **Kastrati A**. One-Year Ischemic and Bleeding Events According to Renal Function in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Third-Generation Antiplatelet Drugs. *Am J Cardiol* 2022;**176**:15-23, 10.1016/j.amjcard.2022.04.040
63. Ndrepepa G, Holdenrieder S, Xhepa E, Cassese S, Lahu S, Kufner S, **Kastrati A**. Alkaline phosphatase and prognosis in patients with diabetes mellitus and ischemic heart disease. *Clin Chim Acta* 2022;**533**:1-7, 10.1016/j.cca.2022.05.024

64. Ndrepepa G, Holdenrieder S, **Kastrati A**. Prognostic value of De Ritis ratio in patients with acute myocardial infarction. *Clin Chim Acta* 2022;**535**:75-81, 10.1016/j.cca.2022.08.016
65. Ndrepepa G, Holdenrieder S, Bernlochner I, **Kastrati A**. Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes. *Clin Res Cardiol* 2022;**111**(7):838-842, 10.1007/s00392-021-01976-y
66. Nano N, Aytekin A, Ndrepepa G, Seguchi M, Bresha J, Alvarez Covarrubias HA, Nicol P, Lenz T, Lahu S, Gewalt S, Voll F, Rheude T, Wiebe J, Schunkert H, Kufner S, Cassese S, Joner M, **Kastrati A**, Xhepa E. Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis. *Clin Res Cardiol* 2022;**111**(7):827-837, 10.1007/s00392-022-02024-z
67. Lahu S, Scalomogna M, Ndrepepa G, Menichelli M, Valina C, Hemetsberger R, Witzenbichler B, Bernlochner I, Joner M, Xhepa E, Hapfelmeier A, Kufner S, Sager HB, Mayer K, Kessler T, Laugwitz KL, Richardt G, Schunkert H, Neumann FJ, **Kastrati A**, Cassese S. Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial. *J Am Heart Assoc* 2022;**11**(24):e027257, 10.1161/JAHA.122.027257
68. Lahu S, Presch A, Ndrepepa G, Menichelli M, Valina C, Hemetsberger R, Witzenbichler B, Bernlochner I, Joner M, Xhepa E, Hapfelmeier A, Kufner S, Rifatov N, Sager HB, Mayer K, Kessler T, Laugwitz KL, Richardt G, Schunkert H, Neumann FJ, Sibbing D, Angiolillo DJ, **Kastrati A**, Cassese S. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk. *Circ Cardiovasc Interv* 2022;**15**(10):e012204, 10.1161/CIRCINTERVENTIONS.122.012204
69. Lahu S, Ndrepepa G, Neumann FJ, Menichelli M, Bernlochner I, Richardt G, Wohrle J, Witzenbichler B, Hemetsberger R, Mayer K, Akin I, Cassese S, Gewalt S, Xhepa E, Kufner S, Valina C, Sager HB, Joner M, Ibrahim T, Laugwitz KL, Schunkert H, Schupke S, **Kastrati A**. Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial. *Eur Heart J Cardiovasc Pharmacother* 2022;**8**(7):687-694, 10.1093/ehjcvp/pvac007
70. Lahu S, Bristol P, Gewalt S, Goedel A, Giacoppo D, Schupke S, Schunkert H, **Kastrati A**, Sarafoff N. Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y(12) Inhibitor Thereafter. *J Atheroscler Thromb* 2022;**29**(7):1001-1019, 10.5551/jat.63000
71. Lahu S, Behnes M, Ndrepepa G, Neumann FJ, Sibbing D, Bernlochner I, Menichelli M, Mayer K, Richardt G, Gewalt S, Angiolillo DJ, Coughlan JJ, Aytekin A, Witzenbichler B, Hochholzer W, Cassese S, Kufner S, Xhepa E, Sager HB, Joner M, Fusaro M, Laugwitz KL, Schunkert H, Schupke S, **Kastrati A**, Akin I. Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. *Rev Esp Cardiol (Engl Ed)* 2022;**75**(9):747-755, 10.1016/j.rec.2021.11.007
72. Lachmann M, Rippen E, Schuster T, Xhepa E, von Scheidt M, Trenkwalder T, Pellegrini C, Rheude T, Hesse A, Stundl A, Harmsen G, Yuasa S, Schunkert H, **Kastrati A**, Laugwitz KL, Joner M, Kupatt C. Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement. *Open Heart* 2022;**9**(2), 10.1136/openhrt-2022-002068
73. Lachmann M, Rippen E, Rueckert D, Schuster T, Xhepa E, von Scheidt M, Pellegrini C, Trenkwalder T, Rheude T, Stundl A, Thalmann R, Harmsen G, Yuasa S, Schunkert H, **Kastrati A**, Joner M, Kupatt C, Laugwitz KL. Harnessing feature extraction capacities from a pre-trained convolutional neural network (VGG-16) for the unsupervised distinction of aortic outflow velocity profiles in patients with severe aortic stenosis. *Eur Heart J Digit Health* 2022;**3**(2):153-168, 10.1093/ehjdh/ztac004
74. Kunadian V, Baber U, Pivato CA, Cao D, Dangas G, Sartori S, Zhang Z, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff

- MW, Dehghani P, Mehta S, Moliterno DJ, Ohman EM, Escaned J, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Dzavik V, Gurbel P, Hamm CW, Henry T, **Kastrati A**, Marx SO, Oldroyd K, Steg PG, Pocock S, Mehran R. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. *JACC Cardiovasc Interv* 2022;**15**(19):1948-1960, 10.1016/j.jcin.2022.07.039
75. Kufner S, Rai H, Wiebe J, Altevogt F, Pyxaras S, Joner M, Xhepa E, Cassese S, Colleran R, Schunkert H, Zrenner B, **Kastrati A**, Byrne RA, Intracoronary S, Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis AI. A prospective trial of a novel low-dose paclitaxel-coated balloon therapy in patients with restenosis in drug-eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-stent REstenosis 3A (ISAR-DESIRE 3A). *Catheter Cardiovasc Interv* 2022;**99**(3):754-762, 10.1002/ccd.30014
76. Koch T, Voll F, Xhepa E, Wiebe J, Cassese S, Tolg R, Laugwitz KL, Neumann FJ, **Kastrati A**, Kufner S. Association between duration of drug-coated balloon inflation and efficacy in patients with drug-eluting stent restenosis. *Coron Artery Dis* 2022;**33**(3):239-241, 10.1097/MCA.0000000000001045
77. **Kastrati A**, Dibra A. No Matter How Slowly You Go as Long as You Do Not Stop. *JACC Cardiovasc Interv* 2022;**15**(18):1861-1863, 10.1016/j.jcin.2022.08.019
78. Hemetsberger R, Richardt G, Lahu S, Valina C, Menichelli M, Abdelghani M, Wohrle J, Toelg R, Witzenbichler B, Mankarious N, Liebetau C, Bernlochner I, Hamm CW, Allali A, Joner M, Fusaro M, Xhepa E, Hapfelmeier A, Kufner S, Sager HB, Schupke S, Laugwitz KL, Schunkert H, Neumann FJ, **Kastrati A**, Cassese S. Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy. *Cardiovasc Revasc Med* 2022;**41**:122-128, 10.1016/j.carrev.2021.12.029
79. Heer T, von Scheidt M, Boening A, Heyken C, Gusmini F, de Waha A, Kuna C, Fach A, Grothusen C, Oberhoffer M, Knosalla C, Walther T, Danner BC, Misfeld M, Wimmer-Greinecker G, Siepe M, Grubitzsch H, Joost A, Schaefer A, Conradi L, Cremer J, Hamm C, Lange R, Radke PW, Schulz R, Laufer G, Grieshaber P, Attmann T, Schmoeckel M, Meyer A, Ziegelhoffer T, Hambrecht R, Sandner SE, **Kastrati A**, Schunkert H, Zeymer U. Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial. *Eur J Cardiothorac Surg* 2022;**62**(3), 10.1093/ejcts/ezac048
80. Han Y, Claessen BE, Chen SL, Chunguang Q, Zhou Y, Xu Y, Hailong L, Chen J, Qiang W, Zhang R, Luo S, Li Y, Zhu J, Zhao X, Cheng X, Wang J, Su X, Tao J, Sun Y, Wang G, Li Y, Bian L, Goel R, Sartori S, Zhang Z, Angiolillo DJ, Cohen DJ, Gibson CM, **Kastrati A**, Krucoff M, Mehta SR, Ohman EM, Steg PG, Liu Y, Dangas G, Sharma S, Baber U, Mehran R. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. *Circ Cardiovasc Interv* 2022;**15**(4):e009495, 10.1161/CIRCINTERVENTIONS.120.009495
81. Gewalt S, Lahu S, Ndrepepa G, Pellegrini C, Bernlochner I, Neumann FJ, Menichelli M, Morath T, Witzenbichler B, Wohrle J, Hoppe K, Richardt G, Laugwitz KL, Schunkert H, **Kastrati A**, Schupke S, Mayer K. Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial. *J Atheroscler Thromb* 2022;**29**(5):747-761, 10.5551/jat.62776
82. Gallone G, Bruno F, Trenkwalder T, D'Ascenzo F, Islas F, Leone PP, Nicol P, Pellegrini C, Incaminato E, Jimenez-Quevedo P, Alvarez-Covarrubias HA, Bragato R, Andreis A, Salizzoni S, Rinaldi M, **Kastrati A**, Conrotto F, Joner M, Stefanini G, Nombela-Franco L, Xhepa E, Escaned J, De Ferrari GM. Prognostic implications of impaired longitudinal left ventricular systolic function assessed by tissue Doppler imaging prior to transcatheter aortic valve implantation for severe aortic stenosis. *Int J Cardiovasc Imaging* 2022, 10.1007/s10554-021-02519-2

83. Fitzgerald S, Allali A, Toelg R, Sulimov DS, Geist V, **Kastrati A**, Thiele H, Neumann FJ, Richardt G, Abdel-Wahab M. Angiographic predictors of unplanned rotational atherectomy in complex calcified coronary artery disease: a pooled analysis from the randomised ROTAXUS and PREPARE-CALC trials. *EuroIntervention* 2022;**17**(18):1506-1513, 10.4244/EIJ-D-21-00612
84. Dutsch A, Graesser C, Voll F, Novacek S, Eggerstedt R, Armbruster NL, Laugwitz KL, Cassese S, Schunkert H, Ndrepepa G, **Kastrati A**, Kessler T, Sager HB. Association of In-Hospital Hemoglobin Drop With Decreased Myocardial Salvage and Increased Long-Term Mortality in Patients With Acute ST-Segment-Elevation Myocardial Infarction. *J Am Heart Assoc* 2022;**11**(17):e024857, 10.1161/JAHA.121.024857
85. Dangas G, Baber U, Sharma S, Giustino G, Sartori S, Nicolas J, Goel R, Mehta S, Cohen D, Angiolillo DJ, Zhang Z, Camaj A, Cao D, Briguori C, Dudek D, Escaned J, Huber K, Collier T, Kornowski R, Kunadian V, Moliterno DJ, Ohman EM, Weisz G, Gil R, Krucoff MW, Kaul U, Oldroyd KG, Sardella G, Shlofmitz R, Witzentichler B, **Kastrati A**, Han YL, Steg PG, Pocock S, Gibson CM, Mehran R. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. *EuroIntervention* 2022;**17**(16):1330-1339, 10.4244/EIJ-D-21-00721
86. Coughlan JJ, Maeng M, Raber L, Brugaletta S, Aytekin A, Okkels Jensen L, Bar S, Ortega-Paz L, Laugwitz KL, Madsen M, Heg D, Sabate M, Kufner S, Warnakula Olesen KK, **Kastrati A**, Windecker S, Cassese S. Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. *Rev Esp Cardiol (Engl Ed)* 2022, 10.1016/j.rec.2022.02.003
87. Coughlan JJ, **Kastrati A**. Bivalirudin in patients with ST-segment elevation myocardial infarction. *Lancet* 2022;**400**(10366):1822-1823, 10.1016/S0140-6736(22)02162-6
88. Coughlan JJ, Aytekin A, Xhepa E, Cassese S, Joner M, Koch T, Wiebe J, Lenz T, Rheude T, Pellegrini C, Gewalt S, Ibrahim T, Laugwitz KL, Schunkert H, **Kastrati A**, Kufner S. Target and non-target vessel related events at 10 years post percutaneous coronary intervention. *Clin Res Cardiol* 2022;**111**(7):787-794, 10.1007/s00392-022-01986-4
89. Coughlan JJ, Aytekin A, Lenz T, Koch T, Wiebe J, Cassese S, Joner M, Koppa T, Xhepa E, Kessler T, Ibrahim T, Laugwitz KL, Schunkert H, **Kastrati A**, Kufner S. Ten-Year Clinical Outcomes in Patients With Acute Coronary Syndrome Treated With Biodegradable, Permanent-Polymer or Polymer-Free Drug-Eluting Stents. *J Invasive Cardiol* 2022;**34**(4):E266-E273,
90. Coughlan JJ, Aytekin A, Koch T, Wiebe J, Lenz T, Cassese S, Joner M, Koppa T, Xhepa E, Ibrahim T, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**, Kufner S. Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap. *Catheter Cardiovasc Interv* 2022;**99**(3):541-551, 10.1002/ccd.29944
91. Colleran R, Joner M, Cutlip D, Urban P, Maeng M, Jauhar R, Barakat M, Michel JM, Mehran R, Kirtane AJ, Maillard L, **Kastrati A**, Byrne RA, investigators C-R. Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). *Cardiovasc Revasc Med* 2022;**34**:17-24, 10.1016/j.carrev.2021.01.022
92. Colleran R, Byrne RA, Ndrepepa G, Alvarez-Covarrubias HA, Mayer K, Kuna C, Rai H, **Kastrati A**, Cassese S. Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. *Cardiovasc Revasc Med* 2022;**36**:99-106, 10.1016/j.carrev.2021.05.013
93. Chiarito M, Baber U, Cao D, Sharma SK, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, Dudek D, Dzavik V, Escaned J, Gil R, Hamm CW, Henry T, Huber K, **Kastrati A**, Kaul U, Kornowski R, Krucoff M, Kunadian V, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Zhongjie Z, Sartori S, Stefanini G, Shlofmitz R, Steg PG, Weisz G, Witzentichler B, Han YL, Pocock S, Gibson CM, Mehran R. Ticagrelor Monotherapy After PCI in

- High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. *JACC Cardiovasc Interv* 2022;**15**(3):282-293, 10.1016/j.jcin.2021.11.005
94. Capodanno D, Baber U, Bhatt DL, Collet JP, Dangas G, Franchi F, Gibson CM, Gwon HC, **Kastrati A**, Kimura T, Lemos PA, Lopes RD, Mehran R, O'Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey RF, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention. *Nat Rev Cardiol* 2022;**19**(12):829-844, 10.1038/s41569-022-00725-6
 95. Araki M, Park SJ, Dauerman HL, Uemura S, Kim JS, Di Mario C, Johnson TW, Guagliumi G, **Kastrati A**, Joner M, Holm NR, Alfonso F, Wijns W, Adriaenssens T, Nef H, Rioufol G, Amabile N, Souteyrand G, Meneveau N, Gerbaud E, Opolski MP, Gonzalo N, Tearney GJ, Bouma B, Aguirre AD, Mintz GS, Stone GW, Bourantas CV, Raber L, Gili S, Mizuno K, Kimura S, Shinke T, Hong MK, Jang Y, Cho JM, Yan BP, Porto I, Niccoli G, Montone RA, Thondapu V, Papafaklis MI, Michalis LK, Reynolds H, Saw J, Libby P, Weisz G, Iannaccone M, Gori T, Toutouzas K, Yonetsu T, Minami Y, Takano M, Raffel OC, Kurihara O, Soeda T, Sugiyama T, Kim HO, Lee T, Higuma T, Nakajima A, Yamamoto E, Bryniarski KL, Di Vito L, Vergallo R, Fracassi F, Russo M, Seegers LM, McNulty I, Park S, Feldman M, Escaned J, Prati F, Arbustini E, Pinto FJ, Waksman R, Garcia-Garcia HM, Maehara A, Ali Z, Finn AV, Virmani R, Kini AS, Daemen J, Kume T, Hibi K, Tanaka A, Akasaka T, Kubo T, Yasuda S, Croce K, Granada JF, Lerman A, Prasad A, Regar E, Saito Y, Sankardas MA, Subban V, Weissman NJ, Chen Y, Yu B, Nicholls SJ, Barlis P, West NEJ, Arbab-Zadeh A, Ye JC, Dijkstra J, Lee H, Narula J, Crea F, Nakamura S, Kakuta T, Fujimoto J, Fuster V, Jang IK. Optical coherence tomography in coronary atherosclerosis assessment and intervention. *Nat Rev Cardiol* 2022;**19**(10):684-703, 10.1038/s41569-022-00687-9
 96. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, Venegas LM, Sherliker P, Koyama S, Ishigaki K, Asvold BO, Brown MR, Brumpton B, de Vries PS, Giannakopoulou O, Giardoglou P, Gudbjartsson DF, Guldener U, Haider SMI, Helgadottir A, Ibrahim M, **Kastrati A**, Kessler T, Kyriakou T, Konopka T, Li L, Ma L, Meitinger T, Mucha S, Munz M, Murgia F, Nielsen JB, Nothen MM, Pang S, Reinberger T, Schnitzler G, Smedley D, Thorleifsson G, von Scheidt M, Ulirsch JC, Biobank J, Epic CVD, Arnar DO, Burt NP, Costanzo MC, Flannick J, Ito K, Jang DK, Kamatani Y, Khera AV, Komuro I, Kullo IJ, Lotta LA, Nelson CP, Roberts R, Thorgeirsson G, Thorsteinsdottir U, Webb TR, Baras A, Bjorkegren JLM, Boerwinkle E, Dedoussis G, Holm H, Hveem K, Melander O, Morrison AC, Orho-Melander M, Rallidis LS, Ruusalepp A, Sabatine MS, Stefansson K, Zalloua P, Ellinor PT, Farrall M, Danesh J, Ruff CT, Finucane HK, Hopewell JC, Clarke R, Gupta RM, Erdmann J, Samani NJ, Schunkert H, Watkins H, Willer CJ, Deloukas P, Kathiresan S, Butterworth AS, Consortium CAD. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat Genet* 2022;**54**(12):1803-1815, 10.1038/s41588-022-01233-6
 97. Angiolillo DJ, Galli M, Collet JP, **Kastrati A**, O'Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. *EuroIntervention* 2022;**17**(17):e1371-e1396, 10.4244/EIJ-D-21-00904
 98. Allali A, Toelg R, Abdel-Wahab M, Hemetsberger R, **Kastrati A**, Mankerious N, Traboulsi H, Elbasha K, Rheude T, Landt M, Geist V, Richardt G. Combined rotational atherectomy and cutting balloon angioplasty prior to drug-eluting stent implantation in severely calcified coronary lesions: The PREPARE-CALC-COMBO study. *Catheter Cardiovasc Interv* 2022;**100**(6):979-989, 10.1002/ccd.30423
 99. Alfonso F, Coughlan JJ, **Kastrati A**. How should we treat "undilatable" coronary stents?: Treating "undilatable" coronary stents. *AsiaIntervention* 2022;**8**(1):9-13, 10.4244/AIJ-E-22-00002
 100. Alfonso F, Coughlan JJ, Giacoppo D, **Kastrati A**, Byrne RA. Management of in-stent

- restenosis. *EuroIntervention* 2022;**18**(2):e103-e123, 10.4244/EIJ-D-21-01034
101. Xhepa E, Cassese S, Ndrepepa G, Joner M, Kufner S, Aytekin A, Lahmann AL, Voll F, Fusaro M, Pinieck S, Schunkert H, **Kastrati A**, Fusaro M. Clinical and angiographic outcomes of crossing techniques for coronary chronic total occlusions: the ISAR-CTO registry. *EuroIntervention* 2021;**17**(8):e656-e663, 10.4244/EIJ-D-20-01248
 102. Xhepa E, Bresha J, Joner M, Hapfelmeier A, Rivero F, Ndrepepa G, Nano N, Cuesta J, Kufner S, Cassese S, Bastante T, Aytekin A, Rroku A, Garcia-Guimaraes M, Lahmann AL, Pinieck S, Rai H, Fusaro M, Schunkert H, Perez-Vizcayno MJ, Gonzalo N, Alfonso F, **Kastrati A**. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. *EuroIntervention* 2021;**17**(5):e388-e395, 10.4244/EIJ-D-20-00662
 103. Wohrle J, Seeger J, Lahu S, Mayer K, Bernlochner I, Gewalt S, Menichelli M, Witzenbichler B, Hochholzer W, Sibbing D, Cassese S, Angiolillo DJ, Hemetsberger R, Valina C, Kufner S, Xhepa E, Hapfelmeier A, Sager HB, Joner M, Richardt G, Laugwitz KL, Neumann FJ, Schunkert H, Schupke S, **Kastrati A**, Ndrepepa G. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate. *JACC Cardiovasc Interv* 2021;**14**(17):1857-1866, 10.1016/j.jcin.2021.06.028
 104. Wierer M, Werner J, Wobst J, **Kastrati A**, Cepele G, Aherrahrou R, Sager HB, Erdmann J, Dichgans M, Flockerzi V, Civelek M, Dietrich A, Mann M, Schunkert H, Kessler T. A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy. *Eur Heart J* 2021;**42**(18):1773-1785, 10.1093/eurheartj/ehab140
 105. Wiebe J, Rai H, Kuna C, Cassese S, Kessler T, Rheude T, Colleran R, Schunkert H, Koch T, Kufner S, Joner M, **Kastrati A**, Byrne RA. Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice. *Catheter Cardiovasc Interv* 2021;**98**(5):857-862, 10.1002/ccd.29225
 106. Wiebe J, Ndrepepa G, Kufner S, Lahmann AL, Xhepa E, Kuna C, Voll F, Gosetti R, Laugwitz KL, Joner M, **Kastrati A**, Cassese S. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. *J Am Heart Assoc* 2021;**10**(2):e018304, 10.1161/JAHA.120.018304
 107. Wiebe J, Hoppmann P, Cassese S, Rheude T, Colleran R, Kuna C, Rai H, Valeskini M, Ibrahim T, Joner M, Schunkert H, Laugwitz KL, **Kastrati A**, Byrne RA. Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. *Rev Esp Cardiol (Engl Ed)* 2021;**74**(7):584-590, 10.1016/j.rec.2020.07.005
 108. Voll F, Kuna C, Ndrepepa G, **Kastrati A**, Cassese S. Antithrombotic treatment in primary percutaneous coronary intervention. *Expert Rev Cardiovasc Ther* 2021;**19**(4):313-324, 10.1080/14779072.2021.1902807
 109. Sibbing D, **Kastrati A**. Guided P2Y(12) inhibitor therapy after percutaneous coronary intervention. *Lancet* 2021;**397**(10283):1423-1425, 10.1016/S0140-6736(21)00728-5
 110. Rheude T, Rai H, Richardt G, Allali A, Abdel-Wahab M, Sulimov DS, Mashayekhi K, Ayoub M, Cuculi F, Bossard M, Kufner S, Xhepa E, **Kastrati A**, Fusaro M, Joner M, Byrne RA, Cassese S. Super high-pressure balloon versus scoring balloon to prepare severely calcified coronary lesions: the ISAR-CALC randomised trial. *EuroIntervention* 2021;**17**(6):481-488, 10.4244/EIJ-D-20-01000
 111. Rai H, Colleran R, Cassese S, Joner M, **Kastrati A**, Byrne RA. Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. *Inflamm Res* 2021;**70**(10-12):1075-1087, 10.1007/s00011-021-01505-7
 112. Rai H, Alfonso F, Maeng M, Bradaric C, Wiebe J, Cuesta J, Christiansen EH, Cassese S, Hoppmann P, Colleran R, Harzer F, Bresha J, Nano N, Schneider S, Laugwitz KL, Joner M, **Kastrati A**, Byrne RA. Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus

- eluting stents in the ISAR-Absorb MI trial. *Int J Cardiovasc Imaging* 2021;**37**(10):2815-2826, 10.1007/s10554-021-02251-x
113. Ott I, Rumpf PM, Kasel M, **Kastrati A**, Kaemmerer H, Schunkert H, Ewert P, Tutarel O. Transcatheter valve repair in congenitally corrected transposition of the great arteries. *EuroIntervention* 2021;**17**(9):744-746, 10.4244/EIJ-D-20-01093
114. Nicol P, Hoppman P, Euller K, Xhepa E, Lenz T, Rai H, Jinnouchi H, Bulin A, Castellanos MI, Lahmann AL, Koppara T, **Kastrati A**, Joner M. Validation and application of OCT tissue attenuation index for the detection of neointimal foam cells. *Int J Cardiovasc Imaging* 2021;**37**(1):25-35, 10.1007/s10554-020-01956-9
115. Neumann FJ, Valina C, **Kastrati A**. Reply: Prasugrel Versus Ticagrelor in Non-ST-Segment-Elevation Acute Coronary Syndrome. *J Am Coll Cardiol* 2021;**77**(11):1484, 10.1016/j.jacc.2021.01.009
116. Ndrepepa G, Neumann FJ, Menichelli M, Holdenrieder S, Richardt G, Mayer K, Cassese S, Xhepa E, Kufner S, Wiebe J, Joner M, Kessler T, Laugwitz KL, Schunkert H, **Kastrati A**. Prognostic value of haemoglobin drop in patients with acute coronary syndromes. *Eur J Clin Invest* 2021;**51**(12):e13670, 10.1111/eci.13670
117. Ndrepepa G, Neumann FJ, Menichelli M, Bernlochner I, Richardt G, Wohrle J, Witzenbichler B, Mayer K, Cassese S, Gewalt S, Xhepa E, Kufner S, Sager HB, Joner M, Ibrahim T, Laugwitz KL, Schunkert H, Schupke S, **Kastrati A**. Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. *J Am Heart Assoc* 2021;**10**(22):e021418, 10.1161/JAHA.121.021418
118. Ndrepepa G, Holdenrieder S, Neumann FJ, Lahu S, Cassese S, Joner M, Xhepa E, Kufner S, Wiebe J, Laugwitz KL, Gewalt S, Schunkert H, **Kastrati A**. Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. *Clin Chim Acta* 2021;**523**:106-113, 10.1016/j.cca.2021.09.007
119. Ndrepepa G, Holdenrieder S, Cassese S, **Kastrati A**. Creatine kinase and bleeding in patients with acute coronary syndromes. *Eur J Clin Invest* 2021;**51**(7):e13514, 10.1111/eci.13514
120. Muller AM, Rappale V, Bradaric C, Koppara T, Kehl V, Fusaro M, Cassese S, Ott I, **Kastrati A**, Laugwitz KL, Ibrahim T. Outcomes of endovascular treatment for infrapopliteal peripheral artery disease based on the updated TASC II classification. *Vasc Med* 2021;**26**(1):18-25, 10.1177/1358863X20967091
121. Michel JM, Hashorva D, Kretschmer A, Alvarez-Covarrubias HA, Mayr NP, Pellegrini C, Rheude T, Frangieh AH, Giacoppo D, **Kastrati A**, Schunkert H, Xhepa E, Joner M, Kasel AM. Evaluation of a Low-Dose Radiation Protocol During Transcatheter Aortic Valve Implantation. *Am J Cardiol* 2021;**139**:71-78, 10.1016/j.amjcard.2020.10.035
122. Michel JM, Frangieh AH, Giacoppo D, Alvarez-Covarrubias HA, Pellegrini C, Rheude T, Deutsch O, Mayr NP, Rumpf PM, Stahli BE, **Kastrati A**, Schunkert H, Xhepa E, Joner M, Kasel AM. Safety and efficacy of minimalist transcatheter aortic valve implantation using a new-generation balloon-expandable transcatheter heart valve in bicuspid and tricuspid aortic valves. *Clin Res Cardiol* 2021;**110**(12):1993-2006, 10.1007/s00392-021-01935-7
123. Mayer K, Hein-Rothweiler R, Schupke S, Janisch M, Bernlochner I, Ndrepepa G, Sibbing D, Gori T, Borst O, Holdenrieder S, Kupka D, Petzold T, Bradaric C, Okrojek R, Leistner DM, Trippel TD, Munzel T, Landmesser U, Pieske B, Zeiher AM, Gawaz MP, Hapfelmeier A, Laugwitz KL, Schunkert H, **Kastrati A**, Massberg S. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. *JAMA Cardiol* 2021;**6**(7):753-761, 10.1001/jamacardio.2021.0475
124. Mayer K, Gewalt S, Morath T, Emmer C, Hilz R, Linhardt M, Hoppe K, Schmidt R,

- Bott-Flugel L, Laugwitz KL, Schunkert H, **Kastrati A**, Schupke S, Sarafoff N. Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture in Patients on Oral Anticoagulation - Post Hoc Analysis of the ISAR-CLOSURE Trial. *J Invasive Cardiol* 2021;**33**(9):E709-E715,
125. Madhavan MV, Bikdeli B, Redfors B, Biondi-Zoccai G, Varunok NJ, Burton JR, Crowley A, Francese DP, Gupta A, C DERN, Chatterjee S, Palmerini T, Benedetto U, You SC, Ohman EM, **Kastrati A**, Steg PG, Gibson CM, Angiolillo DJ, Krumholz HM, Stone GW. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. *Minerva Cardiol Angiol* 2021;**69**(4):398-407, 10.23736/S2724-5683.20.05353-0
 126. Lenz T, Koch T, Joner M, Xhepa E, Wiebe J, Coughlan JJ, Aytekin A, Ibrahim T, Fusaro M, Cassese S, Laugwitz KL, Schunkert H, **Kastrati A**, Kufner S, dagger I-TI. Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. *J Am Heart Assoc* 2021;**10**(12):e020165, 10.1161/JAHA.120.020165
 127. Lahu S, Ndrepepa G, Gewalt S, Schupke S, Pellegrini C, Bernlochner I, Aytekin A, Neumann FJ, Menichelli M, Richardt G, Cassese S, Xhepa E, Kufner S, Sager HB, Joner M, Ibrahim T, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**, Mayer K. Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes. *Int J Cardiol* 2021;**338**:8-13, 10.1016/j.ijcard.2021.06.011
 128. Lachmann M, Rippen E, Schuster T, Xhepa E, von Scheidt M, Pellegrini C, Trenkwalder T, Rheude T, Stundl A, Thalmann R, Harmsen G, Yuasa S, Schunkert H, **Kastrati A**, Laugwitz KL, Kupatt C, Joner M. Subphenotyping of Patients With Aortic Stenosis by Unsupervised Agglomerative Clustering of Echocardiographic and Hemodynamic Data. *JACC Cardiovasc Interv* 2021;**14**(19):2127-2140, 10.1016/j.jcin.2021.08.034
 129. Konig KC, Lahm H, Dressen M, Doppler SA, Eichhorn S, Beck N, Kraehschuetz K, Doll S, Holdenrieder S, **Kastrati A**, Lange R, Krane M. AggreCan: a new biomarker for acute type A aortic dissection. *Sci Rep* 2021;**11**(1):10371, 10.1038/s41598-021-89653-y
 130. Koch T, Lenz T, Joner M, Xhepa E, Koppa T, Wiebe J, Coughlan JJ, Aytekin A, Ibrahim T, Kessler T, Cassese S, Laugwitz KL, Schunkert H, **Kastrati A**, Kufner S, Intracoronary S, Angiographic Results: Test Efficacy of S, ProbucoL-Eluting Versus ZotarolimUS- Eluting Stents I. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and ProbucoL- and ZotarolimUS-Eluting Stents (ISAR-TEST 5) trial. *Clin Res Cardiol* 2021;**110**(10):1586-1598, 10.1007/s00392-021-01854-7
 131. Kessler T, Cassese S, **Kastrati A**. Letter by Kessler et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials". *Circulation* 2021;**143**(6):e230-e231, 10.1161/CIRCULATIONAHA.120.049650
 132. Katritsis DG, Pantos I, Zografos T, Spahillari A, de Waha A, Kopanidis A, Foussas S, Stone PH, **Kastrati A**, Cutlip D. Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. *Am J Cardiol* 2021;**141**:7-15, 10.1016/j.amjcard.2020.11.012
 133. **Kastrati A**, Hapfelmeier A. The Bayesian Approach and the Results of the ISAR-REACT 5 Trial. *JACC Cardiovasc Interv* 2021;**14**(2):231-232, 10.1016/j.jcin.2020.12.001
 134. **Kastrati A**, Coughlan JJ, Pellegrini C. Stent Thrombosis in Patients Treated for Acute or Chronic Coronary Syndrome. *JACC Cardiovasc Interv* 2021;**14**(10):1091-1093, 10.1016/j.jcin.2021.04.014
 135. **Kastrati A**, Coughlan JJ, Ndrepepa G. Primary PCI, Late Presenting STEMI, and the Limits of Time. *J Am Coll Cardiol* 2021;**78**(13):1306-1308, 10.1016/j.jacc.2021.08.001

136. Holmberg O, Lenz T, Koch V, Alyagoob A, Utsch L, Rank A, Sabic E, Seguchi M, Xhepa E, Kufner S, Cassese S, **Kastrati A**, Marr C, Joner M, Nicol P. Histopathology-Based Deep-Learning Predicts Atherosclerotic Lesions in Intravascular Imaging. *Front Cardiovasc Med* 2021;**8**:779807, 10.3389/fcvm.2021.779807
137. Hemetsberger R, Toelg R, Mankerious N, Allali A, Traboulsi H, Sulimov DS, El-Mawardy M, Byrne RA, Robinson DR, **Kastrati A**, Abdel-Wahab M, Richardt G. Impact of Calcified Lesion Complexity on the Success of Percutaneous Coronary Intervention With Upfront High-Speed Rotational Atherectomy or Modified Balloons - A Subgroup-Analysis From the Randomized PREPARE-CALC Trial. *Cardiovasc Revasc Med* 2021;**33**:26-31, 10.1016/j.carrev.2021.01.002
138. Gosetti R, Sarafoff N, Laugwitz KL, **Kastrati A**, Bernlochner I, Goedel A. Clopidogrel response in patients receiving the nonvitamin K antagonist oral anticoagulants apixaban and rivaroxaban. *Coron Artery Dis* 2021;**32**(2):167-169, 10.1097/MCA.0000000000000933
139. Frohlich GM, Jeschke E, Eichler U, Thiele H, Alhariri L, Reinthaler M, **Kastrati A**, Leistner DM, Skurk C, Landmesser U, Gunster C. Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. *Clin Res Cardiol* 2021;**110**(7):1041-1050, 10.1007/s00392-020-01783-x
140. Coughlan JJ, Aytakin A, Ndrepepa G, Schupke S, Bernlochner I, Mayer K, Neumann FJ, Menichelli M, Richardt G, Wohrle J, Xhepa E, Kufner S, Sager HB, Joner M, Ibrahim T, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**, Cassese S. Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial. *Eur Heart J Acute Cardiovasc Care* 2021;**10**(10):1117-1124, 10.1093/ehjacc/zuab077
141. Coughlan JJ, Aytakin A, Ndrepepa G, Schupke S, Bernlochner I, Mayer K, Neumann FJ, Menichelli M, Richardt G, Wohrle J, Witzembichler B, Gewalt S, Xhepa E, Kufner S, Sager HB, Joner M, Ibrahim T, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**, Cassese S. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. *Circ Cardiovasc Interv* 2021;**14**(7):e010565, 10.1161/CIRCINTERVENTIONS.121.010565
142. Coughlan JJ, Aytakin A, Lahu S, Ndrepepa G, Menichelli M, Mayer K, Wohrle J, Bernlochner I, Gewalt S, Witzembichler B, Hochholzer W, Sibbing D, Cassese S, Angiolillo DJ, Hemetsberger R, Valina C, Muller A, Kufner S, Liebetau C, Xhepa E, Hapfelmeier A, Sager HB, Joner M, Fusaro M, Richardt G, Laugwitz KL, Neumann FJ, Schunkert H, Schupke S, **Kastrati A**. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. *JAMA Cardiol* 2021;**6**(10):1121-1129, 10.1001/jamacardio.2021.2228
143. Correa-Sadouet C, Rodriguez-Granillo AM, Gallardo C, Mieres J, Fontana L, Curotto MV, Wainer P, Allende NG, Fernandez-Pereira C, H MV, la Hoz RP, **Kastrati A**, Rodriguez AE, investigators O. Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention. *Future Cardiol* 2021;**17**(4):539-547, 10.2217/fca-2020-0161
144. Bossard M, Gao P, Boden W, Steg G, Tanguay JF, Joyner C, Granger CB, **Kastrati A**, Faxon D, Budaj A, Pais P, Di Pasquale G, Valentin V, Flather M, Moccetti T, Yusuf S, Mehta SR. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. *Heart* 2021;**107**(21):1739-1747, 10.1136/heartjnl-2020-318045
145. Banning AS, Adriaenssens T, Berry C, Bogaerts K, Erglis A, Distelmaier K, Guagliumi G, Haine S, **Kastrati A**, Massberg S, Orban M, Myrmel T, Vuylsteke A, Alfonso F, Van de Werf F, Verheugt F, Flather M, Sabate M, Vrints C, Gershlick AH, Collaborators. Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial.

- EuroIntervention 2021;**16**(15):e1227-e1236, 10.4244/EIJ-D-20-01076
146. Alushi B, Ndrepepa G, Lauten A, Lahmann AL, Bongiovanni D, Kufner S, Xhepa E, Laugwitz KL, Joner M, Landmesser U, Thiele H, **Kastrati A**, Cassese S. Hypothermia in patients with acute myocardial infarction: a meta-analysis of randomized trials. *Clin Res Cardiol* 2021;**110**(1):84-92, 10.1007/s00392-020-01652-7
 147. Alushi B, Jost-Brinkmann F, **Kastrati A**, Cassese S, Fusaro M, Stangl K, Landmesser U, Thiele H, Lauten A. High-Sensitivity Cardiac Troponin T in Patients with Severe Chronic Kidney Disease and Suspected Acute Coronary Syndrome. *J Clin Med* 2021;**10**(18), 10.3390/jcm10184216
 148. Alfonso F, **Kastrati A**. Clinical burden and implications of coronary interventions for in-stent restenosis. *EuroIntervention* 2021;**17**(5):e355-e357, 10.4244/EIJV17I5A60
 149. Wiebe J, Kuna C, Ibrahim T, Losl M, Cassese S, Kufner S, Schunkert H, Byrne RA, Laugwitz KL, Valgimigli M, Richardt G, Mehilli J, **Kastrati A**. Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. *JACC Cardiovasc Interv* 2020;**13**(19):2266-2274, 10.1016/j.jcin.2020.07.017
 150. Wiebe J, Baquet M, Dorr O, Hoppmann P, Jochheim D, Rheude T, Boeder N, Grundmann D, Blachutzik F, Theiss H, Cassese S, Hofmann FJ, Gschwendtner S, Elsasser A, Massberg S, Hamm C, Laugwitz KL, Byrne RA, Mehilli J, **Kastrati A**, Nef H. Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. *Int J Cardiol* 2020;**312**:42-47, 10.1016/j.ijcard.2020.02.062
 151. von Scheidt M, Bongiovanni D, Tebbe U, Nowak B, Stritzke J, Zhao Q, Zhu Y, **Kastrati A**, Cassese S, Schunkert H. Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials. *Eur J Cardiothorac Surg* 2020;**57**(3):520-528, 10.1093/ejcts/ezz260
 152. Vitadello T, Kunze KP, Nekolla SG, Langwieser N, Bradaric C, Weis F, Cassese S, Fusaro M, Hapfelmeier A, Lewalter T, Schwaiger M, **Kastrati A**, Laugwitz KL, Rischpler C, Ibrahim T. Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions. *Eur J Nucl Med Mol Imaging* 2020;**47**(13):3074-3083, 10.1007/s00259-020-04877-w
 153. Valina C, Neumann FJ, Menichelli M, Mayer K, Wohrle J, Bernlochner I, Aytekin A, Richardt G, Witzembichler B, Sibbing D, Cassese S, Angiolillo DJ, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, Trenk D, Laugwitz KL, Schunkert H, Schupke S, **Kastrati A**. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. *J Am Coll Cardiol* 2020;**76**(21):2436-2446, 10.1016/j.jacc.2020.09.584
 154. Stahli BE, Varbella F, Schwarz B, Nordbeck P, Felix SB, Lang IM, Toma A, Moccetti M, Valina C, Vercellino M, Rigopoulos AG, Rohla M, Schindler M, Wischnowsky M, Linke A, Schulze PC, Richardt G, Laugwitz KL, Weidinger F, Rottbauer W, Achenbach S, Huber K, Neumann FJ, **Kastrati A**, Ford I, Ruschitzka F, Maier W, Investigators MA. Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. *Am Heart J* 2020;**228**:98-108, 10.1016/j.ahj.2020.07.016
 155. Schupke S, **Kastrati A**. Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor. *Eur Heart J* 2020;**41**(33):3153-3155, 10.1093/eurheartj/ehz938
 156. Schupke S, **Kastrati A**. Ticagrelor or Prasugrel in Acute Coronary Syndromes. Reply. *N Engl J Med* 2020;**382**(5):487, 10.1056/NEJMc1915621
 157. Schneider V, Dirschinger R, Wustrow I, Muller A, Cassese S, Fusaro M, **Kastrati A**, Koppa T, Bergmann K, Laugwitz KL, Ibrahim T, Bradaric C. Endovascular therapy of subclavian artery occlusive disease involving the vertebral artery origin. *Vasa* 2020;**49**(3):205-213, 10.1024/0301-1526/a000842

158. Schaefer A, Conradi L, Schneeberger Y, Reichenspurner H, Sandner S, Tebbe U, Nowak B, Stritzke J, **Kastrati A**, Schunkert H, von Scheidt M, Ti CABi. Clinical outcomes of complete versus incomplete revascularization in patients treated with coronary artery bypass grafting: insights from the TiCAB trial. *Eur J Cardiothorac Surg* 2020, 10.1093/ejcts/ezaa330
159. Sandner SE, Schunkert H, **Kastrati A**, Wiedemann D, Misfeld M, Boning A, Tebbe U, Nowak B, Stritzke J, Laufer G, von Scheidt M, Ti CABi. Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. *Eur J Cardiothorac Surg* 2020;**57**(4):732-739, 10.1093/ejcts/ezz313
160. Rheude T, Toelg R, Byrne RA, Allali A, Wiebe J, Sulimov DS, Voll F, Cassese S, Richardt G, **Kastrati A**, Abdel-Wahab M. Outcomes of rotational atherectomy versus modified balloon angioplasty in severely calcified coronary lesions based on target lesion location: a post hoc analysis of the PREPARE-CALC randomised trial. *EuroIntervention* 2020;**16**(4):e322-e324, 10.4244/EIJ-D-19-00488
161. Rheude T, Pellegrini C, Cassese S, Wiebe J, Wagner S, Trenkwalder T, Alvarez H, Mayr NP, Hengstenberg C, Schunkert H, **Kastrati A**, Husser O, Joner M. Predictors of haemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves. *EuroIntervention* 2020;**15**(14):1233-1239, 10.4244/EIJ-D-19-00710
162. Rai H, Hussein H, Colleran R, Xhepa E, Wiebe J, Pinieck S, Cassese S, Joner M, **Kastrati A**, Byrne RA, Foley DP. Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent. *Cardiovasc Revasc Med* 2020;**21**(3):277-285, 10.1016/j.carrev.2019.05.004
163. Pellegrini C, Rheude T, Michel J, Alvarez-Covarrubias HA, Wunsch S, Mayr NP, Xhepa E, **Kastrati A**, Schunkert H, Joner M, Kasel M. Comparison of latest generation supra-annular and intra-annular self-expanding transcatheter heart valves. *J Thorac Dis* 2020;**12**(11):6769-6779, 10.21037/jtd-20-1700
164. Ndrepepa G, **Kastrati A**, Menichelli M, Neumann FJ, Wohrle J, Bernlochner I, Richardt G, Witzembichler B, Sibbing D, Gewalt S, Angiolillo DJ, Hamm CW, Hapfelmeier A, Trenk D, Laugwitz KL, Schunkert H, Schupke S, Mayer K. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. *JACC Cardiovasc Interv* 2020;**13**(19):2238-2247, 10.1016/j.jcin.2020.07.032
165. Ndrepepa G, **Kastrati A**. Obesity paradox after percutaneous coronary intervention - closing in on the truth behind the phenomenon. *EuroIntervention* 2020;**15**(13):1120-1122, 10.4244/EIJV15I13A208
166. Ndrepepa G, Holdenrieder S, Cassese S, Xhepa E, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Aspartate aminotransferase and mortality in patients with ischemic heart disease. *Nutr Metab Cardiovasc Dis* 2020;**30**(12):2335-2342, 10.1016/j.numecd.2020.07.033
167. Ndrepepa G, Holdenrieder S, Cassese S, Xhepa E, Fusaro M, **Kastrati A**. Hypocholesterolaemia and mortality in patients with coronary artery disease. *Eur J Clin Invest* 2020;**50**(2):e13194, 10.1111/eci.13194
168. Ndrepepa G, Cassese S, Xhepa E, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Relation of Hypocholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. *Am J Cardiol* 2020;**125**(7):1026-1032, 10.1016/j.amjcard.2019.12.044
169. Michel J, Pellegrini C, Rheude T, von Scheidt M, Trenkwalder T, Elhmidi Y, Mayr NP, Brecker S, Kasel AM, **Kastrati A**, Schunkert H, Husser O, Bleiziffer S, Hengstenberg C. The Clinical Impact of Psoas Muscle Cross-Sectional Area on Medium-Term Mortality After Transcatheter Aortic Valve Implantation. *Heart Lung Circ* 2020;**29**(6):904-913, 10.1016/j.hlc.2019.05.095
170. Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Wohrle J, Bernlochner I, Richardt G,

- Witzenbichler B, Sibbing D, Gewalt S, Angiolillo DJ, Lahu S, Hamm CW, Hapfelmeier A, Trenk D, Laugwitz KL, Schunkert H, Schupke S, **Kastrati A**. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial. *Ann Intern Med* 2020;**173**(6):436-444, 10.7326/M20-1806
171. Mehilli J, Baquet M, Hochholzer W, Mayer K, Tesche C, Aradi D, Xu Y, Thienel M, Gschwendtner S, Zadrozny M, Jochheim D, Sibbing D, Schupke S, Mansmann U, Hoffmann E, **Kastrati A**, Neumann FJ, Massberg S. Randomized Comparison of Intensified and Standard P2Y(12)-Receptor-Inhibition Before Elective Percutaneous Coronary Intervention: The SASSICAIA Trial. *Circ Cardiovasc Interv* 2020;**13**(6):e008649, 10.1161/CIRCINTERVENTIONS.119.008649
172. Mayer K, Bongiovanni D, Karschin V, Sibbing D, Angiolillo DJ, Schunkert H, Laugwitz KL, Schupke S, **Kastrati A**, Bernlochner I. Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial. *J Am Coll Cardiol* 2020;**76**(21):2569-2571, 10.1016/j.jacc.2020.09.586
173. Lahmann AL, Bongiovanni D, Berkefeld A, Ketter M, Martinez L, Okrojek R, Hoppmann P, Laugwitz KL, Mayr P, Cassese S, Byrne R, Kufner S, Xhepa E, Schunkert H, **Kastrati A**, Joner M. Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest - A propensity score-matched analysis. *PLoS One* 2020;**15**(1):e0218634, 10.1371/journal.pone.0218634
174. Kufner S, Ernst M, Cassese S, Joner M, Mayer K, Colleran R, Koppa T, Xhepa E, Koch T, Wiebe J, Ibrahim T, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**, Byrne RA, Investigators I-T-. 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. *J Am Coll Cardiol* 2020;**76**(2):146-158, 10.1016/j.jacc.2020.05.026
175. Koch T, Cassese S, Xhepa E, Mayer K, Tolg R, Hoppmann P, Laugwitz KL, Byrne RA, **Kastrati A**, Kufner S. Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. *Catheter Cardiovasc Interv* 2020;**96**(5):1008-1015, 10.1002/ccd.28638
176. Kessler T, Wiebe J, Graf T, Schunkert H, **Kastrati A**, Sager HB. SARS-CoV-2 Infection in Asymptomatic Patients Hospitalized for Cardiac Emergencies: Implications for Patient Management. *Front Cardiovasc Med* 2020;**7**:599299, 10.3389/fcvm.2020.599299
177. Kessler T, Graf T, Hilgendorf I, Rizas K, Martens E, von Zur Muhlen C, Kraemer P, Meyer-Saraei R, Neumann FJ, Bode C, Laugwitz KL, Massberg S, Schunkert H, Weil J, **Kastrati A**, Sager HB. Hospital admissions with acute coronary syndromes during the COVID-19 pandemic in German cardiac care units. *Cardiovasc Res* 2020;**116**(11):1800-1801, 10.1093/cvr/cvaa192
178. **Kastrati A**, Cassese S. In-Stent Restenosis in the United States: Time to Enrich its Treatment Armamentarium. *J Am Coll Cardiol* 2020;**76**(13):1532-1535, 10.1016/j.jacc.2020.08.035
179. Hoppmann P, Rai H, Colleran R, Kufner S, Wiebe J, Cassese S, Joner M, Laugwitz KL, **Kastrati A**, Byrne RA. Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography. *Cardiovasc Revasc Med* 2020;**21**(3):361-366, 10.1016/j.carrev.2019.05.023
180. Harada Y, Schneider S, Colleran R, Rai H, Bohner J, Kuna C, Kufner S, Giacoppo D, Schupke S, Joner M, Ibrahim T, Laugwitz KL, **Kastrati A**, Byrne RA. Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated? *Rev Esp Cardiol (Engl Ed)* 2020;**73**(3):225-231, 10.1016/j.rec.2019.01.005
181. Giacoppo D, **Kastrati A**, Byrne RA, Investigators DS. Reply: Drug-Coated Balloons Versus Drug-Eluting Stents for Coronary In-Stent Restenosis. *J Am Coll Cardiol*

- 2020;**76**(11):1392-1393, 10.1016/j.jacc.2020.07.038
182. Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Jensen C, Perez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, Baan J, Cuesta J, Park DW, Schunkert H, Colleran R, Kukla P, Jimenez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park SJ, Henriques JPS, **Kastrati A**, Byrne RA. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). *Eur Heart J* 2020;**41**(38):3715-3728, 10.1093/eurheartj/ehz594
183. Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Jensen C, Perez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, Baan J, Cuesta J, Park DW, Kukla P, Jimenez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park SJ, Henriques JPS, **Kastrati A**, Byrne RA. Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. *J Am Coll Cardiol* 2020;**75**(21):2664-2678, 10.1016/j.jacc.2020.04.006
184. Cassese S, Ndrepepa G, Byrne RA, Laugwitz KL, Schunkert H, Fusaro M, Alfonso F, **Kastrati A**. Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials. *Am Heart J* 2020;**219**:109-116, 10.1016/j.ahj.2019.08.020
185. Cassese S, Katagiri Y, Byrne RA, Brugaletta S, Alfonso F, Raber L, Maeng M, Iniguez A, Kretov E, Onuma Y, Joner M, Sabate M, Laugwitz KL, Windecker S, **Kastrati A**, Serruys PW. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. *EuroIntervention* 2020;**15**(16):1451-1457, 10.4244/EIJ-D-18-01080
186. Cassese S, **Kastrati A**. Long-Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST-Segment-Elevation Myocardial Infarction. *J Am Heart Assoc* 2020;**9**(5):e015726, 10.1161/JAHA.120.015726
187. Bikdeli B, McAndrew T, Crowley A, Chen S, Mehdipoor G, Redfors B, Liu Y, Zhang Z, Liu M, Zhang Y, Francese DP, Erlinge D, James SK, Han Y, Li Y, **Kastrati A**, Schupke S, Stables RH, Shahzad A, Steg PG, Goldstein P, Frigoli E, Mehran R, Valgimigli M, Stone GW. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. *Thromb Haemost* 2020;**120**(2):348-362, 10.1055/s-0039-1700872
188. Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, Briguori C, Cha JY, Collier T, Dudek D, Dzavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, **Kastrati A**, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta S, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM, Mehran R. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. *Eur Heart J* 2020;**41**(37):3533-3545, 10.1093/eurheartj/ehaa670
189. Aytekin A, Ndrepepa G, Neumann FJ, Menichelli M, Mayer K, Wohrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, Trenk D, Fusaro M, Laugwitz KL, Schunkert H, Schupke S, **Kastrati A**. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Circulation* 2020;**142**(24):2329-2337, 10.1161/CIRCULATIONAHA.120.050244
190. Alushi B, Lauten A, Ndrepepa G, Leistner DM, Kufner S, Xhepa E, Landmesser U, **Kastrati A**, Cassese S. Procedural and clinical performance of dual- versus single-catheter strategy for transradial coronary angiography: A meta-analysis of randomized trials. *Catheter Cardiovasc Interv* 2020;**96**(2):276-282, 10.1002/ccd.28458

191. Alfonso F, **Kastrati A**. Ten-Year Follow-Up of Left Main Coronary Artery Revascularization: Still Equipoise Between Percutaneous Interventions and Surgery? *Circulation* 2020;**141**(18):1447-1451, 10.1161/CIRCULATIONAHA.120.046154
192. Zeng L, Ntalla I, Kessler T, **Kastrati A**, Erdmann J, Group UKBCCCW, Danesh J, Watkins H, Samani NJ, Deloukas P, Schunkert H. Genetically modulated educational attainment and coronary disease risk. *Eur Heart J* 2019;**40**(29):2413-2420, 10.1093/eurheartj/ehz328
193. Xhepa E, Cassese S, Rroku A, Joner M, Piniack S, Ndrepepa G, **Kastrati A**, Fusaro M. Subintimal Versus Intraplaque Recanalization of Coronary Chronic Total Occlusions: Mid-Term Angiographic and OCT Findings From the ISAR-OCT-CTO Registry. *JACC Cardiovasc Interv* 2019;**12**(19):1889-1898, 10.1016/j.jcin.2019.04.049
194. Xhepa E, Byrne RA, Rivero F, Rroku A, Cuesta J, Ndrepepa G, Kufner S, Valiente TB, Cassese S, Garcia-Guimaraes M, Lahmann AL, Rai H, Schunkert H, Joner M, Perez-Vizcayno MJ, Gonzalo N, Alfonso F, **Kastrati A**. Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. *Clin Res Cardiol* 2019;**108**(9):1059-1068, 10.1007/s00392-019-01439-5
195. Valgimigli M, Garcia-Garcia HM, Vrijens B, Vranckx P, McFadden EP, Costa F, Pieper K, Vock DM, Zhang M, Van Es GA, Tricoci P, Baber U, Steg G, Montalescot G, Angiolillo DJ, Serruys PW, Farb A, Windecker S, **Kastrati A**, Colombo A, Feres F, Juni P, Stone GW, Bhatt DL, Mehran R, Tijssen JGP. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). *Eur Heart J* 2019;**40**(25):2070-2085, 10.1093/eurheartj/ehy377
196. Trenkwalder T, Pellegrini C, Holzamer A, Rheude T, Riestler J, Reinhard W, Mayr NP, Kasel AM, Gaede L, Blumenstein J, **Kastrati A**, Schunkert H, Joner M, Hilker M, Hengstenberg C, Husser O. Prophylactic ECMO during TAVI in patients with depressed left ventricular ejection fraction. *Clin Res Cardiol* 2019;**108**(4):366-374, 10.1007/s00392-018-1364-6
197. Trenkwalder T, Nelson CP, Musameh MD, Mordi IR, Kessler T, Pellegrini C, Debiec R, Rheude T, Lazovic V, Zeng L, Martinsson A, Gustav Smith J, Gadin JR, Franco-Cereceda A, Eriksson P, Nielsen JB, Graham SE, Willer CJ, Hveem K, **Kastrati A**, Braund PS, Palmer CNA, Aracil A, Husser O, Koenig W, Schunkert H, Lang CC, Hengstenberg C, Samani NJ. Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. *Int J Cardiol* 2019;**276**:212-217, 10.1016/j.ijcard.2018.11.094
198. Thienel M, Lusebrink E, **Kastrati A**, Dannenberg L, Polzin A, Schulz C, Massberg S, Petzold T. Integrin ss1 polymorphisms and bleeding risk after coronary artery stenting. *Mol Biol Rep* 2019;**46**(6):5695-5702, 10.1007/s11033-019-05003-2
199. Sousa-Uva M, Neumann FJ, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, **Kastrati A**, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Group ESCSD. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur J Cardiothorac Surg* 2019;**55**(1):4-90, 10.1093/ejcts/ezy289
200. Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tolg R, Trenk D, Schunkert H, Laugwitz KL, **Kastrati A**, Investigators I-RT. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. *N Engl J Med* 2019;**381**(16):1524-1534, 10.1056/NEJMoa1908973
201. Schupke S, Hein-Rothweiler R, Mayer K, Janisch M, Sibbing D, Ndrepepa G, Hilz R, Laugwitz KL, Bernlochner I, Gschwendtner S, Kupka D, Gori T, Zeiher AM, Schunkert H, Massberg S, **Kastrati A**, Investigators IS-P-T. Revacept, a Novel Inhibitor of Platelet

- Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial. *Thromb Haemost* 2019;**119**(9):1539-1545, 10.1055/s-0039-1692423
202. Schunkert H, Boening A, von Scheidt M, Lanig C, Gusmini F, de Waha A, Kuna C, Fach A, Grothusen C, Oberhoffer M, Knosalla C, Walther T, Danner BC, Misfeld M, Zeymer U, Wimmer-Greinecker G, Siepe M, Grubitzsch H, Joost A, Schaefer A, Conradi L, Cremer J, Hamm C, Lange R, Radke PW, Schulz R, Laufer G, Grieshaber P, Pader P, Attmann T, Schmoeckel M, Meyer A, Ziegelhoffer T, Hambrecht R, **Kastrati A**, Sandner SE. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. *Eur Heart J* 2019;**40**(29):2432-2440, 10.1093/eurheartj/ehz185
203. Sager HB, Husser O, Steffens S, Laugwitz KL, Schunkert H, **Kastrati A**, Ndrepepa G, Kessler T. Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction. *J Transl Med* 2019;**17**(1):180, 10.1186/s12967-019-1934-z
204. Rheude T, Pellegrini C, Nunez J, Joner M, Trenkwalder T, Mayr NP, Holdenrieder S, Bodi V, Koenig W, Kasel AM, Schunkert H, **Kastrati A**, Hengstenberg C, Husser O. Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation. *Rev Esp Cardiol (Engl Ed)* 2019;**72**(11):907-915, 10.1016/j.rec.2018.09.006
205. Rheude T, Pellegrini C, Lessmann L, Wiebe J, Mayr NP, Michel J, Trenkwalder T, Kasel AM, Schunkert H, **Kastrati A**, Joner M, Husser O, Hengstenberg C. Prevalence and Clinical Impact of Iron Deficiency in Patients With Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation. *Am J Cardiol* 2019;**124**(9):1442-1448, 10.1016/j.amjcard.2019.07.051
206. Pellegrini C, Rheude T, Trenkwalder T, Mayr NP, Michel J, **Kastrati A**, Schunkert H, Kasel AM, Joner M, Hengstenberg C, Husser O. One-year clinical outcome with a novel self-expanding transcatheter heart valve. *Catheter Cardiovasc Interv* 2019;**94**(6):783-792, 10.1002/ccd.28144
207. Pellegrini C, Rheude T, Trenkwalder T, Mayr NP, Joner M, **Kastrati A**, Schunkert H, Husser O, Hengstenberg C. One year VARC-2-defined clinical outcomes after transcatheter aortic valve implantation with the SAPIEN 3. *Clin Res Cardiol* 2019;**108**(11):1258-1265, 10.1007/s00392-019-01461-7
208. Pellegrini C, Rheude T, Mahr L, Trenkwalder T, Mayr NP, Michel J, Schunkert H, Kasel AM, Joner M, Hengstenberg C, **Kastrati A**, Husser O, Kessler T. Influence of marital status in patients undergoing transcatheter aortic valve implantation. *J Thorac Dis* 2019;**11**(5):1888-1895, 10.21037/jtd.2019.05.19
209. Pellegrini C, Kim WK, Holzamer A, Walther T, Mayr NP, Michel J, Rheude T, Nunez J, Kasel AM, Trenkwalder T, Kaess BM, Joner M, **Kastrati A**, Schunkert H, Hilker M, Mollmann H, Hengstenberg C, Husser O. Multicenter Evaluation of Prosthesis Oversizing of the SAPIEN 3 Transcatheter Heart Valve. Impact on Device Failure and New Pacemaker Implantations. *Rev Esp Cardiol (Engl Ed)* 2019;**72**(8):641-648, 10.1016/j.rec.2018.06.005
210. Pellegrini C, Husser O, Kim WK, Holzamer A, Walther T, Rheude T, Mayr NP, Trenkwalder T, Joner M, Michel J, Chaustre F, **Kastrati A**, Schunkert H, Burgdorf C, Hilker M, Mollmann H, Hengstenberg C. Predictors of Need for Permanent Pacemaker Implantation and Conduction Abnormalities With a Novel Self-expanding Transcatheter Heart Valve. *Rev Esp Cardiol (Engl Ed)* 2019;**72**(2):145-153, 10.1016/j.rec.2018.01.011
211. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, **Kastrati A**, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Group ESCSD. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;**40**(2):87-165, 10.1093/eurheartj/ehy394
212. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA,

- Collet JP, Falk V, Head SJ, Juni P, **Kastrati A**, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. *EuroIntervention* 2019;**14**(14):1435-1534, 10.4244/EIJY19M01_01
213. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, **Kastrati A**, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. [2018 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)]. *G Ital Cardiol (Rome)* 2019;**20**(7-8 Suppl 1):1S-61S, 10.1714/3203.31801
214. Ndrepepa G, Kufner S, Mayer K, Cassese S, Xhepa E, Fusaro M, Hasimi E, Schupke S, Laugwitz KL, Schunkert H, **Kastrati A**. Sex differences in the outcome after percutaneous coronary intervention - A propensity matching analysis. *Cardiovasc Revasc Med* 2019;**20**(2):101-107, 10.1016/j.carrev.2018.05.010
215. Ndrepepa G, **Kastrati A**. High-sensitivity cardiac troponin T in patients with ST-segment elevation myocardial infarction. *J Cardiol* 2019;**73**(4):333-334, 10.1016/j.jjcc.2018.11.002
216. Ndrepepa G, Holdenrieder S, Colleran R, Cassese S, Xhepa E, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease. *Clin Chim Acta* 2019;**496**:55-61, 10.1016/j.cca.2019.06.021
217. Ndrepepa G, Cassese S, Xhepa E, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Association of shock index with short-term and long-term prognosis after ST-segment elevation myocardial infarction. *Coron Artery Dis* 2019;**30**(8):575-583, 10.1097/MCA.0000000000000802
218. Ndrepepa G, Cassese S, Kufner S, Xhepa E, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. *Heart Vessels* 2019;**34**(7):1104-1112, 10.1007/s00380-019-01344-x
219. Ndrepepa G, Cassese S, Hashorva D, Kufner S, Xhepa E, Hasimi E, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Relationship of left ventricular end-diastolic pressure with extent of myocardial ischemia, myocardial salvage and long-term outcome in patients with ST-segment elevation myocardial infarction. *Catheter Cardiovasc Interv* 2019;**93**(5):901-909, 10.1002/ccd.28098
220. Ndrepepa G, Cassese S, Emmer M, Mayer K, Kufner S, Xhepa E, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. *Am J Cardiol* 2019;**123**(2):199-205, 10.1016/j.amjcard.2018.10.007
221. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Dzavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, **Kastrati A**, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. *N Engl J Med* 2019;**381**(21):2032-2042, 10.1056/NEJMoa1908419
222. Kufner S, Schacher N, Ferenc M, Schlundt C, Hoppmann P, Abdel-Wahab M, Mayer K, Fusaro M, Byrne RA, **Kastrati A**. Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. *Catheter Cardiovasc Interv* 2019;**93**(5):912-920, 10.1002/ccd.27979
223. Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, Cassese S, Laugwitz

- KL, Schunkert H, **Kastrati A**, Byrne RA, Investigators I-T. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. *Circulation* 2019;**139**(3):325-333, 10.1161/CIRCULATIONAHA.118.038065
224. Kossmann H, Rischpler C, Hanus F, Nekolla SG, Kunze KP, Gotze K, Goedel A, Sager H, **Kastrati A**, Sinnecker D, Kupatt C, Ibrahim T, Schwaiger M, Laugwitz KL, Dirschinger RJ. Monocyte-platelet aggregates affect local inflammation in patients with acute myocardial infarction. *Int J Cardiol* 2019;**287**:7-12, 10.1016/j.ijcard.2019.04.009
225. Kessler T, Wolf B, Eriksson N, Kofink D, Mahmoodi BK, Rai H, Tragante V, Akerblom A, Becker RC, Bernlochner I, Bopp R, James S, Katus HA, Mayer K, Munz M, Nordio F, O'Donoghue ML, Sager HB, Sibbing D, Solakov L, Storey RF, Wobst J, Asselbergs FW, Byrne RA, Erdmann J, Koenig W, Laugwitz KL, Ten Berg JM, Wallentin L, **Kastrati A**, Schunkert H. Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. *Cardiovasc Res* 2019;**115**(10):1512-1518, 10.1093/cvr/cvz015
226. **Kastrati A**, Kufner S. Progress in Drug-Eluting Stent Technology: Have We Come to the End of the Road? *JACC Cardiovasc Interv* 2019;**12**(17):1661-1664, 10.1016/j.jcin.2019.05.015
227. Hengstenberg C, **Kastrati A**. Genetic testing to guide therapy? Not for ticagrelor! *Eur Heart J* 2019;**40**(24):e1-e3, 10.1093/eurheartj/ehv229
228. Goedel A, Fiedler KA, Mehilli J, Bernlochner I, von Olshausen G, Mayer K, Schupke S, Hoppmann P, Sibbing D, Maeng M, Massberg S, Schunkert H, Laugwitz KL, **Kastrati A**, Sarafoff N. Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. *EuroIntervention* 2019;**15**(8):700-706, 10.4244/EIJ-D-18-00995
229. Byrne RA, Colleran R, **Kastrati A**. Omission of aspirin after ACS or stenting in patients with oral anticoagulation - why have the goalposts moved? *EuroIntervention* 2019;**14**(18):e1793-e1795, 10.4244/EIJV14I18A312
230. Byrne RA, Alfonso F, Schneider S, Maeng M, Wiebe J, Kretov E, Bradaric C, Rai H, Cuesta J, Rivero F, Hoppmann P, Schlichtenmaier J, Christiansen EH, Cassese S, Joner M, Schunkert H, Laugwitz KL, **Kastrati A**. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. *Eur Heart J* 2019;**40**(2):167-176, 10.1093/eurheartj/ehy710
231. Bradaric C, Koppa T, Muller A, Haller B, Ott I, Cassese S, Fusaro M, **Kastrati A**, Laugwitz KL, Ibrahim T. Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery. *EuroIntervention* 2019;**15**(12):e1107-e1114, 10.4244/EIJ-D-19-00187
232. Baquet M, Hoppmann P, Grundmann D, Schmidt W, Kufner S, Theiss HD, Brunner S, Wiebe J, Eickhoff M, Jochheim D, Byrne RA, Laugwitz KL, Schunkert H, Massberg S, **Kastrati A**, Mehilli J. Sex and long-term outcomes after implantation of the Absorb bioresorbable vascular scaffold for treatment of coronary artery disease. *EuroIntervention* 2019;**15**(7):615-622, 10.4244/EIJ-D-18-00603
233. Baber U, Stefanini GG, Giustino G, Stone GW, Leon MB, Sartori S, Aquino M, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, von Birgelen C, Dangas GD, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, **Kastrati A**, Chieffo A, Mehran R. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. *Circ Cardiovasc Interv* 2019;**12**(7):e007734, 10.1161/CIRCINTERVENTIONS.118.007734

234. Xhepa E, **Kastrati A**. Reduction of thrombus burden: a still unmet need in patients with ST-segment elevation myocardial infarction. *Coron Artery Dis* 2018;**29**(3):181-182, 10.1097/MCA.0000000000000584
235. Wustrow I, Sarafoff N, Haller B, Rossner L, Sibbing D, Schupke S, Ibrahim T, Anetsberger A, Schunkert H, Laugwitz KL, **Kastrati A**, Bernlochner I. Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2018;**92**(7):1239-1246, 10.1002/ccd.27678
236. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, **Kastrati A**, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Group ESCSD, Guidelines ESCCfP, Societies ESCNC. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2018;**39**(3):213-260, 10.1093/eurheartj/ehx419
237. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, **Kastrati A**, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Group ESCSD. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Eur J Cardiothorac Surg* 2018;**53**(1):34-78, 10.1093/ejcts/ezx334
238. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, **Kastrati A**, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Rev Esp Cardiol (Engl Ed)* 2018;**71**(1):42, 10.1016/j.rec.2017.11.020
239. Trenkwalder T, Pellegrini C, Holzamer A, Philipp A, Rheude T, Michel J, Reinhard W, Joner M, Kasel AM, **Kastrati A**, Schunkert H, Endemann D, Debl K, Mayr NP, Hilker M, Hengstenberg C, Husser O. Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation: A two-center experience of incidence, outcome and temporal trends from 2010 to 2015. *Catheter Cardiovasc Interv* 2018;**92**(1):149-156, 10.1002/ccd.27385
240. Trenkwalder T, Lahmann AL, Nowicka M, Pellegrini C, Rheude T, Mayr NP, Voss S, Bleiziffer S, Lange R, Joner M, Kasel AM, **Kastrati A**, Schunkert H, Husser O, Hadamitzky M, Hengstenberg C. Incidental findings in multislice computed tomography prior to transcatheter aortic valve implantation: frequency, clinical relevance and outcome. *Int J Cardiovasc Imaging* 2018;**34**(6):985-992, 10.1007/s10554-018-1305-5
241. Steppich B, Schurmann F, Bruskina O, Hadamitzky M, **Kastrati A**, Schunkert H, Fusaro M, Ott I. Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience. *Vasa* 2018;**47**(6):507-512, 10.1024/0301-1526/a000732
242. Shivaraju A, Thilo C, Sawlani N, Ott I, Schunkert H, von Scheidt W, **Kastrati A**, Kasel AM. Aortic Valve Predilatation with a Small Balloon, without Rapid Pacing, prior to Transfemoral Transcatheter Aortic Valve Replacement. *Biomed Res Int* 2018;**2018**:1080597, 10.1155/2018/1080597
243. Shivaraju A, Michel J, Frangieh AH, Ott I, Thilo C, Schunkert H, **Kastrati A**, Leon MB, Dvir D, Kodali S, Bapat V, Guerrero M, Kasel AM. Transcatheter Aortic and Mitral Valve-in-Valve Implantation Using the Edwards Sapien 3 Heart Valve. *J Am Heart Assoc* 2018;**7**(14), 10.1161/JAHA.117.007767
244. Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso A, Anderson CD, Aragam KG, Arking DE, Barnard J, Bartz TM, Benjamin EJ, Bihlmeyer NA, Bis JC, Bloom HL, Boerwinkle E, Bottinger EB, Brody JA, Calkins H,

- Campbell A, Cappola TP, Carlquist J, Chasman DI, Chen LY, Chen YI, Choi EK, Choi SH, Christophersen IE, Chung MK, Cole JW, Conen D, Cook J, Crijs HJ, Cutler MJ, Damrauer SM, Daniels BR, Darbar D, Delgado G, Denny JC, Dichgans M, Dorr M, Dudink EA, Dudley SC, Esa N, Esko T, Eskola M, Fatkin D, Felix SB, Ford I, Franco OH, Geelhoed B, Grewal RP, Gudnason V, Guo X, Gupta N, Gustafsson S, Gutmann R, Hamsten A, Harris TB, Hayward C, Heckbert SR, Hernesniemi J, Hocking LJ, Hofman A, Horimoto A, Huang J, Huang PL, Huffman J, Ingelsson E, Ipek EG, Ito K, Jimenez-Conde J, Johnson R, Jukema JW, Kaab S, Kahonen M, Kamatani Y, Kane JP, **Kastrati A**, Kathiresan S, Katschnig-Winter P, Kavousi M, Kessler T, Kietselaer BL, Kirchhof P, Kleber ME, Knight S, Krieger JE, Kubo M, Launer LJ, Laurikka J, Lehtimaki T, Leineweber K, Lemaitre RN, Li M, Lim HE, Lin HJ, Lin H, Lind L, Lindgren CM, Lokki ML, London B, Loos RJF, Low SK, Lu Y, Lyytikainen LP, Macfarlane PW, Magnusson PK, Mahajan A, Malik R, Mansur AJ, Marcus GM, Margolin L, Margulies KB, Marz W, McManus DD, Melander O, Mohanty S, Montgomery JA, Morley MP, Morris AP, Muller-Nurasyid M, Natale A, Nazarian S, Neumann B, Newton-Cheh C, Niemeijer MN, Nikus K, Nilsson P, Noordam R, Oellers H, Olesen MS, Orho-Melander M, Padmanabhan S, Pak HN, Pare G, Pedersen NL, Pera J, Pereira A, Porteous D, Psaty BM, Pulit SL, Pullinger CR, Rader DJ, Refsgaard L, Ribases M, Ridker PM, Rienstra M, Risch L, Roden DM, Rosand J, Rosenberg MA, Rost N, Rotter JI, Saba S, Sandhu RK, Schnabel RB, Schramm K, Schunkert H, Schurman C, Scott SA, Seppala I, Shaffer C, Shah S, Shalaby AA, Shim J, Shoemaker MB, Siland JE, Sinisalo J, Sinner MF, Slowik A, Smith AV, Smith BH, Smith JG, Smith JD, Smith NL, Soliman EZ, Sotoodehnia N, Stricker BH, Sun A, Sun H, Svendsen JH, Tanaka T, Tanriverdi K, Taylor KD, Teder-Laving M, Teumer A, Theriault S, Trompet S, Tucker NR, Tveit A, Uitterlinden AG, Van Der Harst P, Van Gelder IC, Van Wagoner DR, Verweij N, Vlachopoulou E, Volker U, Wang B, Weeke PE, Weijts B, Weiss R, Weiss S, Wells QS, Wiggins KL, Wong JA, Woo D, Worrall BB, Yang PS, Yao J, Yoneda ZT, Zeller T, Zeng L, Lubitz SA, Lunetta KL, Ellinor PT. Multi-ethnic genome-wide association study for atrial fibrillation. *Nat Genet* 2018;**50**(9):1225-1233, 10.1038/s41588-018-0133-9
245. Rheude T, Pellegrini C, Schmid H, Trenkwalder T, Mayr NP, Joner M, Kasel AM, Holdenrieder S, Nunez J, Sanchis J, Bodi V, Schunkert H, **Kastrati A**, Hengstenberg C, Husser O. Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation. *Am J Cardiol* 2018;**121**(4):461-468, 10.1016/j.amjcard.2017.11.020
246. Rheude T, Pellegrini C, Reinhard W, Trenkwalder T, Koenig W, Mayr NP, Joner M, Nunez J, Holdenrieder S, Schunkert H, **Kastrati A**, Hengstenberg C, Husser O. Determinants of elevated carbohydrate antigen 125 in patients with severe symptomatic aortic valve stenosis referred for transcatheter aortic valve implantation. *Biomarkers* 2018;**23**(3):299-304, 10.1080/1354750X.2018.1423706
247. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, **Kastrati A**, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. [2018 ESC/EACTS Guidelines on myocardial revascularization]. *Kardiol Pol* 2018;**76**(12):1585-1664, 10.5603/KP.2018.0228
248. Ndrepepa G, Kufner S, Hoyos M, Harada Y, Xhepa E, Hieber J, Cassese S, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. *J Cardiol* 2018;**72**(3):220-226, 10.1016/j.jjcc.2018.02.014
249. Ndrepepa G, **Kastrati A**. Rebuttal: Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2018;**92**(3):635-636, 10.1002/ccd.27617

250. Ndrepepa G, **Kastrati A**. Creatine kinase myocardial band - a biomarker to assess prognostically relevant periprocedural myocardial infarction. *Int J Cardiol* 2018;**270**:118-119, 10.1016/j.ijcard.2018.07.077
251. Ndrepepa G, Holdenrieder S, Cassese S, Fusaro M, Xhepa E, Laugwitz KL, Schunkert H, **Kastrati A**. A comparison of gamma-glutamyl transferase and alkaline phosphatase as prognostic markers in patients with coronary heart disease. *Nutr Metab Cardiovasc Dis* 2018;**28**(1):64-70, 10.1016/j.numecd.2017.09.005
252. Ndrepepa G, Colleran R, **Kastrati A**. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. *Clin Chim Acta* 2018;**476**:130-138, 10.1016/j.cca.2017.11.026
253. Ndrepepa G, Colleran R, **Kastrati A**. No-reflow after percutaneous coronary intervention: a correlate of poor outcome in both persistent and transient forms. *EuroIntervention* 2018;**14**(2):139-141, 10.4244/EIJV14I2A21
254. Ndrepepa G, Colleran R, Braun S, Xhepa E, Hieber J, Cassese S, Fusaro M, Kufner S, Laugwitz KL, Schunkert H, **Kastrati A**. Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2018;**91**(2):215-223, 10.1002/ccd.27105
255. Ndrepepa G, Byrne RA, Cassese S, Fusaro M, Colleran R, Hieber J, Laugwitz KL, Schunkert H, **Kastrati A**. Markers of Reperfusion and Long-Term (8-Year) Prognosis after Primary Percutaneous Coronary Intervention. *Am J Cardiol* 2018;**122**(1):39-46, 10.1016/j.amjcard.2018.03.353
256. Muller AM, Langwieser N, Bradaric C, Haller B, Fusaro M, Ott I, von Beckerath N, **Kastrati A**, Laugwitz KL, Ibrahim T. Endovascular Treatment for Steno-Occlusive Iliac Artery Disease: Safety and Long-Term Outcome. *Angiology* 2018;**69**(4):308-315, 10.1177/0003319717720052
257. Mankerious N, Mayer K, Gewalt SM, Helde SM, Ibrahim T, Bott-Flugel L, Laugwitz KL, Schunkert H, **Kastrati A**, Schupke S. Instrumental Sealing of ApsCdvmtI. Comparison of the FemoSeal Vascular Closure Device With Manual Compression After Femoral Artery Puncture - Post-hoc Analysis of a Large-Scale, Randomized Clinical Trial. *J Invasive Cardiol* 2018;**30**(7):235-239,
258. Koskinas KC, Ndrepepa G, Raber L, Karagiannis A, Kufner S, Zanchin T, Hieber J, Hunziker L, Mayer K, Byrne RA, Heg D, Windecker S, **Kastrati A**. Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. *Circ Cardiovasc Interv* 2018;**11**(12):e006752, 10.1161/CIRCINTERVENTIONS.118.006752
259. Koppa T, Tada T, Xhepa E, Kufner S, Byrne RA, Ibrahim T, Laugwitz KL, **Kastrati A**, Joner M. Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. *Int J Cardiol* 2018;**258**:42-49, 10.1016/j.ijcard.2018.01.011
260. Kerkmeijer LS, Claessen BE, Baber U, Sartori S, Chandrasekhar J, Stefanini GG, Stone GW, Steg PG, Chieffo A, Weisz G, Windecker S, Mikhail GW, **Kastrati A**, Morice MC, Dangas GD, de Winter RJ, Mehran R. Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: >From the WIN-DES collaborative patient-level pooled analysis. *Int J Cardiol* 2018;**263**:24-28, 10.1016/j.ijcard.2018.04.047
261. **Kastrati A**, Joner M, Kufner S. What Treatment Should We Dare in Patients With In-Stent Restenosis? *JACC Cardiovasc Interv* 2018;**11**(3):284-286, 10.1016/j.jcin.2017.11.024
262. Joner M, Koppa T, Byrne RA, Castellanos MI, Lewerich J, Novotny J, Guagliumi G, Xhepa E, Adriaenssens T, Godschalk TC, Malik N, Alfonso F, Tada T, Neumann FJ, Desmet W, Ten Berg JM, Gershlick AH, Feldman LJ, Massberg S, **Kastrati A**. Prevention of PI. Neoatherosclerosis in Patients With Coronary Stent Thrombosis: Findings From Optical

- Coherence Tomography Imaging (A Report of the PRESTIGE Consortium). *JACC Cardiovasc Interv* 2018;**11**(14):1340-1350, 10.1016/j.jcin.2018.02.029
263. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, **Kastrati A**, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;**39**(2):119-177, 10.1093/eurheartj/ehx393
264. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, **Kastrati A**, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P. [2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.]. *Kardiol Pol* 2018;**76**(2):229-313, 10.5603/KP.2018.0041
265. Harada Y, Koskinas KC, Ndrepepa G, Raber L, Braun S, Zanchin T, Kufner S, Hunziker L, Byrne RA, Heg D, **Kastrati A**, Windecker S. Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. *Cardiovasc Revasc Med* 2018;**19**(5 Pt A):480-486, 10.1016/j.carrev.2017.11.010
266. Gewalt SM, Helde SM, Ibrahim T, Mayer K, Schmidt R, Bott-Flugel L, Hoppe K, Ott I, Hieber J, Morath T, Byrne RA, Kufner S, Cassese S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, **Kastrati A**, Schupke S, Instrumental Sealing of Arterial Puncture Site CDVMCTI. Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. *Circ Cardiovasc Interv* 2018;**11**(8):e006074, 10.1161/CIRCINTERVENTIONS.117.006074
267. Faggioni M, Baber U, Afshar AE, Giustino G, Sartori S, Sorrentino S, Steg PG, Stefanini GG, Windecker S, Leon MB, Stone GW, Wijns W, Serruys PW, Valgimigli M, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, **Kastrati A**, Chieffo A, Dangas GD, Morice MC, Mehran R. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. *JACC Cardiovasc Interv* 2018;**11**(1):68-76, 10.1016/j.jcin.2017.06.060
268. Colleran R, Kufner S, Mehilli J, Rosenbeiger C, Schupke S, Hoppmann P, Joner M, Mankierious N, Fusaro M, Cassese S, Abdel-Wahab M, Neumann FJ, Richardt G, Ibrahim T, Schunkert H, Laugwitz KL, **Kastrati A**, Byrne RA, Investigators I-C. Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. *J Am Coll Cardiol* 2018;**71**(18):1973-1982, 10.1016/j.jacc.2018.03.456
269. Colleran R, **Kastrati A**. Percutaneous coronary intervention: balloons, stents and scaffolds. *Clin Res Cardiol* 2018;**107**(Suppl 2):55-63, 10.1007/s00392-018-1328-x
270. Colleran R, Joner M, Kufner S, Altevogt F, Neumann FJ, Abdel-Wahab M, Bohner J, Valina C, Richardt G, Zrenner B, Cassese S, Ibrahim T, Laugwitz KL, Schunkert H, **Kastrati A**, Byrne RA, Intracoronary S, Angiographic Results: Optimizing treatment of Drug Eluting Stent In-Stent R, investigators. Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 (ISAR-DESIRE 3 and ISAR-DESIRE 4) trials. *Int J Cardiol* 2018;**252**:57-62, 10.1016/j.ijcard.2017.11.076
271. Chandrasekhar J, Baber U, Sartori S, Stefanini GG, Sarin M, Vogel B, Farhan S, Camenzind E, Leon MB, Stone GW, Serruys PW, Wijns W, Steg PG, Weisz G, Chieffo A, **Kastrati A**, Windecker S, Morice MC, Smits PC, von Birgelen C, Mikhail GW, Itchhaporia D, Mehta L,

- Kim HS, Valgimigli M, Jeger RV, Kimura T, Galatius S, Kandzari D, Dangas G, Mehran R. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. *JACC Cardiovasc Interv* 2018;**11**(1):53-65, 10.1016/j.jcin.2017.11.020
272. Cassese S, Xu B, Habara S, Rittger H, Byrne RA, Waliszewski M, Perez-Vizcayno MJ, Gao R, **Kastrati A**, Alfonso F. Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation. *Rev Esp Cardiol (Engl Ed)* 2018;**71**(8):620-627, 10.1016/j.rec.2017.08.005
273. Cassese S, Xhepa E, Ndrepepa G, Kufner S, Colleran R, Giacoppo D, Koppa T, Mankerious N, Byrne RA, Laugwitz KL, Schunkert H, Fusaro M, **Kastrati A**, Joner M. Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials. *Eur Heart J Cardiovasc Imaging* 2018;**19**(11):1294-1301, 10.1093/ehjci/jex334
274. Cassese S, Ndrepepa G, Byrne RA, Kufner S, Lahmann AL, Mankerious N, Xhepa E, Laugwitz KL, Schunkert H, Fusaro M, **Kastrati A**, Joner M. Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. *EuroIntervention* 2018;**14**(2):224-231, 10.4244/EIJ-D-18-00024
275. Cassese S, Byrne RA, Juni P, Wykrzykowska JJ, Puricel S, Ndrepepa G, Schunkert H, Fusaro M, Cook S, Kimura T, Henriques JPS, Serruys PW, Windecker S, **Kastrati A**. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. *EuroIntervention* 2018;**13**(13):1565-1573, 10.4244/EIJ-D-17-00492
276. Byrne RA, Stefanini GG, Capodanno D, Onuma Y, Baumbach A, Escaned J, Haude M, James S, Joner M, Juni P, **Kastrati A**, Oktay S, Wijns W, Serruys PW, Windecker S. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. *EuroIntervention* 2018;**13**(13):1574-1586, 10.4244/EIJ20170912-01
277. Byrne RA, Stefanini GG, Capodanno D, Onuma Y, Baumbach A, Escaned J, Haude M, James S, Joner M, Juni P, **Kastrati A**, Oktay S, Wijns W, Serruys PW, Windecker S. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. *Eur Heart J* 2018;**39**(18):1591-1601, 10.1093/eurheartj/ehx488
278. Byrne RA, Colleran R, **Kastrati A**. Strengths and Limitations of Real World Data in Patients Treated With Coronary Stents. *Circ Cardiovasc Interv* 2018;**11**(9):e007239, 10.1161/CIRCINTERVENTIONS.118.007239
279. Alushi B, Lauten A, Landmesser U, **Kastrati A**. Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials: response to letter by Zaman et al. *Clin Res Cardiol* 2018;**107**(12):1189-1191, 10.1007/s00392-018-1306-3
280. Alushi B, Lauten A, Cassese S, Colleran R, Schupke S, Rai H, Schunkert H, Meier B, Landmesser U, **Kastrati A**. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials. *Clin Res Cardiol* 2018;**107**(9):788-798, 10.1007/s00392-018-1246-y
281. Abdel-Wahab M, Toelg R, Byrne RA, Geist V, El-Mawardy M, Allali A, Rheude T, Robinson DR, Abdelghani M, Sulimov DS, **Kastrati A**, Richardt G. High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. *Circ Cardiovasc Interv* 2018;**11**(10):e007415, 10.1161/CIRCINTERVENTIONS.118.007415
282. Xhepa E, Tada T, Kufner S, Ndrepepa G, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K,

- Valgimigli M, Tolg R, Cassese S, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, **Kastrati A**. Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials. *Catheter Cardiovasc Interv* 2017;**89**(1):1-10, 10.1002/ccd.26645
283. Wiebe J, Hoppmann P, Colleran R, Kufner S, Valeskini M, Cassese S, Schneider S, Joner M, Schunkert H, Laugwitz KL, **Kastrati A**, Byrne RA. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry. *JACC Cardiovasc Interv* 2017;**10**(12):1222-1229, 10.1016/j.jcin.2017.03.029
284. Wiebe J, Dorr O, Iltad H, Husser O, Liebetau C, Boeder N, Bauer T, Mollmann H, **Kastrati A**, Hamm CW, Nef HM. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison. *JACC Cardiovasc Interv* 2017;**10**(5):477-485, 10.1016/j.jcin.2016.11.034
285. Webb TR, Erdmann J, Stirrups KE, Stitzel NO, Masca NG, Jansen H, Kanoni S, Nelson CP, Ferrario PG, König IR, Eicher JD, Johnson AD, Hamby SE, Betsholtz C, Ruusalepp A, Franzen O, Schadt EE, Björkegren JL, Weeke PE, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kruppa J, Mahajan A, Scott RA, Willenborg C, Braund PS, van Capelleveen JC, Doney AS, Donnelly LA, Asselta R, Merlini PA, Duga S, Marziliano N, Denny JC, Shaffer C, El-Mokhtari NE, Franke A, Heilmann S, Hengstenberg C, Hoffmann P, Holmen OL, Hveem K, Jansson JH, Jockel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, McCarthy MI, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Virtamo J, Nikpay M, Olivieri O, Provost S, AlQarawi A, Robertson NR, Akansansya KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson RD, Stahl E, Müller-Nurasyid M, Strauch K, Varga TV, Waldenberger M, Wellcome Trust Case Control C, Zeng L, Chowdhury R, Salomaa V, Ford I, Jukema JW, Amouyel P, Kontto J, Investigators M, Nordestgaard BG, Ferrières J, Saleheen D, Sattar N, Surendran P, Wagner A, Young R, Howson JM, Butterworth AS, Danesh J, Ardissino D, Bottinger EP, Erbel R, Franks PW, Girelli D, Hall AS, Hovingh GK, **Kastrati A**, Lieb W, Meitinger T, Kraus WE, Shah SH, McPherson R, Orho-Melandar M, Melander O, Metspalu A, Palmer CN, Peters A, Rader DJ, Reilly MP, Loos RJ, Reiner AP, Roden DM, Tardif JC, Thompson JR, Wareham NJ, Watkins H, Willer CJ, Samani NJ, Schunkert H, Deloukas P, Kathiresan S, Myocardial Infarction G, Investigators CAEC. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. *J Am Coll Cardiol* 2017;**69**(7):823-836, 10.1016/j.jacc.2016.11.056
286. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, **Kastrati A**, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]. *Kardiol Pol* 2017;**75**(12):1217-1299, 10.5603/KP.2017.0224
287. Steppich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, **Kastrati A**, Ott I. Regeneration of Vital Myocardium in STSEMIBESI. Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. *BMC Cardiovasc Disord* 2017;**17**(1):38, 10.1186/s12872-016-0464-3
288. Stefanini GG, Byrne RA, Windecker S, **Kastrati A**. State of the art: coronary artery stents - past, present and future. *EuroIntervention* 2017;**13**(6):706-716, 10.4244/EIJ-D-17-00557
289. Rheude T, Pellegrini C, Michel J, Trenkwalder T, Mayr NP, Kessler T, Kasel AM, Schunkert H, **Kastrati A**, Hengstenberg C, Husser O. Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. *Int J Cardiol* 2017;**244**:93-99, 10.1016/j.ijcard.2017.06.024

290. Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Ahn JM, Park SJ, Schupke S, **Kastrati A**, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. *J Am Coll Cardiol* 2017;**69**(16):2011-2022, 10.1016/j.jacc.2017.02.029
291. Ott I, Shivaraju A, Schaffer NR, Frangieh AH, Michel J, Husser O, Hengstenberg C, Mayr P, Colleran R, Pellegrini C, Cassese S, Fusaro M, Schunkert H, **Kastrati A**, Kasel AM. Parallel suture technique with ProGlide: a novel method for management of vascular access during transcatheter aortic valve implantation (TAVI). *EuroIntervention* 2017;**13**(8):928-934, 10.4244/EIJ-D-16-01036
292. Ott I, Cassese S, Groha P, Steppich B, Voll F, Hadamitzky M, Ibrahim T, Kufner S, Dewitz K, Wittmann T, Kasel AM, Laugwitz KL, Schunkert H, **Kastrati A**, Fusaro M. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial. *J Am Heart Assoc* 2017;**6**(7), 10.1161/JAHA.117.006321
293. Ott I, Cassese S, Groha P, Steppich B, Hadamitzky M, Ibrahim T, Kufner S, Dewitz K, Hiendlmayer R, Laugwitz KL, Schunkert H, **Kastrati A**, Fusaro M. Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH). *Circulation* 2017;**135**(23):2218-2226, 10.1161/CIRCULATIONAHA.116.025329
294. Orban M, Orban M, Lesevic H, Braun D, Deseive S, Sonne C, Hutterer L, Grebmer C, Khandoga A, Pache J, Mehilli J, Schunkert H, **Kastrati A**, Hagl C, Bauer A, Massberg S, Boekstegers P, Nabauer M, Ott I, Hausleiter J. Predictors for long-term survival after transcatheter edge-to-edge mitral valve repair. *J Interv Cardiol* 2017;**30**(3):226-233, 10.1111/joic.12376
295. Nelson CP, Goel A, Butterworth AS, Kanoni S, Webb TR, Marouli E, Zeng L, Ntalla I, Lai FY, Hopewell JC, Giannakopoulou O, Jiang T, Hamby SE, Di Angelantonio E, Assimes TL, Bottinger EP, Chambers JC, Clarke R, Palmer CNA, Cubbon RM, Ellinor P, Ermel R, Evangelou E, Franks PW, Grace C, Gu D, Hingorani AD, Howson JMM, Ingelsson E, **Kastrati A**, Kessler T, Kyriakou T, Lehtimäki T, Lu X, Lu Y, Marz W, McPherson R, Metspalu A, Pujades-Rodriguez M, Ruusalepp A, Schadt EE, Schmidt AF, Sweeting MJ, Zalloua PA, AlGhalayini K, Keavney BD, Kooner JS, Loos RJF, Patel RS, Rutter MK, Tomaszewski M, Tzoulaki I, Zeggini E, Erdmann J, Dedoussis G, Björkegren JLM, Consortium E-C, CardioGramplusC4D, group UKBCCCw, Schunkert H, Farrall M, Danesh J, Samani NJ, Watkins H, Deloukas P. Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat Genet* 2017;**49**(9):1385-1391, 10.1038/ng.3913
296. Ndrepepa G, Xhepa E, Colleran R, Braun S, Cassese S, Fusaro M, Laugwitz KL, **Kastrati A**. Gamma-glutamyl transferase and atrial fibrillation in patients with coronary artery disease. *Clin Chim Acta* 2017;**465**:17-21, 10.1016/j.cca.2016.12.003
297. Ndrepepa G, Xhepa E, Braun S, Cassese S, Fusaro M, Schunkert H, **Kastrati A**. Alkaline phosphatase and prognosis in patients with coronary artery disease. *Eur J Clin Invest* 2017;**47**(5):378-387, 10.1111/eci.12752
298. Ndrepepa G, **Kastrati A**. Response to the letter to the editor: Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention. *Clin Biochem* 2017;**50**(18):1328-1329, 10.1016/j.clinbiochem.2017.07.014
299. Ndrepepa G, Holdenrieder S, Xhepa E, Cassese S, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Prognostic value of alkaline phosphatase in patients with acute coronary syndromes. *Clin Biochem* 2017;**50**(15):828-834, 10.1016/j.clinbiochem.2017.05.020
300. Ndrepepa G, Colleran R, **Kastrati A**. Reperfusion injury in ST-segment elevation myocardial

- infarction: the final frontier. *Coron Artery Dis* 2017;**28**(3):253-262, 10.1097/MCA.0000000000000468
301. Ndrepepa G, Colleran R, **Kastrati A**. Reply: Baseline or Post-Procedural High-Sensitivity Troponin? Probably Both. *J Am Coll Cardiol* 2017;**69**(15):1994-1995, 10.1016/j.jacc.2017.01.055
302. Lesevic H, Sonne C, Kasel AM, Breuer D, **Kastrati A**, Schunkert H, Ott I. Implantation of a MitraClip between two previously implanted MitraClips to treat recurrent severe mitral regurgitation. *J Cardiol Cases* 2017;**15**(2):50-52, 10.1016/j.jccase.2016.10.009
303. Lesevic H, Karl M, Braun D, Barthel P, Orban M, Pache J, Hadamitzky M, Mehilli J, Stecher L, Massberg S, Ott I, Schunkert H, **Kastrati A**, Sonne C, Hausleiter J. Long-Term Outcomes After MitraClip Implantation According to the Presence or Absence of EVEREST Inclusion Criteria. *Am J Cardiol* 2017;**119**(8):1255-1261, 10.1016/j.amjcard.2016.12.027
304. Kufner S, Joner M, Schneider S, Tolg R, Zrenner B, Repp J, Starkmann A, Xhepa E, Ibrahim T, Cassese S, Fusaro M, Ott I, Hengstenberg C, Schunkert H, Abdel-Wahab M, Laugwitz KL, **Kastrati A**, Byrne RA, Investigators I-D. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. *JACC Cardiovasc Interv* 2017;**10**(13):1332-1340, 10.1016/j.jcin.2017.04.024
305. Kim YG, Suh JW, Sibbing D, **Kastrati A**, Ko YG, Jang Y, Cho YS, Youn TJ, Chae IH, Choi DJ, Kim HS. A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis. *Am Heart J* 2017;**188**:53-64, 10.1016/j.ahj.2017.03.006
306. Kessler T, Wobst J, Wolf B, Eckhold J, Vilne B, Hollstein R, von Ameln S, Dang TA, Sager HB, Moritz Rumpf P, Aherrahrou R, **Kastrati A**, Bjorkegren JLM, Erdmann J, Lusus AJ, Civelek M, Kaiser FJ, Schunkert H. Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus. *Circulation* 2017;**136**(5):476-489, 10.1161/CIRCULATIONAHA.116.024152
307. Joner M, Giacoppo D, **Kastrati A**. Molecular multimodality imaging: has a long-standing dream come true? *Eur Heart J* 2017;**38**(6):456-458, 10.1093/eurheartj/ehv768
308. Jobs A, Mehta SR, Montalescot G, Vicaut E, Van't Hof AWJ, Badings EA, Neumann FJ, **Kastrati A**, Sciahbasi A, Reuter PG, Lapostolle F, Milosevic A, Stankovic G, Milasinovic D, Vonthein R, Desch S, Thiele H. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. *Lancet* 2017;**390**(10096):737-746, 10.1016/S0140-6736(17)31490-3
309. Iijima R, Ndrepepa G, Kujath V, Harada Y, Kufner S, Schunkert H, Nakamura M, **Kastrati A**. A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis. *Heart Vessels* 2017;**32**(4):376-384, 10.1007/s00380-016-0889-8
310. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevanos JA, Halvorsen S, Hindricks G, **Kastrati A**, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Rev Esp Cardiol (Engl Ed)* 2017;**70**(12):1082, 10.1016/j.rec.2017.11.010
311. Husser O, Nunez J, Burgdorf C, Holzamer A, Templin C, Kessler T, Bodi V, Sanchis J, Pellegrini C, Luchner A, Maier LS, Schmid C, Luscher TF, Schunkert H, **Kastrati A**, Hilker M, Hengstenberg C. Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE. *Rev Esp Cardiol (Engl Ed)* 2017;**70**(3):186-193, 10.1016/j.rec.2016.08.004
312. Husser O, Kim WK, Pellegrini C, Holzamer A, Walther T, Mayr PN, Joner M, Kasel AM, Trenkwalder T, Michel J, Rheude T, **Kastrati A**, Schunkert H, Burgdorf C, Hilker M, Mollmann H, Hengstenberg C. Multicenter Comparison of Novel Self-Expanding Versus

- Balloon-Expandable Transcatheter Heart Valves. *JACC Cardiovasc Interv* 2017;**10**(20):2078-2087, 10.1016/j.jcin.2017.06.026
313. Head SJ, da Costa BR, Beumer B, Stefanini GG, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Kappetein AP, **Kastrati A**, Knuuti J, Kolh P, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Windecker S, Juni P, Sousa-Uva M. Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2017;**52**(2):206-217, 10.1093/ejcts/ezx115
314. Harada Y, Michel J, Lohaus R, Mayer K, Emmer R, Lahmann AL, Colleran R, Giacoppo D, Wolk A, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Wohrle J, Kufner S, Morath T, Ibrahim T, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Mehilli J, Byrne RA, **Kastrati A**, Schulz-Schupke S. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. *Thromb Haemost* 2017;**117**(10):1989-1999, 10.1160/TH17-02-0101
315. Harada Y, Colleran R, Piniack S, Giacoppo D, Michel J, Kufner S, Cassese S, Joner M, Ibrahim T, Laugwitz KL, **Kastrati A**, Byrne RA. Angiographic and clinical outcomes of patients treated with drug-coated balloon angioplasty for in-stent restenosis after coronary bifurcation stenting with a two-stent technique. *EuroIntervention* 2017;**12**(17):2132-2139, 10.4244/EIJ-D-16-00226
316. Godschalk TC, Byrne RA, Adriaenssens T, Malik N, Feldman LJ, Guagliumi G, Alfonso F, Neumann FJ, Trenk D, Joner M, Schulz C, Steg PG, Goodall AH, Wojdyla R, Dudek D, Wykrzykowska JJ, Hlinomaz O, Zaman AG, Curzen N, Dens J, Sinnaeve P, Desmet W, Gershlick AH, **Kastrati A**, Massberg S, Ten Berg JM, Investigators P. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry. *JACC Cardiovasc Interv* 2017;**10**(24):2548-2556, 10.1016/j.jcin.2017.09.019
317. Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, **Kastrati A**, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JAMA Cardiol* 2017;**2**(8):855-862, 10.1001/jamacardio.2017.1978
318. Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S, Dangas G, **Kastrati A**, Mehran R, Tamburino C, Capodanno D. Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. *Circ Cardiovasc Interv* 2017;**10**(5), 10.1161/CIRCINTERVENTIONS.116.004383
319. Giacoppo D, Colleran R, Cassese S, Frangieh AH, Wiebe J, Joner M, Schunkert H, **Kastrati A**, Byrne RA. Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis. *JAMA Cardiol* 2017;**2**(10):1079-1088, 10.1001/jamacardio.2017.2895
320. D'Ascenzo F, Iannaccone M, Saint-Hilary G, Bertaina M, Schulz-Schupke S, Wahn Lee C, Chieffo A, Helft G, Gili S, Barbero U, Biondi Zoccai G, Moretti C, Ugo F, D'Amico M, Garbo R, Stone G, Rettegno S, Omede P, Conrotto F, Templin C, Colombo A, Park SJ, **Kastrati A**, Hildick-Smith D, Gasparini M, Gaita F. Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network

- meta-analysis of 64 randomized controlled trials and 102 735 patients. *Eur Heart J* 2017;**38**(42):3160-3172, 10.1093/eurheartj/ehx437
321. Colleran R, Kufner S, Harada Y, Giacoppo D, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Schneider S, Ibrahim T, Laugwitz KL, **Kastrati A**, Byrne RA, Intracoronary S, Angiographic Results: Test Efficacy of S, Probucoel-Eluting Versus Zotarolimus-Eluting Stents I. Five-year follow-up of polymer-free sirolimus- and probuocol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. *Catheter Cardiovasc Interv* 2017;**89**(3):367-374, 10.1002/ccd.26597
322. Colleran R, **Kastrati A**. Don't think twice: BMS is never nice. *EuroIntervention* 2017;**12**(13):1566-1567, 10.4244/EIJV12I13A258
323. Colleran R, Harada Y, Kufner S, Giacoppo D, Joner M, Cassese S, Ibrahim T, Laugwitz KL, **Kastrati A**, Byrne RA. Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. *EuroIntervention* 2017;**13**(8):962-969, 10.4244/EIJ-D-16-00939
324. Cassese S, Xhepa E, **Kastrati A**. Biodegradable-polymer drug-eluting stents: back to the future? *Heart* 2017;**103**(2):91-92, 10.1136/heartjnl-2016-310213
325. Cassese S, Ndrepepa G, Kufner S, Byrne RA, Giacoppo D, Ott I, Laugwitz KL, Schunkert H, **Kastrati A**, Fusaro M. Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis. *EuroIntervention* 2017;**13**(4):483-489, 10.4244/EIJ-D-16-00735
326. Cassese S, Ndrepepa G, Byrne RA, Kufner S, Xhepa E, de Waha A, Rheude T, Colleran R, Giacoppo D, Harada Y, Laugwitz KL, Schunkert H, Fusaro M, **Kastrati A**. Outcomes of patients treated with durable polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomised trials. *EuroIntervention* 2017;**13**(8):986-993, 10.4244/EIJ-D-16-00871
327. Cassese S, **Kastrati A**, Fusaro M. Bioresorbable vascular scaffolds for complex coronary anatomies: "Icarus' flight" for interventional cardiologists? *Cardiovasc Diagn Ther* 2017;**7**(Suppl 2):S98-S101, 10.21037/cdt.2017.01.10
328. Cassese S, Husser O, **Kastrati A**. Adverse events with bioresorbable vascular scaffolds in routine percutaneous coronary interventions: "coup de theatre" or unfinished play? *J Thorac Dis* 2017;**9**(8):2303-2307, 10.21037/jtd.2017.07.74
329. Byrne RA, Stone GW, Ormiston J, **Kastrati A**. Coronary balloon angioplasty, stents, and scaffolds. *Lancet* 2017;**390**(10096):781-792, 10.1016/S0140-6736(17)31927-X
330. Bradaric C, Eser K, Preuss S, Dommasch M, Wustrow I, Langwieser N, Haller B, Ott I, Fusaro M, Heemann U, Laugwitz KL, **Kastrati A**, Ibrahim T. Drug-eluting stents versus bare metal stents for the prevention of restenosis in patients with renovascular disease. *EuroIntervention* 2017;**13**(2):e248-e255, 10.4244/EIJ-D-16-00697
331. Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, De Cock D, Komukai K, Tada T, Cuesta J, Sirbu V, Feldman LJ, Neumann FJ, Goodall AH, Heestermans T, Buysschaert I, Hlinomaz O, Belmans A, Desmet W, Ten Berg JM, Gershlick AH, Massberg S, **Kastrati A**, Guagliumi G, Byrne RA, Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort I. Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). *Circulation* 2017;**136**(11):1007-1021, 10.1161/CIRCULATIONAHA.117.026788
332. Wiebe J, Hoppmann P, Kufner S, Harada Y, Colleran R, Michel J, Giacoppo D, Schneider S, Cassese S, Ibrahim T, Schunkert H, Laugwitz KL, **Kastrati A**, Byrne RA. Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry. *EuroIntervention* 2016;**12**(2):e137-43, 10.4244/EIY16M05_03
333. Wiebe J, Colleran R, **Kastrati A**. Drug-Eluting Balloons or Stents for Bare-Metal Stent

- Restenosis. *JACC Cardiovasc Interv* 2016;**9**(12):1256-1258, 10.1016/j.jcin.2016.05.007
334. Steppich B, Hadamitzky M, Ibrahim T, Groha P, Schunkert H, Laugwitz KL, **Kastrati A**, Ott I, Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells Study I. Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction. Long-term results of the REVIVAL-2 trial. *Thromb Haemost* 2016;**115**(4):864-8, 10.1160/TH15-07-0589
335. Sinha N, Rai H, Cassese S, Kumar S, Kapoor A, **Kastrati A**. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients. *Coron Artery Dis* 2016;**27**(5):385-90, 10.1097/MCA.0000000000000378
336. Sibbing D, **Kastrati A**, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? *Eur Heart J* 2016;**37**(16):1284-95, 10.1093/eurheartj/ehv717
337. Shivaraju A, Ott I, Cassese S, Bourier F, **Kastrati A**, Thilo C, von Scheidt W, Kasel AM. Fluoroscopic calcification-guided optimal deployment projection during transcatheter aortic valve replacement--"The eye of the pigtail." (Follow the right cusp rule--Part II). *Catheter Cardiovasc Interv* 2016;**87**(5):996-8, 10.1002/ccd.25929
338. Schneider S, Spinner CD, Cassese S, Promny D, Hapfelmeier A, Byrne RA, Baumann M, Jager H, Steinlechner E, Laugwitz KL, **Kastrati A**. Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. *AIDS* 2016;**30**(9):1413-21, 10.1097/QAD.0000000000001063
339. Rohla M, Tentzeris I, Freynhofer MK, Farhan S, Jarai R, Egger F, Weiss TW, Wojta J, Geppert A, **Kastrati A**, Stone GW, Huber K. Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience. *Wien Klin Wochenschr* 2016;**128**(23-24):906-915, 10.1007/s00508-016-1078-6
340. Rischpler C, Dirschinger RJ, Nekolla SG, Kossmann H, Nicolosi S, Hanus F, van Marwick S, Kunze KP, Meinicke A, Gotze K, **Kastrati A**, Langwieser N, Ibrahim T, Nahrendorf M, Schwaiger M, Laugwitz KL. Prospective Evaluation of 18F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome. *Circ Cardiovasc Imaging* 2016;**9**(4):e004316, 10.1161/CIRCIMAGING.115.004316
341. Riegger J, Byrne RA, Joner M, Chandraratne S, Gershlick AH, Ten Berg JM, Adriaenssens T, Guagliumi G, Godschalk TC, Neumann FJ, Trenk D, Feldman LJ, Steg PG, Desmet W, Alfonso F, Goodall AH, Wojdyla R, Dudek D, Philippi V, Opinaldo S, Titova A, Malik N, Cotton J, Jhagroe DA, Heestermans AA, Sinnaeve P, Vermeersch P, Valina C, Schulz C, **Kastrati A**, Massberg S, Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort I. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. *Eur Heart J* 2016;**37**(19):1538-49, 10.1093/eurheartj/ehv419
342. Ndrepepa G, **Kastrati A**. Mechanical strategies to enhance myocardial salvage during primary percutaneous coronary intervention in patients with STEMI. *EuroIntervention* 2016;**12**(3):319-28, 10.4244/EIJV12I3A52
343. Ndrepepa G, **Kastrati A**. Gamma-glutamyl transferase and cardiovascular disease. *Ann Transl Med* 2016;**4**(24):481, 10.21037/atm.2016.12.27
344. Ndrepepa G, Iijima R, Kufner S, Braun S, Cassese S, Byrne RA, Sorges J, Schulz-Schupke S, Hoppmann P, Fussaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. *Am Heart J* 2016;**177**:9-16, 10.1016/j.ahj.2016.03.016
345. Ndrepepa G, Groha P, Lahmann AL, Lohaus R, Cassese S, Schulz-Schupke S, Kufner S, Mayer K, Bernlochner I, Byrne RA, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**.

- Increased bleeding risk during percutaneous coronary interventions by arterial hypertension. *Catheter Cardiovasc Interv* 2016;**88**(2):184-90, 10.1002/ccd.26272
346. Ndrepepa G, Colleran R, Luttert A, Braun S, Cassese S, Kufner S, Hieber J, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. *Clin Biochem* 2016;**49**(15):1127-1132, 10.1016/j.clinbiochem.2016.05.018
347. Ndrepepa G, Colleran R, Braun S, Cassese S, Hieber J, Fusaro M, Kufner S, Ott I, Byrne RA, Husser O, Hengstenberg C, Laugwitz KL, Schunkert H, **Kastrati A**. High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2016;**68**(21):2259-2268, 10.1016/j.jacc.2016.08.059
348. Ndrepepa G, Braun S, Schunkert H, Laugwitz KL, **Kastrati A**. Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. *Clin Chim Acta* 2016;**452**:155-60, 10.1016/j.cca.2015.11.013
349. Ndrepepa G, Braun S, Cassese S, Mayer K, Lohaus R, Lahmann AL, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Prognostic Value of High-sensitivity Troponin T After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. *Rev Esp Cardiol (Engl Ed)* 2016;**69**(8):746-53, 10.1016/j.rec.2016.04.002
350. Ndrepepa G, Braun S, Cassese S, Fusaro M, Laugwitz KL, Schunkert H, **Kastrati A**. Relation of Gamma-Glutamyl Transferase to Cardiovascular Events in Patients With Acute Coronary Syndromes. *Am J Cardiol* 2016;**117**(9):1427-32, 10.1016/j.amjcard.2016.02.004
351. Myocardial Infarction G, Investigators CAEC, Stitzel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, Konig IR, Weeke PE, Webb TR, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kanoni S, Kruppa J, Mahajan A, Scott RA, Willenberg C, Braund PS, van Capelleveen JC, Doney AS, Donnelly LA, Asselta R, Merlini PA, Duga S, Marziliano N, Denny JC, Shaffer CM, El-Mokhtari NE, Franke A, Gottesman O, Heilmann S, Hengstenberg C, Hoffman P, Holmen OL, Hveem K, Jansson JH, Jockel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, McCarthy MI, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Muller-Nurasyid M, Nikpay M, Olivieri O, Lemieux Perreault LP, AlQarawi A, Robertson NR, Akinsanya KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson RD, Stahl E, Strauch K, Varga TV, Waldenberger M, Zeng L, Kraja AT, Liu C, Ehret GB, Newton-Cheh C, Chasman DI, Chowdhury R, Ferrario M, Ford I, Jukema JW, Kee F, Kuulasmaa K, Nordestgaard BG, Perola M, Saleheen D, Sattar N, Surendran P, Tregouet D, Young R, Howson JM, Butterworth AS, Danesh J, Ardissino D, Bottinger EP, Erbel R, Franks PW, Girelli D, Hall AS, Hovingh GK, **Kastrati A**, Lieb W, Meitinger T, Kraus WE, Shah SH, McPherson R, Orho-Melander M, Melander O, Metspalu A, Palmer CN, Peters A, Rader D, Reilly MP, Loos RJ, Reiner AP, Roden DM, Tardif JC, Thompson JR, Wareham NJ, Watkins H, Willer CJ, Kathiresan S, Deloukas P, Samani NJ, Schunkert H. Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. *N Engl J Med* 2016;**374**(12):1134-44, 10.1056/NEJMoa1507652
352. Lohaus R, Michel J, Mayer K, Lahmann AL, Byrne RA, Wolk A, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Wohrle J, Kufner S, Morath T, Ibrahim T, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Mehilli J, **Kastrati A**, Schulz-Schupke S. Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. *Sci Rep* 2016;**6**:33054, 10.1038/srep33054
353. Lansky AJ, **Kastrati A**, Edelman ER, Parise H, Ng VG, Ormiston J, Wijns W, Byrne RA. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). *Am J Cardiol* 2016;**117**(4):532-538, 10.1016/j.amjcard.2015.11.044
354. Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Rheude T,

- Ibrahim T, Massberg S, Laugwitz KL, **Kastrati A**, Byrne RA, Investigators I-T-. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. *JACC Cardiovasc Interv* 2016;**9**(8):784-792, 10.1016/j.jcin.2016.01.009
355. Kufner S, Cassese S, Ndrepepa G, **Kastrati A**, Fusaro M. Diagnosis and management of intramyocardial hematoma after coronary artery perforation: case studies of the Deutsches Herzzentrum Munchen. *Coron Artery Dis* 2016;**27**(4):327-30, 10.1097/MCA.0000000000000356
356. Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hoppmann P, Schneider S, Laugwitz KL, Schunkert H, **Kastrati A**, Intracoronary S, Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents I. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. *EuroIntervention* 2016;**11**(12):1372-9, 10.4244/EIJY14M11_02
357. **Kastrati A**, Colleran R, Ndrepepa G. Cardiogenic Shock: How Long Does the Storm Last? *J Am Coll Cardiol* 2016;**67**(7):748-50, 10.1016/j.jacc.2015.12.004
358. Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Kasel AM, **Kastrati A**, Schunkert H, Hengstenberg C. Predictors of Permanent Pacemaker Implantations and New-Onset Conduction Abnormalities With the SAPIEN 3 Balloon-Expandable Transcatheter Heart Valve. *JACC Cardiovasc Interv* 2016;**9**(3):244-254, 10.1016/j.jcin.2015.09.036
359. Husser O, Kessler T, Burgdorf C, Templin C, Pellegrini C, Schneider S, Kasel AM, **Kastrati A**, Schunkert H, Hengstenberg C. Conduction Abnormalities and Pacemaker Implantations After SAPIEN 3 Vs SAPIEN XT Prosthesis Aortic Valve Implantation. *Rev Esp Cardiol (Engl Ed)* 2016;**69**(2):141-8, 10.1016/j.rec.2015.06.024
360. Hoppmann P, Kufner S, Cassese S, Wiebe J, Schneider S, Pinieck S, Scheler L, Bernlochner I, Joner M, Schunkert H, Laugwitz KL, **Kastrati A**, Byrne RA. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. *Catheter Cardiovasc Interv* 2016;**87**(5):822-9, 10.1002/ccd.26346
361. Harada Y, Michel J, Koenig W, Rheude T, Colleran R, Giacoppo D, **Kastrati A**, Byrne RA. Prognostic Value of Cardiac Troponin T and Sex in Patients Undergoing Elective Percutaneous Coronary Intervention. *J Am Heart Assoc* 2016;**5**(12), 10.1161/JAHA.116.004464
362. Harada Y, **Kastrati A**. Interventional cardiology: Polymer-free drug-eluting stents - a safe and effective option for ACS. *Nat Rev Cardiol* 2016;**13**(8):447-8, 10.1038/nrcardio.2016.110
363. Harada Y, Colleran R, Kufner S, Giacoppo D, Rheude T, Michel J, Cassese S, Ibrahim T, Laugwitz KL, **Kastrati A**, Byrne RA, Intracoronary S, Angiographic Results: Test Efficacy of S, Probucol, Zotarolimus- Eluting Stents I. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. *Cardiovasc Diabetol* 2016;**15**(1):124, 10.1186/s12933-016-0429-y
364. Guha Roy A, Conjeti S, Carlier SG, Dutta PK, **Kastrati A**, Laine AF, Navab N, Katouzian A, Sheet D. Lumen Segmentation in Intravascular Optical Coherence Tomography Using Backscattering Tracked and Initialized Random Walks. *IEEE J Biomed Health Inform* 2016;**20**(2):606-14, 10.1109/JBHI.2015.2403713
365. Giustino G, Mastoris I, Baber U, Sartori S, Stone GW, Leon MB, Serruys PW, **Kastrati A**, Windecker S, Valgimigli M, Dangas GD, Von Birgelen C, Smits PC, Kandzari D, Galatius S, Wijns W, Steg PG, Stefanini GG, Aquino M, Morice MC, Camenzind E, Weisz G, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Chieffo A, Mehran R. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing

- Percutaneous Coronary Intervention With Drug-Eluting Stents: >From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JACC Cardiovasc Interv* 2016;**9**(18):1890-901, 10.1016/j.jcin.2016.06.022
366. Giustino G, Baber U, Salianski O, Sartori S, Stone GW, Leon MB, Aquino M, Stefanini GG, Steg PG, Windecker S, M OD, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Dangas GD, Cha JY, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, **Kastrati A**, Genereux P, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. *Circ Cardiovasc Interv* 2016;**9**(1):e002995, 10.1161/CIRCINTERVENTIONS.115.002995
367. Giustino G, Baber U, Aquino M, Sartori S, Stone GW, Leon MB, Genereux P, Dangas GD, Chandrasekhar J, Kimura T, Salianski O, Stefanini GG, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Saporito R, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, **Kastrati A**, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. *JACC Cardiovasc Interv* 2016;**9**(7):674-84, 10.1016/j.jcin.2015.12.013
368. Giacoppo D, **Kastrati A**. Optimal periprocedural antithrombotic therapy in percutaneous coronary intervention: Between a rock and a hard place? *Cardiovasc Revasc Med* 2016;**17**(8):491-493, 10.1016/j.carrev.2016.11.007
369. Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, **Kastrati A**, Byrne RA. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. *JACC Cardiovasc Interv* 2016;**9**(16):1731-42, 10.1016/j.jcin.2016.06.008
370. Fiedler KA, Ndrepepa G, Schulz S, Floh S, Hoppmann P, Kufner S, Bernlochner I, Byrne RA, Schunkert H, Laugwitz KL, **Kastrati A**. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. *EuroIntervention* 2016;**11**(11):e1275-82, 10.4244/EIJV11I11A249
371. de Waha A, Sandner S, von Scheidt M, Boening A, Koch-Buettner K, Hammel D, Hambrecht R, Danner BC, Schondube FA, Goerlach G, Fischlein T, Schmoeckel M, Oberhoffer M, Schulz R, Walther T, Ziegelhoffer T, Knosalla C, Schonrath F, Beyersdorf F, Siepe M, Attmann T, Misfeld M, Mohr FW, Sievers HH, Joost A, Putman LM, Laufer G, Hamm C, Zeymer U, **Kastrati A**, Radke PW, Lange R, Cremer J, Schunkert H. A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial. *Am Heart J* 2016;**179**:69-76, 10.1016/j.ahj.2016.05.017
372. Colleran R, Byrne RA, **Kastrati A**. Bifurcation intervention with a two-stent strategy: can one size fit all? *Eur Heart J* 2016;**37**(45):3406-3408, 10.1093/eurheartj/ehw440
373. Cassese S, Ndrepepa G, Liistro F, Fanelli F, Kufner S, Ott I, Laugwitz KL, Schunkert H, **Kastrati A**, Fusaro M. Drug-Coated Balloons for Revascularization of Infrapopliteal Arteries: A Meta-Analysis of Randomized Trials. *JACC Cardiovasc Interv* 2016;**9**(10):1072-80, 10.1016/j.jcin.2016.02.011
374. Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tolg R, Fusaro M, Schunkert H, Laugwitz KL, Mehili J, **Kastrati A**. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. *Clin Res Cardiol* 2016;**105**(7):575-84, 10.1007/s00392-015-0953-x

375. Cassese S, Kufner S, **Kastrati A**. Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm. *J Thorac Dis* 2016;**8**(10):E1413-E1415, 10.21037/jtd.2016.10.70
376. Cassese S, **Kastrati A**. Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism. *J Am Coll Cardiol* 2016;**67**(8):932-935, 10.1016/j.jacc.2015.12.020
377. Cassese S, **Kastrati A**. Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply. *Lancet* 2016;**387**(10031):1904, 10.1016/S0140-6736(16)30427-5
378. Cassese S, Hoppmann P, Kufner S, Byrne RA, Wiebe J, Colleran R, Giacoppo D, Harada Y, Laugwitz KL, Schunkert H, Fusaro M, **Kastrati A**. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents. *Circ Cardiovasc Interv* 2016;**9**(8), 10.1161/CIRCINTERVENTIONS.116.003698
379. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Schunkert H, Fusaro M, Kimura T, **Kastrati A**. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. *Lancet* 2016;**387**(10018):537-544, 10.1016/S0140-6736(15)00979-4
380. Byrne RA, **Kastrati A**. Disappearing scaffolds, dissolving expectations. *Lancet* 2016;**388**(10059):2451-2452, 10.1016/S0140-6736(16)32068-2
381. Braun D, Knipper A, Orban M, Sibbing D, Petzold T, Braun S, Schulz S, Hausleiter J, **Kastrati A**, Mehilli J, Massberg S. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). *Thromb Res* 2016;**137**:72-78, 10.1016/j.thromres.2015.11.016
382. Bernlochner I, Mayer K, Orban M, Morath T, Jaitner J, Rossner L, Gross L, Laugwitz KL, **Kastrati A**, Sibbing D. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. *Platelets* 2016;**27**(8):796-804, 10.1080/09537104.2016.1190007
383. Bernlochner I, Jaitner J, Fries V, Dommasch M, Mayer K, Ott I, Langwieser N, Fusaro M, Laugwitz KL, **Kastrati A**, Ibrahim T. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. *Vasa* 2016;**45**(2):155-61, 10.1024/0301-1526/a000510
384. Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG, Windecker S, Leon MB, Wijns W, Serruys PW, Valgimigli M, Stone GW, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, **Kastrati A**, Chieffo A, Mehran R. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. *JACC Cardiovasc Interv* 2016;**9**(1):28-38, 10.1016/j.jcin.2015.09.023
385. Baber U, Dangas G, Cohen DJ, Gibson CM, Mehta SR, Angiolillo DJ, Pocock SJ, Krucoff MW, **Kastrati A**, Ohman EM, Steg PG, Badimon J, Zafar MU, Chandrasekhar J, Sartori S, Aquino M, Mehran R. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. *Am Heart J* 2016;**182**:125-134, 10.1016/j.ahj.2016.09.006
386. Alfonso F, Cuesta J, Bastante T, Rivero F, Garcia-Guimaraes M, Alvarado T, Benedicto A, Cortese B, Byrne R, **Kastrati A**. Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion? *J Thorac Dis* 2016;**8**(6):E417-23, 10.21037/jtd.2016.03.75
387. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, **Kastrati A**, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. *EuroIntervention* 2015;**10**(9):1024-94, 10.4244/EIJY14M09_01
388. Watanabe H, Morimoto T, Natsuaki M, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K,

- Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, **Kastrati A**, Kimura T, investigators CR-KPCrc-. Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. *PLoS One* 2015;**10**(4):e0124314, 10.1371/journal.pone.0124314
389. StephanWindecker, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, **Kastrati A**, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. *Rev Esp Cardiol (Engl Ed)* 2015;**68**(2):144, 10.1016/j.rec.2014.12.006
390. Stamatielopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, Gatsiou A, Sopova K, Kotakos C, Varounis C, Tellis CC, Kastritis E, Alevizaki M, Tselepis AD, Alexopoulos P, Laske C, Keller T, **Kastrati A**, Dimmeler S, Zeiher AM, Stellos K. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. *J Am Coll Cardiol* 2015;**65**(9):904-16, 10.1016/j.jacc.2014.12.035
391. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, Byrne RA, **Kastrati A**, Meier B, Salanti G, Juni P, Windecker S. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 2015;**386**(9994):655-64, 10.1016/S0140-6736(15)60657-2
392. Shivaraju A, Thilo C, Ott I, Mayr PN, Schunkert H, von Scheidt W, Thoenes M, Byrne R, **Kastrati A**, Kasel AM. Tools and Techniques - Clinical: Fluoroscopic balloon sizing of the aortic annulus before transcatheter aortic valve replacement (TAVR) - follow the "right cusp rule". *EuroIntervention* 2015;**11**(7):840-2, 10.4244/EIJV11I7A170
393. Shivaraju A, Kodali S, Thilo C, Ott I, Schunkert H, von Scheidt W, Leon MB, **Kastrati A**, Kasel AM. Overexpansion of the SAPIEN 3 Transcatheter Heart Valve: A Feasibility Study. *JACC Cardiovasc Interv* 2015;**8**(15):2041-2043, 10.1016/j.jcin.2015.10.006
394. Schulz-Schupke S, **Kastrati A**, Instrumental Sealing of Arterial Puncture Site CDvMCTI. Assessing the benefit of vascular closure devices after femoral artery puncture--reply. *JAMA* 2015;**313**(8):855-6, 10.1001/jama.2015.427
395. Schulz-Schupke S, **Kastrati A**. Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out. *Rev Esp Cardiol (Engl Ed)* 2015;**68**(10):827-9, 10.1016/j.rec.2015.03.015
396. Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, Wöhrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schomig A, Mehilli J, **Kastrati A**, Intracoronary S, Antithrombotic Regimen S, Investigators EFoMDATAD-EST. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. *Eur Heart J* 2015;**36**(20):1252-63, 10.1093/eurheartj/ehu523
397. Schneider S, Koch W, Hoppmann P, Ubrich R, Kemmner S, Steinlechner E, Heemann U, Laugwitz KL, **Kastrati A**, Baumann M. Association of Toll-like receptor 4 polymorphism with age-dependent systolic blood pressure increase in patients with coronary artery disease. *Immun Ageing* 2015;**12**:4, 10.1186/s12979-015-0031-2
398. Schneider S, Hoppmann P, Koch W, Kemmner S, Schmaderer C, Renders L, **Kastrati A**, Laugwitz KL, Heemann U, Baumann M. Obesity-associated hypertension is ameliorated in patients with TLR4 single nucleotide polymorphism (SNP) rs4986790. *J Inflamm (Lond)*

- 2015;**12**:57, 10.1186/s12950-015-0100-5
399. Sarafoff N, Byrne RA, Mehilli J, Sibbing D, Kristensen SD, Laugwitz KL, Maeng M, **Kastrati A**. Reply: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. *J Am Coll Cardiol* 2015;**66**(9):1089-90, 10.1016/j.jacc.2015.06.1312
400. Sarafoff N, Byrne RA, Mehilli J, Sibbing D, Kristensen SD, Laugwitz KL, Maeng M, **Kastrati A**. Reply: Duration of Triple Therapy: A Clinical Question Yet to Be Answered. *J Am Coll Cardiol* 2015;**66**(20):2266-2267, 10.1016/j.jacc.2015.08.886
401. Polsterl S, Singh M, Katouzian A, Navab N, **Kastrati A**, Ladic L, Kamen A. Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects. *BMC Med Inform Decis Mak* 2015;**15**:9, 10.1186/s12911-015-0131-0
402. Ott I, Greenbaum AB, Schunkert H, **Kastrati A**, Kasel M. First use of an expandable sheath and transcaval access for transcatheter Edwards SAPIEN 3 aortic valve implantation. *EuroIntervention* 2015;**11**(7):782-4, 10.4244/EIJY15M05_08
403. Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, Kutys R, Xhepa E, **Kastrati A**, Virmani R, Joner M. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. *Eur Heart J* 2015;**36**(32):2147-59, 10.1093/eurheartj/ehv205
404. Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S, Schulz S, Hoppmann P, Hausleiter J, Tiroch K, Mehilli J, Schunkert H, Massberg S, Laugwitz KL, Sibbing D, **Kastrati A**. The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. *Thromb Res* 2015;**136**(1):87-93, 10.1016/j.thromres.2015.04.029
405. Ndrepepa G, Stephan T, Fiedler KA, Guerra E, Kufner S, **Kastrati A**. Procedure-related bleeding in elective percutaneous coronary interventions. *Eur J Clin Invest* 2015;**45**(3):263-73, 10.1111/eci.12408
406. Ndrepepa G, **Kastrati A**. Minimising bleeding during percutaneous coronary intervention. *BMJ* 2015;**350**:h1395, 10.1136/bmj.h1395
407. Ndrepepa G, **Kastrati A**. Activated clotting time during percutaneous coronary intervention: a test for all seasons or a mind tranquilizer? *Circ Cardiovasc Interv* 2015;**8**(4), 10.1161/CIRCINTERVENTIONS.115.002576
408. Ndrepepa G, Guerra E, Schulz S, Fusaro M, Cassese S, **Kastrati A**. Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. *J Thromb Thrombolysis* 2015;**39**(1):35-42, 10.1007/s11239-014-1084-3
409. Ndrepepa G, Fusaro M, Cassese S, Guerra E, Schunkert H, **Kastrati A**. Relation of body mass index to bleeding during percutaneous coronary interventions. *Am J Cardiol* 2015;**115**(4):434-40, 10.1016/j.amjcard.2014.11.022
410. Ndrepepa G, Braun S, Mayer K, Cassese S, Fusaro M, Byrne RA, Hoppmann P, Schunkert H, Laugwitz KL, **Kastrati A**. Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. *Metabolism* 2015;**64**(10):1308-15, 10.1016/j.metabol.2015.07.009
411. Mayer K, Orban M, Bernlochner I, Braun S, Schulz S, Gross L, Hadamitzky M, Schunkert H, Laugwitz KL, Massberg S, **Kastrati A**, Sibbing D. Predictors of antiplatelet response to prasugrel during maintenance treatment. *Platelets* 2015;**26**(1):53-8, 10.3109/09537104.2013.863857
412. Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, Cala L, Hoppmann P, Schunkert H, Laugwitz KL, **Kastrati A**, Sibbing D. Reply: Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry. *J Am Coll Cardiol* 2015;**65**(19):2154, 10.1016/j.jacc.2015.02.067
413. Martischnig AM, Mehilli J, Pollak J, Petzold T, Fiedler AK, Mayer K, Schulz-Schupke S,

- Sibbing D, Massberg S, **Kastrati A**, Sarafoff N. Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). *Biomed Res Int* 2015;**2015**:798486, 10.1155/2015/798486
414. Lesevic H, Sonne C, Braun D, Orban M, Pache J, **Kastrati A**, Schomig A, Mehilli J, Barthel P, Ott I, Sack G, Massberg S, Hausleiter J. Acute and Midterm Outcome After MitraClip Therapy in Patients With Severe Mitral Regurgitation and Left Ventricular Dysfunction. *Am J Cardiol* 2015;**116**(5):749-56, 10.1016/j.amjcard.2015.05.048
415. Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schupke S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, **Kastrati A**, Byrne RA, Investigators I-D. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. *JACC Cardiovasc Interv* 2015;**8**(7):877-84, 10.1016/j.jcin.2015.01.031
416. Kufner S, Cassese S, Groha P, Byrne RA, Schunkert H, **Kastrati A**, Ott I, Fusaro M. Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. *Cardiovasc Revasc Med* 2015;**16**(3):156-62, 10.1016/j.carrev.2015.02.007
417. Kronzon I, Jelnin V, Ruiz CE, Saric M, Williams MR, Kasel AM, Shivaraju A, Colombo A, **Kastrati A**. Optimal imaging for guiding TAVR: transesophageal or transthoracic echocardiography, or just fluoroscopy? *JACC Cardiovasc Imaging* 2015;**8**(3):361-370, 10.1016/j.jcmg.2015.01.003
418. Kasel AM, Shivaraju A, von Scheidt W, **Kastrati A**, Thilo C. Anatomic guided crossing of a stenotic aortic valve under fluoroscopy: "right cusp rule, part III". *JACC Cardiovasc Interv* 2015;**8**(1 Pt A):119-20, 10.1016/j.jcin.2014.10.009
419. Jochheim D, Abdel-Wahab M, Mehilli J, Ellert J, Wubken-Kleinfeld N, El-Mawardy M, Pache J, Massberg S, **Kastrati A**, Richardt G. Significant aortic regurgitation after transfemoral aortic valve implantation: patients' gender as independent risk factor. *Minerva Cardioangiolog* 2015;**63**(5):371-9,
420. Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Ott I, Kasel AM, Schunkert H, **Kastrati A**, Hengstenberg C. Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve: A Single-Center Experience. *JACC Cardiovasc Interv* 2015;**8**(14):1809-16, 10.1016/j.jcin.2015.08.014
421. Giustino G, Baber U, Stefanini GG, Aquino M, Stone GW, Sartori S, Steg PG, Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice MC, Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C, Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, **Kastrati A**, Chieffo A, Mehran R. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. *Am J Cardiol* 2015;**116**(6):845-52, 10.1016/j.amjcard.2015.06.010
422. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, **Kastrati A**, Sarafoff N. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. *J Am Coll Cardiol* 2015;**65**(16):1619-1629, 10.1016/j.jacc.2015.02.050
423. de Waha A, King LA, Stefanini GG, Byrne RA, Serruys PW, Meier B, Juni P, **Kastrati A**, Windecker S. Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. *EuroIntervention* 2015;**10**(12):1425-31, 10.4244/EIJV10I12A247
424. Cassese S, Ndrepepa G, King LA, Nerad M, Schunkert H, **Kastrati A**, Ott I, Fusaro M. Proximal occlusion versus distal filter for cerebral protection during carotid stenting: updated

- meta-analysis of randomised and observational MRI studies. *EuroIntervention* 2015;**11**(2):238-46, 10.4244/EIJY15M03_01
425. Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A, Ibrahim T, Ott I, Fusaro M, Schunkert H, Laugwitz KL, **Kastrati A**. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. *Eur Heart J* 2015;**36**(2):94-9, 10.1093/eurheartj/ehu383
426. Cassese S, Byrne RA, Ndrepepa G, Schunkert H, Fusaro M, **Kastrati A**. Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. *Clin Res Cardiol* 2015;**104**(10):887-901, 10.1007/s00392-015-0860-1
427. Cassese S, Byrne RA, Laugwitz KL, Schunkert H, Berger PB, **Kastrati A**. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. *EuroIntervention* 2015;**11**(2):196-203, 10.4244/EIJY14M08_01
428. Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M, Oktay S, Juni P, **Kastrati A**, Sianos G, Stefanini GG, Wijns W, Windecker S. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. *Eur Heart J* 2015;**36**(38):2608-20, 10.1093/eurheartj/ehv203
429. Byrne RA, **Kastrati A**. Bioresorbable drug-eluting stents: an immature technology in need of mature application. *JACC Cardiovasc Interv* 2015;**8**(1 Pt B):198-200, 10.1016/j.jcin.2014.11.010
430. Byrne RA, **Kastrati A**. Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. *Eur Heart J* 2015;**36**(20):1212-5, 10.1093/eurheartj/ehv062
431. Byrne RA, Joner M, **Kastrati A**. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. *Eur Heart J* 2015;**36**(47):3320-31, 10.1093/eurheartj/ehv511
432. Bradaric C, Kuhs K, Groha P, Dommasch M, Langwieser N, Haller B, Ott I, Fusaro M, Theiss W, von Beckerath N, **Kastrati A**, Laugwitz KL, Ibrahim T. Endovascular therapy for steno-occlusive subclavian and innominate artery disease. *Circ J* 2015;**79**(3):537-43, 10.1253/circj.CJ-14-0855
433. Bernlochner I, Goedel A, Plischke C, Schupke S, Haller B, Schulz C, Mayer K, Morath T, Braun S, Schunkert H, Siess W, **Kastrati A**, Laugwitz KL. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. *Eur Heart J* 2015;**36**(45):3202-10, 10.1093/eurheartj/ehv326
434. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, **Kastrati A**, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J* 2015;**36**(27):1762-71, 10.1093/eurheartj/ehv104
435. Xhepa E, Tada T, Cassese S, King L, Ott I, Fusaro M, **Kastrati A**, Byrne RA. Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. *Indian Heart J* 2014;**66**(3):345-9, 10.1016/j.ihj.2014.05.003
436. Xhepa E, Byrne RA, Schulz S, Helde S, Gewalt S, Cassese S, Linhardt M, Ibrahim T, Mehilli J, Hoppe K, Grupp K, Kufner S, Bottiger C, Hoppmann P, Burgdorf C, Fusaro M, Ott I, Schneider S, Hengstenberg C, Schunkert H, Laugwitz KL, **Kastrati A**, investigators I-C. Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial. *EuroIntervention* 2014;**10**(2):198-203, 10.4244/EIJV10I2A33

437. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Siletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, **Kastrati A**, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Juni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ* 2014;**348**:g3859, 10.1136/bmj.g3859
438. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, **Kastrati A**, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Grupa Robocza Europejskiego Towarzystwa K, Europejskie Stowarzyszenie Chirurgii Serca i Klatki Piersiowej do spraw rewaskularyzacji miesnia s, European Association for Percutaneous Cardiovascular I. [2014 ESC/EACTS Guidelines on myocardial revascularization]. *Kardiol Pol* 2014;**72**(12):1253-379, 10.5603/KP.2014.0224
439. Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, **Kastrati A**, Investigators I-LMS. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease. *JACC Cardiovasc Interv* 2014;**7**(1):29-36, 10.1016/j.jcin.2013.08.013
440. Tada T, **Kastrati A**, Byrne RA, Schuster T, Cuni R, King LA, Cassese S, Joner M, Pache J, Massberg S, Schomig A, Mehilli J. Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. *Int J Cardiovasc Imaging* 2014;**30**(3):495-504, 10.1007/s10554-014-0376-1
441. Shivaraju A, Ott I, **Kastrati A**, Kasel AM. Valve-in-valve transfemoral TAVR: Sapien 3 valve within a failed core valve bioprosthesis. *Eur Heart J* 2014;**35**(38):2684, 10.1093/eurheartj/ehu266
442. Schulz-Schupke S, Helde S, Gewalt S, Ibrahim T, Linhardt M, Haas K, Hoppe K, Bottiger C, Groha P, Bradaric C, Schmidt R, Bott-Flugel L, Ott I, Goedel J, Byrne RA, Schneider S, Burgdorf C, Morath T, Kufner S, Joner M, Cassese S, Hoppmann P, Hengstenberg C, Pache J, Fusaro M, Massberg S, Mehilli J, Schunkert H, Laugwitz KL, **Kastrati A**, Instrumental Sealing of Arterial Puncture Site CDvMCTI. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. *JAMA* 2014;**312**(19):1981-7, 10.1001/jama.2014.15305
443. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Tolg R, Anette Fiedler K, Abdel-Wahab M, Kufner S, Schneider S, Schunkert H, Ibrahim T, Mehilli J, **Kastrati A**, Bavarian Reperfusion Alternatives Evaluation I. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. *Eur Heart J* 2014;**35**(34):2285-94, 10.1093/eurheartj/ehu182
444. Schulz S, Richardt G, Laugwitz KL, Mehran R, Gershlick AH, Morath T, Mayer K, Neudecker J, Tolg R, Ibrahim T, Hauschke D, Braun D, Schunkert H, **Kastrati A**, Mehilli J, Bavarian Reperfusion Alternatives Evaluation I. Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. *Clin Cardiol* 2014;**37**(5):270-6, 10.1002/clc.22268
445. Schulz S, Angiolillo DJ, Antoniucci D, Bernlochner I, Hamm C, Jaitner J, Laugwitz KL, Mayer K, von Merzljak B, Morath T, Neumann FJ, Richardt G, Ruf J, Schomig G, Schühlen H, Schunkert H, **Kastrati A**, Intracoronary S, Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 Trial I. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. *J Cardiovasc Transl Res* 2014;**7**(1):91-100, 10.1007/s12265-013-9527-3

446. Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S, Schulz S, Hoppmann P, Hausleiter J, Tiroch K, Mehilli J, Schunkert H, Massberg S, Laugwitz KL, Sibbing D, **Kastrati A**. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. *Thromb Haemost* 2014;**112**(6):1190-7, 10.1160/TH14-06-0489
447. Ndrepepa G, Schulz S, Neumann FJ, Laugwitz KL, Richardt G, Byrne RA, Pohler A, **Kastrati A**, Pache J. Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. *EuroIntervention* 2014;**10**(1):83-9, 10.4244/EIJV10I1A14
448. Ndrepepa G, Neumann FJ, Schulz S, Fusaro M, Cassese S, Byrne RA, Richardt G, Laugwitz KL, **Kastrati A**. Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. *Catheter Cardiovasc Interv* 2014;**83**(2):182-9, 10.1002/ccd.25189
449. Ndrepepa G, Neumann FJ, Cassese S, Fusaro M, Ott I, Schulz S, Hoppmann P, Richardt G, Laugwitz KL, Schunkert H, **Kastrati A**. Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. *Clin Res Cardiol* 2014;**103**(1):49-56, 10.1007/s00392-013-0622-x
450. Ndrepepa G, **Kastrati A**. Bleeding complications in patients undergoing percutaneous coronary interventions: current status and perspective. *Coron Artery Dis* 2014;**25**(3):247-57, 10.1097/MCA.0000000000000096
451. Ndrepepa G, Guerra E, Schulz S, Hoppmann P, Laugwitz KL, **Kastrati A**. Correlates of poor outcome among patients with bleeding after coronary interventions. *Coron Artery Dis* 2014;**25**(6):456-62, 10.1097/MCA.0000000000000126
452. Ndrepepa G, Braun S, Tada T, King L, Cassese S, Fusaro M, Keta D, **Kastrati A**, Schmidt R. Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. *Indian J Med Res* 2014;**140**(3):392-400,
453. Ndrepepa G, Braun S, Tada T, Guerra E, Schunkert H, Laugwitz KL, **Kastrati A**. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. *Cardiovasc Revasc Med* 2014;**15**(3):131-6, 10.1016/j.carrev.2014.02.003
454. Myocardial Infarction Genetics Consortium I, Stitzel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, Konig I, Asselta R, Merlini PA, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, **Kastrati A**, Laugwitz KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O'Donnell CJ, Abecasis G, Sunaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S. Inactivating mutations in NPC1L1 and protection from coronary heart disease. *N Engl J Med* 2014;**371**(22):2072-82, 10.1056/NEJMoa1405386
455. Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, **Kastrati A**, Sibbing D. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. *Thromb Haemost* 2014;**112**(2):342-51, 10.1160/TH13-10-0874
456. Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, Cala L, Hoppmann P, Schunkert H, Laugwitz KL, **Kastrati A**, Sibbing D. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. *J Am Coll Cardiol*

- 2014;**64**(9):863-71, 10.1016/j.jacc.2014.05.049
457. Langhans B, Nadjiri J, Jahnichen C, **Kastrati A**, Martinoff S, Hadamitzky M. Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99m-sestamibi SPECT. *Int J Cardiovasc Imaging* 2014;**30**(7):1357-63, 10.1007/s10554-014-0467-z
458. Kufner S, **Kastrati A**. Drug-eluting stents for drug-eluting stent restenosis: stick with the old or switch to a new one? *Coron Artery Dis* 2014;**25**(8):633-5, 10.1097/MCA.000000000000171
459. Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, **Kastrati A**, Intracoronary S, Angiographic Results: Drug Eluting Stents for In-Stent Restenosis I. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. *Cardiovasc Revasc Med* 2014;**15**(2):69-75, 10.1016/j.carrev.2014.02.001
460. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, **Kastrati A**, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, European Society of Cardiology Committee for Practice G, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Committee ECG, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL, Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association of Percutaneous Cardiovascular I. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardiothorac Surg* 2014;**46**(4):517-92, 10.1093/ejcts/ezu366
461. Kasel AM, Shivaraju A, Schneider S, Krapf S, Oertel F, Burgdorf C, Ott I, Sumer C, **Kastrati A**, von Scheidt W, Thilo C. Standardized methodology for transfemoral transcatheter aortic valve replacement with the Edwards Sapien XT valve under fluoroscopy guidance. *J Invasive Cardiol* 2014;**26**(9):451-61,
462. Kasel AM, Cassese S, Ischinger T, Leber A, Antoni D, Riess G, Vogel J, **Kastrati A**, Eichinger W, Hoffmann E. A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis. *Am J Cardiovasc Dis* 2014;**4**(2):87-99,
463. Hoppmann P, Koch W, Laugwitz KL, **Kastrati A**. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. *Coron Artery Dis* 2014;**25**(8):658-64, 10.1097/MCA.000000000000149
464. Hadamitzky M, Langhans B, Hausleiter J, Sonne C, Byrne RA, Mehili J, **Kastrati A**, Schomig A, Martinoff S, Ibrahim T. Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. *Eur Heart J Cardiovasc Imaging* 2014;**15**(2):216-25, 10.1093/ehjci/jet176
465. Guerra E, Ndrepepa G, Schulz S, Byrne R, Hoppmann P, Kufner S, Ibrahim T, Tada T, Schunkert H, Laugwitz KL, **Kastrati A**. Impact of inhospital stent thrombosis and

- cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. *Am Heart J* 2014;**168**(6):862-8 e1, 10.1016/j.ahj.2014.08.015
466. Guerra E, Hadamitzky M, Ndrepepa G, Bauer C, Ibrahim T, Ott I, Laugwitz KL, Schunkert H, **Kastrati A**. Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. *Int J Cardiovasc Imaging* 2014;**30**(6):1087-95, 10.1007/s10554-014-0430-z
467. Guerra E, Byrne RA, **Kastrati A**. Pharmacological inhibition of coronary restenosis: systemic and local approaches. *Expert Opin Pharmacother* 2014;**15**(15):2155-71, 10.1517/14656566.2014.948844
468. Fiedler KA, Mehilli J, Kufner S, Schlichting A, Ibrahim T, Sibbing D, Ott I, Schunkert H, Laugwitz KL, **Kastrati A**, Schulz S. Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. *Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION*. *Thromb Haemost* 2014;**111**(6):1041-9, 10.1160/TH13-11-0900
469. Fiedler KA, Byrne RA, Schulz S, Sibbing D, Mehilli J, Ibrahim T, Maeng M, Laugwitz KL, **Kastrati A**, Sarafoff N. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. *Am Heart J* 2014;**167**(4):459-465 e1, 10.1016/j.ahj.2014.01.005
470. Dzijan-Horn M, Langwieser N, Groha P, Bradaric C, Linhardt M, Bottiger C, Byrne RA, Steppich B, Koppa T, Godel J, Hadamitzky M, Ott I, von Beckerath N, **Kastrati A**, Laugwitz KL, Ibrahim T. Safety and efficacy of a potential treatment algorithm by using manual compression repair and ultrasound-guided thrombin injection for the management of iatrogenic femoral artery pseudoaneurysm in a large patient cohort. *Circ Cardiovasc Interv* 2014;**7**(2):207-15, 10.1161/CIRCINTERVENTIONS.113.000836
471. D'Ascenzo F, Cerrato E, Appleton D, Moretti C, Calcagno A, Abouzaki N, Vetrovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, **Kastrati A**, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, DiNicolantonio JJ, Omede P, Bonora S, Gaita F, Abbate A, Zoccai GB. Percutaneous coronary i, surgical revascularization in HIVDSI. Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. *Thromb Res* 2014;**134**(3):558-64, 10.1016/j.thromres.2014.05.037
472. Cassese S, Fusaro M, Byrne RA, Tada T, Hoppmann P, Joner M, Laugwitz KL, Schunkert H, **Kastrati A**. Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. *Int J Cardiol* 2014;**175**(3):484-91, 10.1016/j.ijcard.2014.06.014
473. Cassese S, De Luca G, Ribichini F, Cernigliaro C, Sansa M, Versaci F, Proietti I, Stankovic G, Stojkovic S, Fernandez-Pereira C, Tomai F, Vassanelli C, Antonucci D, Serruys PW, **Kastrati A**, Rodriguez AE. ORAL immunosuppressive therapy to prevent in-Stent restenosis (RAMSES) cooperation: a patient-level meta-analysis of randomized trials. *Atherosclerosis* 2014;**237**(2):410-7, 10.1016/j.atherosclerosis.2014.09.021
474. Cassese S, Byrne RA, Tada T, Piniack S, Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL, **Kastrati A**. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. *Heart* 2014;**100**(2):153-9, 10.1136/heartjnl-2013-304933
475. Byrne RA, **Kastrati A**. Drug-eluting stent trials: too much non-inferiority, too little progress? *Lancet* 2014;**383**(9915):386-8, 10.1016/S0140-6736(13)62240-0
476. Byrne RA, Joner M, Alfonso F, **Kastrati A**. Drug-coated balloon therapy in coronary and

- peripheral artery disease. *Nat Rev Cardiol* 2014;**11**(1):13-23, 10.1038/nrcardio.2013.165
477. Braun D, Lesevic H, Orban M, Michalk F, Barthel P, Hoppe K, Sonne C, Pache J, Mehilli J, **Kastrati A**, Hausleiter J, Massberg S. Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation. *Catheter Cardiovasc Interv* 2014;**84**(1):137-46, 10.1002/ccd.25331
478. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, **Kastrati A**, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;**35**(37):2541-619, 10.1093/eurheartj/ehu278
479. Alfonso F, Byrne RA, Rivero F, **Kastrati A**. Current treatment of in-stent restenosis. *J Am Coll Cardiol* 2014;**63**(24):2659-73, 10.1016/j.jacc.2014.02.545
480. Verschuren JJ, Trompet S, Sampietro ML, Heijmans BT, Koch W, **Kastrati A**, Houwing-Duistermaat JJ, Slagboom PE, Quax PH, Jukema JW. Pathway analysis using genome-wide association study data for coronary restenosis--a potential role for the PARVB gene. *PLoS One* 2013;**8**(8):e70676, 10.1371/journal.pone.0070676
481. Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, **Kastrati A**. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. *JACC Cardiovasc Interv* 2013;**6**(12):1267-74, 10.1016/j.jcin.2013.06.015
482. Tada T, Byrne RA, Schuster T, Cuni R, Kitabata H, Tiroch K, Dirninger A, Gratze F, Kaspar K, Zenker G, Joner M, Schomig A, **Kastrati A**. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. *Cardiovasc Revasc Med* 2013;**14**(2):84-9, 10.1016/j.carrev.2012.12.003
483. Tada T, Byrne RA, Cassese S, King L, Schulz S, Mehilli J, Schomig A, **Kastrati A**. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. *Am Heart J* 2013;**165**(1):80-6, 10.1016/j.ahj.2012.10.019
484. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, **Kastrati A**, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. *Lancet* 2013;**382**(9908):1879-88, 10.1016/S0140-6736(13)61782-1
485. Schulz S, **Kastrati A**, Ferenc M, Massberg S, Birkmeier KA, Laugwitz KL, Kufner S, Gick M, Dommasch M, Schuhlen H, Schomig A, Berger PB, Mehilli J, Neumann FJ, Intracoronary S, Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4 Trial I. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. *EuroIntervention* 2013;**9**(4):430-6, 10.4244/EIJV9I4A71
486. Schulz S, **Kastrati A**. Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. *Eur Heart J* 2013;**34**(12):872-4, 10.1093/eurheartj/ehf026
487. Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, **Kastrati A**. Triple

- therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. *J Am Coll Cardiol* 2013;**61**(20):2060-6, 10.1016/j.jacc.2013.02.036
488. Rivera NV, Carreras-Torres R, Roncarati R, Viviani-Anselmi C, De Micco F, Mezzelani A, Koch W, Hoppmann P, **Kastrati A**, Stewart AF, Chen L, Roberts R, Karszen LC, Amin N, Trimarco V, Izzo R, Iaccarino G, Condorelli G, Puca AA, Pagnotta P, Airolidi F, Trimarco B, van Duijn CM, Condorelli G, Briguori C. Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. *BMC Med Genet* 2013;**14**:11, 10.1186/1471-2350-14-11
489. Urban M, Joner M, Riegger J, Steigerwald K, Tada T, Ibrahim T, Laugwitz KL, Byrne RA, **Kastrati A**, Massberg S. Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation. *EuroIntervention* 2013;**9**(3):412-3, 10.4244/EIJV9I3A66
490. Ndrepepa G, Schulz S, Neumann FJ, Byrne RA, Hoppmann P, Cassese S, Ott I, Fusaro M, Ibrahim T, Tada T, Richardt G, Laugwitz KL, Schunkert H, **Kastrati A**. Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. *Am Heart J* 2013;**166**(3):534-40, 10.1016/j.ahj.2013.07.006
491. Ndrepepa G, Neumann FJ, Richardt G, Schulz S, Tolg R, Stoyanov KM, Gick M, Ibrahim T, Fiedler KA, Berger PB, Laugwitz KL, **Kastrati A**. Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. *Circ Cardiovasc Interv* 2013;**6**(4):354-61, 10.1161/CIRCINTERVENTIONS.113.000433
492. Ndrepepa G, King L, Cassese S, Fusaro M, Tada T, Schomig A, **Kastrati A**. Prehospital statin therapy and one-year mortality in patients with stable coronary artery disease undergoing percutaneous coronary intervention. *Eur J Intern Med* 2013;**24**(2):145-50, 10.1016/j.ejim.2012.10.008
493. Ndrepepa G, **Kastrati A**. Intravenous beta-blockers in primary percutaneous coronary intervention: new hope for an old therapy. *Circulation* 2013;**128**(14):1487-9, 10.1161/CIRCULATIONAHA.113.005500
494. Ndrepepa G, Fusaro M, King L, Cassese S, Tada T, Schomig A, **Kastrati A**. Statin pretreatment and presentation patterns in patients with coronary artery disease. *Cardiol J* 2013;**20**(1):52-8, 10.5603/CJ.2013.0009
495. Ndrepepa G, Cassese S, Braun S, Fusaro M, King L, Tada T, Schomig A, **Kastrati A**, Schmidt R. A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. *Nutr Metab Cardiovasc Dis* 2013;**23**(12):1195-201, 10.1016/j.numecd.2013.03.005
496. Ndrepepa G, Braun S, King L, Fusaro M, Tada T, Cassese S, Hadamitzky M, Haase HU, Schomig A, **Kastrati A**. Uric acid and prognosis in angiography-proven coronary artery disease. *Eur J Clin Invest* 2013;**43**(3):256-66, 10.1111/eci.12039
497. Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, Tada T, Schomig A, **Kastrati A**. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. *Am J Cardiol* 2013;**111**(6):804-10, 10.1016/j.amjcard.2012.11.060
498. Ndrepepa G, Braun S, King L, Cassese S, Tada T, Fusaro M, Hadamitzky M, Haase HU, Schomig A, **Kastrati A**. Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. *Clin Sci (Lond)* 2013;**124**(4):259-68, 10.1042/CS20120336
499. Ndrepepa G, Braun S, Cassese S, Fusaro M, King L, **Kastrati A**, Schmidt R. C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. *Cardiovasc Revasc Med* 2013;**14**(5):264-9, 10.1016/j.carrev.2013.07.002

500. Mehilli J, Richardt G, Valgimigli M, Schulz S, Singh A, Abdel-Wahab M, Tiroch K, Pache J, Hausleiter J, Byrne RA, Ott I, Ibrahim T, Fusaro M, Seyfarth M, Laugwitz KL, Massberg S, **Kastrati A**, Investigators I-L-MS. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2013;**62**(22):2075-82, 10.1016/j.jacc.2013.07.044
501. Mehilli J, Neumann FJ, Ndrepepa G, King L, Schulz S, Maimor Rodrigues da Cunha F, Jochheim D, Byrne RA, Hausleiter J, Ott I, Massberg S, **Kastrati A**, Pache J. Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. *Am Heart J* 2013;**165**(4):537-43, 10.1016/j.ahj.2012.12.021
502. Malle C, Tada T, Steigerwald K, Ughi GJ, Schuster T, Nakano M, Massberg S, Jehle J, Guagliumi G, **Kastrati A**, Virmani R, Byrne RA, Joner M. Tissue characterization after drug-eluting stent implantation using optical coherence tomography. *Arterioscler Thromb Vasc Biol* 2013;**33**(6):1376-83, 10.1161/ATVBAHA.113.301227
503. Leibundgut G, Pache J, Schulz S, Berger PB, Ferenc M, Gick M, Mehilli J, **Kastrati A**, Neumann FJ. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. *J Interv Cardiol* 2013;**26**(6):623-9, 10.1111/joic.12067
504. Kufner S, Byrne RA, Mehilli J, Massberg S, Birkmeier KA, Schulz S, Pache J, Schomig A, **Kastrati A**. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial. *Catheter Cardiovasc Interv* 2013;**82**(6):E769-76, 10.1002/ccd.24741
505. Koch W, Mueller JC, Schrempf M, Wolferstetter H, Kirchhofer J, Schomig A, **Kastrati A**. Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene. *Ann Hum Genet* 2013;**77**(1):47-55, 10.1111/j.1469-1809.2012.00739.x
506. King LA, **Kastrati A**, Byrne RA. Treatment of coronary drug-eluting stent restenosis: a journey back to the future? *Expert Rev Med Devices* 2013;**10**(4):423-7, 10.1586/17434440.2013.811830
507. King L, Byrne RA, Mehilli J, Schomig A, **Kastrati A**, Pache J. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. *Catheter Cardiovasc Interv* 2013;**81**(1):E23-8, 10.1002/ccd.24375
508. **Kastrati A**, Neumann FJ. SORT OUT V: a new episode in the DES wars. *Lancet* 2013;**381**(9867):609-11, 10.1016/S0140-6736(13)60055-0
509. Kasel AM, Cassese S, Leber AW, von Scheidt W, **Kastrati A**. Fluoroscopy-guided aortic root imaging for TAVR: "follow the right cusp" rule. *JACC Cardiovasc Imaging* 2013;**6**(2):274-5, 10.1016/j.jcmg.2012.06.014
510. Kasel AM, Cassese S, Bleiziffer S, Amaki M, Hahn RT, **Kastrati A**, Sengupta PP. Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. *JACC Cardiovasc Imaging* 2013;**6**(2):249-62, 10.1016/j.jcmg.2012.12.005
511. Hyseni A, Roest M, Braun SL, Barendrecht AD, de Groot PG, Ndrepepa G, **Kastrati A**. Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. *Thromb Res* 2013;**131**(3):198-203, 10.1016/j.thromres.2012.12.001
512. Hadamitzky M, Langhans B, Hausleiter J, Sonne C, **Kastrati A**, Martinoff S, Schomig A, Ibrahim T. The assessment of area at risk and myocardial salvage after coronary revascularization in acute myocardial infarction: comparison between CMR and SPECT. *JACC Cardiovasc Imaging* 2013;**6**(3):358-69, 10.1016/j.jcmg.2012.10.018
513. Fusaro M, Cassese S, Ndrepepa G, Tepe G, King L, Ott I, Nerad M, Schunkert H, **Kastrati A**. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis

- of randomized trials. *JACC Cardiovasc Interv* 2013;**6**(12):1284-93, 10.1016/j.jcin.2013.08.007
514. Fusaro M, Cassese S, Ndrepepa G, King LA, Tada T, Ott I, **Kastrati A**. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. *Int J Cardiol* 2013;**168**(4):4002-9, 10.1016/j.ijcard.2013.06.081
515. de Waha A, Stefanini GG, King LA, Byrne RA, Serruys PW, Kufner S, Meier B, Juni P, **Kastrati A**, Windecker S. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. *Int J Cardiol* 2013;**168**(6):5162-6, 10.1016/j.ijcard.2013.07.263
516. Cassese S, Desch S, **Kastrati A**, Byrne RA, King L, Tada T, Lauer B, Schomig A, Thiele H, Pache J. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials. *Rev Esp Cardiol (Engl Ed)* 2013;**66**(6):435-42, 10.1016/j.rec.2012.11.016
517. Byrne RA, Neumann FJ, Mehilli J, Piniack S, Wolff B, Tiroch K, Schulz S, Fusaro M, Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz KL, Massberg S, **Kastrati A**, investigators I-D. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 2013;**381**(9865):461-7, 10.1016/S0140-6736(12)61964-3
518. Byrne RA, **Kastrati A**. Unmet aspirations--where to now for catheter thrombectomy? *N Engl J Med* 2013;**369**(17):1649-50, 10.1056/NEJMe1310361
519. Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, Mehilli J, Pache J, **Kastrati A**. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. *EuroIntervention* 2013;**9**(7):797-802, 10.4244/EIJV9I7A132
520. Byrne RA, Cassese S, Linhardt M, **Kastrati A**. Vascular access and closure in coronary angiography and percutaneous intervention. *Nat Rev Cardiol* 2013;**10**(1):27-40, 10.1038/nrcardio.2012.160
521. Braun D, Orban M, Michalk F, Barthel P, Hoppe K, Sonne C, Lesevic H, Pache J, Mehilli J, **Kastrati A**, Hausleiter J, Massberg S. Three-dimensional transoesophageal echocardiography for the assessment of clip attachment to the leaflets in percutaneous edge-to-edge repair of the mitral valve. *EuroIntervention* 2013;**8**(12):1379-87, 10.4244/EIJV8I12A211
522. Bernlochner I, Morath T, Brown PB, Zhou C, Baker BA, Gupta N, Jakubowski JA, Winters KJ, Schomig A, **Kastrati A**, Sibbing D. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. *Platelets* 2013;**24**(1):15-25, 10.3109/09537104.2011.654003
523. Bernlochner I, Mayer K, Morath T, Orban M, Schulz S, Schomig A, Braun S, **Kastrati A**, Sibbing D. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. *Thromb Haemost* 2013;**109**(3):517-24, 10.1160/TH12-08-0552
524. Bernlochner I, Mayer K, Morath T, Braun S, Schulz S, Schomig A, Koch W, **Kastrati A**, Sibbing D. High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring. *Platelets* 2013;**24**(6):500-2, 10.3109/09537104.2012.715218
525. Trenk D, Stone GW, Gawaz M, **Kastrati A**, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet

- Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. *J Am Coll Cardiol* 2012;**59**(24):2159-64, 10.1016/j.jacc.2012.02.026
526. Task Force on the management of ST-segment elevation myocardial infarction, Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, **Kastrati A**, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;**33**(20):2569-619, 10.1093/eurheartj/ehs215
527. Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, **Kastrati A**, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T, Investigators CR-KPCRC-. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. *Circ Cardiovasc Interv* 2012;**5**(3):381-91, 10.1161/CIRCINTERVENTIONS.111.967463
528. Tada T, Byrne RA, **Kastrati A**. A case where the principle of "one question, one answer" may work better. *Am Heart J* 2012;**163**(2):133-5, 10.1016/j.ahj.2011.09.023
529. Stein A, Mohr F, Laux M, Thieme S, Lorenz B, Cetindis M, Hackl J, Groha P, Demetz G, Schulz S, Mehilli J, Schomig A, **Kastrati A**, Ott I. Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. *Thromb Haemost* 2012;**107**(4):769-74, 10.1160/TH11-08-0552
530. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P, Schomig A, Windecker S, **Kastrati A**. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *Eur Heart J* 2012;**33**(10):1214-22, 10.1093/eurheartj/ehs086
531. Sibbing D, Hochholzer W, **Kastrati A**. Influence of smoking on treatment with clopidogrel. *JAMA* 2012;**308**(13):1322-3; author reply 1323-4, 10.1001/2012.jama.11187
532. Sibbing D, Bernlochner I, Schulz S, Massberg S, Schomig A, Mehilli J, **Kastrati A**. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. *J Am Coll Cardiol* 2012;**60**(5):369-77, 10.1016/j.jacc.2012.02.044
533. Sibbing D, Bernlochner I, Schulz S, Massberg S, Schomig A, Mehilli J, **Kastrati A**. The impact of smoking on the antiplatelet action of clopidogrel in non-ST-elevation myocardial infarction patients: results from the ISAR-REACT 4 platelet substudy. *J Thromb Haemost* 2012;**10**(10):2199-202, 10.1111/j.1538-7836.2012.04867.x
534. Roos M, Schuster T, Ndrepepa G, Baumann M, Lutz J, Braun S, Martinof S, Schomig A, Heemann U, **Kastrati A**, Hausleiter J. Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium. *Heart Vessels* 2012;**27**(4):352-9, 10.1007/s00380-011-0166-9
535. Orban M, Riegger J, Joner M, Tada T, Okrojek R, Hausleiter J, **Kastrati A**, Massberg S, Sibbing D. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. *Platelets* 2012;**23**(5):395-8, 10.3109/09537104.2012.691189
536. Ndrepepa G, Tada T, Fusaro M, Cassese S, King L, Hadamitzky M, Haase HU, Schomig A, **Kastrati A**, Pache J. Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease. *Clin*

- Res Cardiol 2012;**101**(12):1003-11, 10.1007/s00392-012-0490-9
537. Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, Richardt G, Schulz S, Laugwitz KL, Massberg S, Schomig A, **Kastrati A**. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. *Circulation* 2012;**125**(11):1424-31, 10.1161/CIRCULATIONAHA.111.060871
538. Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schomig A, **Kastrati A**, Stone GW. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. *Circ Cardiovasc Interv* 2012;**5**(5):705-12, 10.1161/CIRCINTERVENTIONS.112.972869
539. Ndrepepa G, Braun S, King L, Hadamitzky M, Haase HU, Birkmeier KA, Schomig A, **Kastrati A**. Association of uric acid with mortality in patients with stable coronary artery disease. *Metabolism* 2012;**61**(12):1780-6, 10.1016/j.metabol.2012.05.014
540. Ndrepepa G, Braun S, Haase HU, Schulz S, Ranftl S, Hadamitzky M, Mehilli J, Schomig A, **Kastrati A**. Prognostic value of uric acid in patients with acute coronary syndromes. *Am J Cardiol* 2012;**109**(9):1260-5, 10.1016/j.amjcard.2011.12.018
541. Ndrepepa G, Alger P, Kufner S, Mehilli J, Schomig A, **Kastrati A**. ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. *Cardiol J* 2012;**19**(1):61-9, 10.5603/cj.2012.0009
542. **Kastrati A**, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. [Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial]. *Vestn Rentgenol Radiol* 2012(2):52-60,
543. **Kastrati A**. New anti-platelet agents: the end of resistance? *Thromb Res* 2012;**130 Suppl 1**:S53-5, 10.1016/j.thromres.2012.08.275
544. Jaitner J, Morath T, Byrne RA, Braun S, Gebhard D, Bernlochner I, Schulz S, Mehilli J, Schomig A, Koch W, **Kastrati A**, Sibbing D. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. *Circ Cardiovasc Interv* 2012;**5**(1):82-8, S1-2, 10.1161/CIRCINTERVENTIONS.111.965400
545. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schomig A, **Kastrati A**. Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. *Clin Res Cardiol* 2012;**101**(6):461-7, 10.1007/s00392-012-0414-8
546. Cortese B, Piti A, **Kastrati A**, Sibbing D. In the bivalirudin era, are we still looking for a potent antiplatelet agent? *Curr Vasc Pharmacol* 2012;**10**(4):476-8, 10.2174/157016112800812700
547. Cortese B, Bertolotti A, De Matteis S, Danzi GB, **Kastrati A**. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. *Int J Cardiol* 2012;**161**(2):73-82, 10.1016/j.ijcard.2011.04.016
548. Cassese S, Tada T, **Kastrati A**. Lost contact with vessel wall, signed contract with stent thrombosis? *Eur Heart J* 2012;**33**(11):1305-8, 10.1093/eurheartj/ehs039
549. Cassese S, Ndrepepa G, King LA, Tada T, Fusaro M, **Kastrati A**. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison. *Heart* 2012;**98**(22):1632-40, 10.1136/heartjnl-2012-302519
550. Cassese S, **Kastrati A**. New-generation drug-eluting stents for patients with myocardial infarction. *JAMA* 2012;**308**(8):814-5, 10.1001/2012.jama.10465
551. Cassese S, **Kastrati A**. Not all drug-eluting balloons are equally good for patients, not all

- patients are equally suitable for drug-eluting balloons. *EuroIntervention* 2012;**8**(4):417-21, 10.4244/EIJV8I4A65
552. Cassese S, de Waha A, Ndrepepa G, Ranftl S, King L, Schomig A, **Kastrati A**. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials. *Am Heart J* 2012;**164**(1):58-65 e1, 10.1016/j.ahj.2012.05.001
553. Cassese S, Byrne RA, Tada T, King LA, **Kastrati A**. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. *Eur Heart J* 2012;**33**(24):3078-87, 10.1093/eurheartj/ehs318
554. Cassese S, Byrne RA, Ott I, Ndrepepa G, Nerad M, **Kastrati A**, Fusaro M. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. *Circ Cardiovasc Interv* 2012;**5**(4):582-9, 10.1161/CIRCINTERVENTIONS.112.969972
555. Byrne RA, **Kastrati A**, Hausleiter J. The battle against stent thrombosis--to protect and to serve. *Lancet* 2012;**380**(9851):1365-7, 10.1016/S0140-6736(12)61385-3
556. Byrne RA, **Kastrati A**. No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. *Expert Rev Cardiovasc Ther* 2012;**10**(4):429-32, 10.1586/erc.12.29
557. Byrne RA, Joner M, Tada T, **Kastrati A**. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. *Minerva Cardioangiolog* 2012;**60**(5):473-89,
558. von Steinburg SP, Klein E, Langwieser N, **Kastrati A**, Schneider KT, Zohlhofer D. Coronary stenting after myocardial infarction during twin pregnancy--a case report. *Hypertens Pregnancy* 2011;**30**(4):485-9, 10.3109/10641955.2010.486457
559. Steppich BA, Demetz G, Schulz S, von Wedel J, Pogatsa-Murray G, Braun SL, Stein A, **Kastrati A**, Schomig A, Ott I. Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. *Thromb Res* 2011;**127**(2):119-21, 10.1016/j.thromres.2010.11.004
560. Sibbing D, Pfeufer A, Perisic T, Mannes AM, Fritz-Wolf K, Unwin S, Sinner MF, Gieger C, Gloeckner CJ, Wichmann HE, Kremmer E, Schafer Z, Walch A, Hinterseer M, Nabauer M, Kaab S, **Kastrati A**, Schomig A, Meitinger T, Bornkamm GW, Conrad M, von Beckerath N. Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. *Eur Heart J* 2011;**32**(9):1121-33, 10.1093/eurheartj/ehq507
561. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schomig A, **Kastrati A**. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. *Eur Heart J* 2011;**32**(13):1605-13, 10.1093/eurheartj/ehr155
562. Sibbing D, Byrne RA, **Kastrati A**. Role of platelet function testing in clinical practice: current concepts and future perspectives. *Curr Drug Targets* 2011;**12**(12):1836-47, 10.2174/138945011797635786
563. Sibbing D, Byrne RA, Bernlochner I, **Kastrati A**. High platelet reactivity and clinical outcome - fact and fiction. *Thromb Haemost* 2011;**106**(2):191-202, 10.1160/TH11-01-0040
564. Sibbing D, Bernlochner I, **Kastrati A**, Pare G, Eikelboom JW. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. *Circ Cardiovasc Interv* 2011;**4**(5):505-13; discussion 513, 10.1161/CIRCINTERVENTIONS.111.962183
565. Schulz S, Mehilli J, Ndrepepa G, Dotzer F, Dommasch M, Kufner S, Birkmeier KA, Tiroch K, Byrne RA, Schomig A, **Kastrati A**. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. *Clin Res Cardiol* 2011;**100**(8):691-9, 10.1007/s00392-011-0299-y

566. Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schomig A, **Kastrati A**, Sibbing D. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. *Am Heart J* 2011;**161**(3):605-10, 10.1016/j.ahj.2010.11.010
567. Sampietro ML, Trompet S, Verschuren JJ, Talens RP, Deelen J, Heijmans BT, de Winter RJ, Tio RA, Doevendans PA, Ganesh SK, Nabel EG, Westra HJ, Franke L, van den Akker EB, Westendorp RG, Zwinderman AH, **Kastrati A**, Koch W, Slagboom PE, de Knijff P, Jukema JW. A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. *Hum Mol Genet* 2011;**20**(23):4748-57, 10.1093/hmg/ddr389
568. Pare G, Eikelboom JW, Sibbing D, Bernlochner I, **Kastrati A**. Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2011;**4**(5):514-21; discussion 521, 10.1161/CIRCINTERVENTIONS.111.962142
569. Ndrepepa G, Schomig A, **Kastrati A**. Efficacy of reperfusion with primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction. *Clin Res Cardiol* 2011;**100**(11):1047-8, 10.1007/s00392-011-0352-x
570. Ndrepepa G, King L, **Kastrati A**. More deserved focus on diabetic patients. *Circ Cardiovasc Interv* 2011;**4**(2):115-7, 10.1161/CIRCINTERVENTIONS.111.961516
571. Ndrepepa G, **Kastrati A**. Need for critical reappraisal of intra-aortic balloon counterpulsation. *JAMA* 2011;**306**(12):1376-7, 10.1001/jama.2011.1288
572. Ndrepepa G, Braun S, Schulz S, Mehilli J, Schomig A, **Kastrati A**. High-sensitivity troponin T level and angiographic severity of coronary artery disease. *Am J Cardiol* 2011;**108**(5):639-43, 10.1016/j.amjcard.2011.04.012
573. Ndrepepa G, Braun S, Schulz S, Fusaro M, Keta D, Pache J, Seyfarth M, Mehilli J, Schomig A, **Kastrati A**. Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. *Eur J Clin Invest* 2011;**41**(10):1054-62, 10.1111/j.1365-2362.2011.02500.x
574. Ndrepepa G, Braun S, Schulz S, Byrne RA, Pache J, Mehilli J, Schomig A, **Kastrati A**. Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. *Clin Chim Acta* 2011;**412**(15-16):1350-6, 10.1016/j.cca.2011.03.037
575. Ndrepepa G, Braun S, Schomig A, **Kastrati A**. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. *Clin Res Cardiol* 2011;**100**(4):327-33, 10.1007/s00392-010-0247-2
576. Ndrepepa G, Braun S, Mehilli J, Birkmeier KA, Byrne RA, Ott I, Hosl K, Schulz S, Fusaro M, Pache J, Hausleiter J, Laugwitz KL, Massberg S, Seyfarth M, Schomig A, **Kastrati A**. Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. *Am Heart J* 2011;**161**(1):68-75, 10.1016/j.ahj.2010.09.018
577. Ndrepepa G, Alger P, Fusaro M, Kufner S, Seyfarth M, Keta D, Mehilli J, Schomig A, **Kastrati A**. Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. *EuroIntervention* 2011;**7**(1):128-35, 10.4244/EIJV7I1A21
578. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schomig A, **Kastrati A**. Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts I. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. *Lancet* 2011;**378**(9796):1071-8, 10.1016/S0140-6736(11)61255-5
579. Massberg S, Byrne RA, **Kastrati A**, Schulz S, Pache J, Hausleiter J, Ibrahim T, Fusaro M, Ott I, Schomig A, Laugwitz KL, Mehilli J, Intracoronary S, Angiographic Results: Test

- Efficacy of S, Probucol-Eluting Versus Zotarolimus- Eluting Stents I. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. *Circulation* 2011;**124**(5):624-32, 10.1161/CIRCULATIONAHA.111.026732
580. Kufner S, Massberg S, Dommasch M, Byrne RA, Tiroch K, Ranftl S, Fusaro M, Schomig A, **Kastrati A**, Mehilli J, Intracoronary S, Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents Trial I. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. *Catheter Cardiovasc Interv* 2011;**78**(2):161-6, 10.1002/ccd.22823
581. Kufner S, de Waha A, Tomai F, Park SW, Lee SW, Lim DS, Kim MH, Galloe AM, Maeng M, Briguori C, Dibra A, Schomig A, **Kastrati A**. A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. *Am Heart J* 2011;**162**(4):740-7, 10.1016/j.ahj.2011.07.003
582. Koch W, Wolferstetter H, Schatke A, Schomig A, **Kastrati A**. Interleukin 18 gene variation and risk of acute myocardial infarction. *Cytokine* 2011;**56**(3):786-91, 10.1016/j.cyto.2011.09.006
583. Koch W, Turk S, Erl A, Hoppmann P, Pfeufer A, King L, Schomig A, **Kastrati A**. The chromosome 9p21 region and myocardial infarction in a European population. *Atherosclerosis* 2011;**217**(1):220-6, 10.1016/j.atherosclerosis.2011.03.014
584. Koch W, Schatke A, Wolferstetter H, Mueller JC, Schomig A, **Kastrati A**. Extended evidence for association between the melanoma inhibitory activity 3 gene and myocardial infarction. *Thromb Haemost* 2011;**105**(4):670-5, 10.1160/TH10-10-0641
585. Koch W, Hoppmann P, Schomig A, **Kastrati A**. Variations of specific non-candidate genes and risk of myocardial infarction: a replication study. *Int J Cardiol* 2011;**147**(1):38-41, 10.1016/j.ijcard.2009.07.028
586. Khattab AA, Ndrepepa G, Schulz S, Neumann FJ, Mehilli J, Buttner HJ, Pache J, Seyfarth M, Dirschinger J, **Kastrati A**, Berger PB, Schomig A, Richardt G. Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. *Clin Res Cardiol* 2011;**100**(7):579-85, 10.1007/s00392-011-0282-7
587. Katritsis DG, Siontis GC, **Kastrati A**, van't Hof AW, Neumann FJ, Siontis KC, Ioannidis JP. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. *Eur Heart J* 2011;**32**(1):32-40, 10.1093/eurheartj/ehq276
588. Katritsis DG, Efsthopoulos EP, Pantos I, Tzanalaridou E, De Waha A, Siontis GC, Toutouzias K, Redwood S, **Kastrati A**, Stefanadis C. Ruptured versus stable plaques in human coronary arteries. *Coron Artery Dis* 2011;**22**(5):345-51, 10.1097/MCA.0b013e3283471f95
589. **Kastrati A**, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schomig A, Berger PB, Mehilli J, Investigators I-RT. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. *N Engl J Med* 2011;**365**(21):1980-9, 10.1056/NEJMoa1109596
590. **Kastrati A**, Massberg S, Ndrepepa G. Is diabetes the achilles' heel of limus-eluting stents? *Circulation* 2011;**124**(8):869-72, 10.1161/CIRCULATIONAHA.111.049544
591. **Kastrati A**, Byrne RA, Schulz S. Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation? *JACC Cardiovasc Interv* 2011;**4**(10):1129-32, 10.1016/j.jcin.2011.08.003
592. **Kastrati A**, Byrne R. New roads, new ruts: lessons from drug-eluting stent restenosis. *JACC Cardiovasc Interv* 2011;**4**(2):165-7, 10.1016/j.jcin.2010.11.008
593. Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schomig A, **Kastrati A**, Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. *Thromb Haemost* 2011;**105**(1):107-12, 10.1160/TH10-07-0440

594. Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schomig A, Neumann FJ, **Kastrati A**, Wiviott SD, Sibbing D. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. *Am Heart J* 2011;**162**(3):518-26 e5, 10.1016/j.ahj.2011.06.005
595. Hadamitzky M, Distler R, Meyer T, Hein F, **Kastrati A**, Martinoff S, Schomig A, Hausleiter J. Prognostic value of coronary computed tomographic angiography in comparison with calcium scoring and clinical risk scores. *Circ Cardiovasc Imaging* 2011;**4**(1):16-23, 10.1161/CIRCIMAGING.110.955351
596. de Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Schomig A, **Kastrati A**. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. *Clin Res Cardiol* 2011;**100**(7):561-70, 10.1007/s00392-010-0278-8
597. de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, Laugwitz KL, Massberg S, Schomig A, **Kastrati A**. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. *Circ Cardiovasc Interv* 2011;**4**(4):371-7, 10.1161/CIRCINTERVENTIONS.111.963256
598. de Boer SP, Barnes EH, Westerhout CM, Simes RJ, Granger CB, **Kastrati A**, Widimsky P, de Boer MJ, Zijlstra F, Boersma E. High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. *Am Heart J* 2011;**161**(3):500-507 e1, 10.1016/j.ahj.2010.11.022
599. Byrne RA, **Kastrati A**, Massberg S, Wiecek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schomig A, Mehilli J, Investigators I-T. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. *J Am Coll Cardiol* 2011;**58**(13):1325-31, 10.1016/j.jacc.2011.06.027
600. Byrne RA, **Kastrati A**. Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice? *EuroIntervention* 2011;**7** **Suppl K**:K47-52, 10.4244/EIJV7SKA8
601. Birkmeier KA, **Kastrati A**, Byrne RA, Holle H, Schulz S, Tiroch K, Kufner S, Massberg S, Laugwitz KL, Schomig A, Mehilli J. Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. *Catheter Cardiovasc Interv* 2011;**77**(4):494-501, 10.1002/ccd.22757
602. Bernlochner I, Byrne RA, **Kastrati A**, Sibbing D. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. *Expert Rev Cardiovasc Ther* 2011;**9**(8):999-1014, 10.1586/erc.11.80
603. Banerjee S, Weideman RA, Weideman MW, Little BB, Kelly KC, Gunter JT, Tortorice KL, Shank M, Cryer B, Reilly RF, Rao SV, **Kastrati A**, de Lemos JA, Brilakis ES, Bhatt DL. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. *Am J Cardiol* 2011;**107**(6):871-8, 10.1016/j.amjcard.2010.10.073
604. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, **Kastrati A**, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. *J Am Coll Cardiol* 2011;**58**(15):1569-77, 10.1016/j.jacc.2011.06.049
605. von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schomig A, **Kastrati A**. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. *Blood Coagul Fibrinolysis* 2010;**21**(1):46-52, 10.1097/MBC.0b013e328332dbd4

606. Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A, **Kastrati A**. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. *Am Heart J* 2010;**160**(3):506-12, 10.1016/j.ahj.2010.06.039
607. Tiroch KA, Byrne RA, **Kastrati A**. Pharmacological prevention and management of restenosis. *Expert Opin Pharmacother* 2010;**11**(11):1855-72, 10.1517/14656566.2010.485610
608. Stein A, Zohnhofer D, Pogatsa-Murray G, von Wedel J, Steppich BA, Schomig A, **Kastrati A**, Ott I. Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. *Thromb Haemost* 2010;**103**(3):638-43, 10.1160/TH09-09-0657
609. Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Schomig A, **Kastrati A**. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. *Eur Heart J* 2010;**31**(10):1205-11, 10.1093/eurheartj/ehq023
610. Sibbing D, Steinhubl SR, Schulz S, Schomig A, **Kastrati A**. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. *J Am Coll Cardiol* 2010;**56**(4):317-8, 10.1016/j.jacc.2010.03.048
611. Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Seyfarth M, **Kastrati A**, von Beckerath N, Schomig A. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. *J Am Coll Cardiol* 2010;**55**(6):558-65, 10.1016/j.jacc.2009.09.038
612. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schomig A, von Beckerath N, **Kastrati A**. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. *J Thromb Haemost* 2010;**8**(2):250-6, 10.1111/j.1538-7836.2009.03709.x
613. Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schomig A, **Kastrati A**, von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. *Thromb Haemost* 2010;**103**(1):151-9, 10.1160/TH09-05-0284
614. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von Beckerath N, **Kastrati A**. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation* 2010;**121**(4):512-8, 10.1161/CIRCULATIONAHA.109.885194
615. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, Von Beckerath N, Mehilli J, Schomig A, Schuster T, **Kastrati A**. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. *J Thromb Haemost* 2010;**8**(8):1685-93, 10.1111/j.1538-7836.2010.03921.x
616. Schulz S, Sibbing D, Braun S, Morath T, Mehilli J, Massberg S, Byrne RA, Schomig A, **Kastrati A**. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. *Am Heart J* 2010;**160**(2):355-61, 10.1016/j.ahj.2010.05.003
617. Schulz S, Mehilli J, Schomig A, **Kastrati A**. ISAR--a story of trials with impact on practice. *Circ J* 2010;**74**(9):1771-8, 10.1253/circj.cj-10-0738
618. Schulz S, Mehilli J, Neumann FJ, Schuster T, Massberg S, Valina C, Seyfarth M, Pache J, Laugwitz KL, Buttner HJ, Ndrepepa G, Schomig A, **Kastrati A**, Intracoronary S, Antithrombotic Regimen: Rapid Early Action for Coronary Treatment ATI. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. *Eur Heart J* 2010;**31**(20):2482-91, 10.1093/eurheartj/ehq330
619. Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, Richardt G, Berger PB, Schomig A, **Kastrati A**, Intracoronary S, Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 3 Trial I. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. *Eur Heart J* 2010;**31**(5):582-7, 10.1093/eurheartj/ehq008
620. Schulz S, Birkmeier KA, Ndrepepa G, Moshage W, Dotzer F, Huber K, Dirschinger J,

- Seyfarth M, Schomig A, **Kastrati A**, Mehilli J. One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. *Clin Res Cardiol* 2010;**99**(12):795-802, 10.1007/s00392-010-0185-z
621. Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, Mehilli J, Schomig A, **Kastrati A**. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. *Thromb Haemost* 2010;**104**(3):626-32, 10.1160/TH09-11-0800
622. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, **Kastrati A**, Schmig A, Investigators R-S. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. *Circ Cardiovasc Interv* 2010;**3**(5):408-13, 10.1161/CIRCINTERVENTIONS.109.904425
623. Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, Mehilli J, Schomig A, **Kastrati A**. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. *Circ Cardiovasc Interv* 2010;**3**(1):27-33, 10.1161/CIRCINTERVENTIONS.109.896225
624. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schomig A, **Kastrati A**. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. *J Am Coll Cardiol* 2010;**55**(21):2383-9, 10.1016/j.jacc.2009.12.054
625. Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, Laugwitz KL, Neumann FJ, Seyfarth M, Berger PB, Schomig A, **Kastrati A**. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. *Am J Cardiol* 2010;**105**(2):163-7, 10.1016/j.amjcard.2009.08.668
626. Ndrepepa G, Mehilli J, Tiroch K, Fusaro M, Kufner S, Ellert J, Goedel J, Schomig A, **Kastrati A**. Myocardial perfusion grade, myocardial salvage indices and long-term mortality in patients with acute myocardial infarction and full restoration of epicardial blood flow after primary percutaneous coronary intervention. *Rev Esp Cardiol* 2010;**63**(7):770-8, 10.1016/s1885-5857(10)70161-4
627. Ndrepepa G, Keta D, Schulz S, Mehilli J, Birkmeier A, Neumann FJ, Schomig A, **Kastrati A**. Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. *Heart Vessels* 2010;**25**(4):294-8, 10.1007/s00380-009-1205-7
628. Ndrepepa G, Keta D, Schulz S, Byrne RA, Mehilli J, Pache J, Seyfarth M, Schomig A, **Kastrati A**. Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. *Clin Res Cardiol* 2010;**99**(1):13-9, 10.1007/s00392-009-0070-9
629. Ndrepepa G, Keta D, Byrne RA, Schulz S, Mehilli J, Seyfarth M, Schomig A, **Kastrati A**. Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. *Heart Vessels* 2010;**25**(1):27-34, 10.1007/s00380-009-1160-3
630. Mehilli J, Tiroch K, **Kastrati A**. [Recanalization of chronic total coronary occlusion: indications and results]. *Dtsch Med Wochenschr* 2010;**135**(39):1931-5, 10.1055/s-0030-1263341
631. Mehilli J, Byrne RA, Tiroch K, Piniack S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A, **Kastrati A**, Investigators I-D. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. *J Am Coll Cardiol* 2010;**55**(24):2710-6, 10.1016/j.jacc.2010.02.009
632. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, **Kastrati A**, Montalescot G, Neumann FJ, Shen L,

- Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA* 2010;**304**(16):1821-30, 10.1001/jama.2010.1543
633. Massberg S, **Kastrati A**. Is it naive to load only clopidogrel-naive patients prior to PCI? *Eur Heart J* 2010;**31**(11):1298-300, 10.1093/eurheartj/ehq082
634. Koch W, Schrempf M, Erl A, Mueller JC, Hoppmann P, Schomig A, **Kastrati A**. 4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries. *Thromb Haemost* 2010;**103**(6):1170-80, 10.1160/TH09-10-0702
635. Koch W, de Waha A, Hoppmann P, Schomig A, **Kastrati A**. Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta-analysis. *Atherosclerosis* 2010;**208**(1):171-6, 10.1016/j.atherosclerosis.2009.08.021
636. **Kastrati A**, Byrne RA, Schomig A. Is it time to jettison complex mechanical thrombectomy in favor of simple manual aspiration devices? *J Am Coll Cardiol* 2010;**56**(16):1307-9, 10.1016/j.jacc.2010.07.003
637. **Kastrati A**, Balducci M, Di Sciascio G, Moccetti T, Bortone AS, Colombo A, Waltenberger J, Hehrlein C, Investigators MA-T. A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. *EuroIntervention* 2010;**5**(8):976-80,
638. **Kastrati A**. Is diabetes a leveler of efficacy of DES types? *Catheter Cardiovasc Interv* 2010;**75**(3):335-7, 10.1002/ccd.22453
639. Jeremias A, Vasu S, Gruberg L, **Kastrati A**, Stone GW, Brown DL. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. *Catheter Cardiovasc Interv* 2010;**75**(6):895-902, 10.1002/ccd.22349
640. Echtler K, Stark K, Lorenz M, Kerstan S, Walch A, Jennen L, Rudelius M, Seidl S, Kremmer E, Emambokus NR, von Bruehl ML, Frampton J, Isermann B, Genzel-Boroviczeny O, Schreiber C, Mehilli J, **Kastrati A**, Schwaiger M, Shivdasani RA, Massberg S. Platelets contribute to postnatal occlusion of the ductus arteriosus. *Nat Med* 2010;**16**(1):75-82, 10.1038/nm.2060
641. Dibra A, Tiroch K, Schulz S, Kelbaek H, Spaulding C, Laarman GJ, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schlij MJ, Violini R, Schomig A, **Kastrati A**. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. *Clin Res Cardiol* 2010;**99**(6):345-57, 10.1007/s00392-010-0133-y
642. Byrne RA, Ndrepepa G, Braun S, Tiroch K, Mehilli J, Schulz S, Schomig A, **Kastrati A**. Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Am J Cardiol* 2010;**106**(9):1212-7, 10.1016/j.amjcard.2010.06.050
643. Byrne RA, **Kastrati A**, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schomig A, Mehilli J, Investigators I-T-. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. *J Am Coll Cardiol* 2010;**55**(23):2536-43, 10.1016/j.jacc.2010.03.020
644. Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schomig A, **Kastrati A**, Sibbing D. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. *Thromb Haemost* 2010;**104**(6):1193-200, 10.1160/TH10-05-0266
645. Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schomig A, **Kastrati A**, Contrast M. Nephrotoxicity Following Coronary Revascularization by

- Angioplasty Trial I. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2009;**2**(5):430-7, 10.1161/CIRCINTERVENTIONS.109.874933
646. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, **Kastrati A**, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Task Force per il Trattamento dell'Infarto Miocardico Acuto c, Sopraslivellamento del Tratto STdSEdC, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F, Societa Europea di C. [Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. *G Ital Cardiol (Rome)* 2009;**10**(7):450-89,
647. Tiroch K, Koch W, Mehilli J, Bottiger C, Schomig A, **Kastrati A**. P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. *Cardiology* 2009;**112**(4):263-9, 10.1159/000151695
648. Task Force on the management of STseami, Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, **Kastrati A**, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M. ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. *Rev Esp Cardiol* 2009;**62**(3):293, e1-47, 10.1016/s1885-5857(09)71559-2
649. Steppich BA, Braun SL, Stein A, Demetz G, Groha P, Schomig A, von Beckerath N, **Kastrati A**, Ott I. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. *Thromb J* 2009;**7**:11, 10.1186/1477-9560-7-11
650. Steigerwald K, Merl S, **Kastrati A**, Wieczorek A, Vorpahl M, Mannhold R, Vogeser M, Hausleiter J, Joner M, Schomig A, Wessely R. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. *Biomaterials* 2009;**30**(4):632-7, 10.1016/j.biomaterials.2008.10.005
651. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrlor K, Morath T, Schomig A, **Kastrati A**, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J* 2009;**30**(8):916-22, 10.1093/eurheartj/ehp041
652. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schomig A, **Kastrati A**, von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. *Thromb Haemost* 2009;**101**(4):714-9,
653. Sibbing D, **Kastrati A**. Risk of combining PPIs with thienopyridines: fact or fiction? *Lancet* 2009;**374**(9694):952-954, 10.1016/S0140-6736(09)61562-2
654. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, **Kastrati A**, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. *J Am Coll Cardiol* 2009;**53**(10):849-56, 10.1016/j.jacc.2008.11.030
655. Seyfarth M, **Kastrati A**, Mann JF, Ndrepepa G, Byrne RA, Schulz S, Mehilli J, Schomig A. Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. *Am J Kidney Dis* 2009;**54**(5):830-9, 10.1053/j.ajkd.2009.04.031
656. Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, Goedel J, Bruskin O, Ulm K, Schomig A, **Kastrati A**. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. *Eur Heart J* 2009;**30**(22):2714-21, 10.1093/eurheartj/ehp275
657. Roos M, Ndrepepa G, Baumann M, Pan CR, Heemann U, Lutz J, Keta D, Schulz S, Byrne RA, Mehilli J, Schomig A, **Kastrati A**. Serum potassium levels on admission and infarct size

- in patients with acute myocardial infarction. *Clin Chim Acta* 2009;**409**(1-2):46-51, 10.1016/j.cca.2009.08.014
658. Ndrepepa G, Schomig A, **Kastrati A**. The only better alternative to rescue percutaneous coronary intervention is primary percutaneous coronary intervention. *J Am Coll Cardiol* 2009;**54**(2):127-9, 10.1016/j.jacc.2009.03.045
659. Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, Pache J, Seyfarth M, Schomig A, **Kastrati A**. Patterns of presentation and outcomes of patients with acute coronary syndromes. *Cardiology* 2009;**113**(3):198-206, 10.1159/000201273
660. Ndrepepa G, **Kastrati A**, Mehilli J, Antoniucci D, Schomig A. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. *JAMA* 2009;**301**(5):487-8, 10.1001/jama.2009.32
661. Ndrepepa G, Braun S, Iijima R, Keta D, Byrne RA, Schulz S, Mehilli J, Schomig A, **Kastrati A**. Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. *Clin Sci (Lond)* 2009;**116**(8):651-8, 10.1042/CS20080298
662. Mehilli J, **Kastrati A**, Schulz S, Frungel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Schomig A, Bavarian Reperfusion Alternatives Evaluation-3 Study I. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. *Circulation* 2009;**119**(14):1933-40, 10.1161/CIRCULATIONAHA.108.818617
663. Mehilli J, **Kastrati A**, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schomig A, Stenting L-MI, Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study I. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2009;**53**(19):1760-8, 10.1016/j.jacc.2009.01.035
664. Kufner S, Hausleiter J, Ndrepepa G, Schulz S, Bruskina O, Byrne RA, Fusaro M, **Kastrati A**, Schomig A, Mehilli J, Investigators OT. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. *JACC Cardiovasc Interv* 2009;**2**(11):1142-8, 10.1016/j.jcin.2009.08.015
665. **Kastrati A**, Ndrepepa G. Cangrelor - a champion lost in translation? *N Engl J Med* 2009;**361**(24):2382-4, 10.1056/NEJMe0910677
666. Iijima R, Ndrepepa G, Mehilli J, Byrne RA, Schulz S, Neumann FJ, Richardt G, Berger PB, Schomig A, **Kastrati A**. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. *Eur Heart J* 2009;**30**(3):290-6, 10.1093/eurheartj/ehn586
667. Iijima R, Byrne RA, Ndrepepa G, Braun S, Mehilli J, Berger PB, Schomig A, **Kastrati A**. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. *Heart* 2009;**95**(2):107-12, 10.1136/hrt.2008.153635
668. Iijima R, Byrne RA, Dibra A, Ndrepepa G, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Suttorp MJ, Violini R, Schomig A, **Kastrati A**. Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. *Rev Esp Cardiol* 2009;**62**(4):354-64, 10.1016/s1885-5857(09)71662-7
669. Hoppmann P, Erl A, Turk S, Tiroch K, Mehilli J, Schomig A, **Kastrati A**, Koch W. No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents. *JACC Cardiovasc Interv* 2009;**2**(11):1149-55, 10.1016/j.jcin.2009.08.021
670. Hausleiter J, Meyer T, Hermann F, Hadamitzky M, Krebs M, Gerber TC, McCollough C,

- Martinoff S, **Kastrati A**, Schomig A, Achenbach S. Estimated radiation dose associated with cardiac CT angiography. *JAMA* 2009;**301**(5):500-7, 10.1001/jama.2009.54
671. Hadamitzky M, Freissmuth B, Meyer T, Hein F, **Kastrati A**, Martinoff S, Schomig A, Hausleiter J. Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. *JACC Cardiovasc Imaging* 2009;**2**(4):404-11, 10.1016/j.jcmg.2008.11.015
672. Finn AV, Oh JS, Hendricks M, Daher M, Cagliero E, Byrne RM, Nadelson J, Crimins J, **Kastrati A**, Schomig A, Bruskina O, Palacios I, John MC, Gold HK. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. *Am Heart J* 2009;**157**(2):383 e1-8, 10.1016/j.ahj.2008.11.013
673. Daemen J, Simoons ML, Wijns W, Bagust A, Bos G, Bowen JM, Braunwald E, Camenzind E, Chevaliers B, DiMario C, Fajadeto J, Gitt A, Guagliumi G, Hillege HL, James S, Juni P, **Kastrati A**, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker SW, Aimonetti A, Allocco D, Berenger M, Boam A, Calle JP, Campo G, Carlier S, de Schepper J, Di Bisceglie G, Dobbels H, Farb A, Ghislain JC, Hellbardt S, ten Hoedt R, Isaia C, de Jong P, Lekehal M, LeNarz L, Mhullain FN, Nagai H, Patteet A, Paunovic D, Potgieter A, Purdy I, Raveau-Landon C, Ternstrom S, Van Wuytswinkel J, Waliszewski M, European Society of C. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. *EuroIntervention* 2009;**4**(4):427-36,
674. Daemen J, Simoons ML, Wijns W, Bagust A, Bos G, Bowen JM, Braunwald E, Camenzind E, Chevalier B, Dimario C, Fajadet J, Gitt A, Guagliumi G, Hillege HL, James S, Juni P, **Kastrati A**, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys PW, Silber S, Steg PG, Tariah I, Wallentin L, Windecker SW, Aimonetti A, Allocco D, Baczynska A, Bagust A, Berenger M, Bos G, Boam A, Bowen JM, Braunwald E, Calle JP, Camenzind E, Campo G, Carlier S, Chevalier B, Daemen J, de Schepper J, Di Bisceglie G, Dimario C, Dobbels H, Fajadet J, Farb A, Ghislain JC, Gitt A, Guagliumi G, Hellbardt S, Hillege HL, Ten Hoedt R, Isaia C, James S, de Jong P, Juni P, **Kastrati A**, Klasen E, Kloth S, Kristensen SD, Krucoff M, Legrand V, Lekehal M, Lenarz L, Ni Mhullain F, Nagai H, Patteet A, Paunovic D, Pfisterer M, Potgieter A, Purdy I, Raveau-Landon C, Rothman M, Serruys PW, Silber S, Simoons ML, Steg PG, Tariah I, Ternstrom S, Van Wuytswinkel J, Waliszewski M, Wallentin L, Wijns W, Windecker SW. ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. *Eur Heart J* 2009;**30**(2):152-61, 10.1093/eurheartj/ehn510
675. Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann FJ, ten Berg JM, Schomig A, **Kastrati A**, Intracoronary S, Antithrombotic Regimen S, Investigators EFoSM DATAD-ES. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. *Am Heart J* 2009;**157**(4):620-4 e2, 10.1016/j.ahj.2008.12.019
676. Byrne RA, Sarafoff N, **Kastrati A**, Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. *Drug Saf* 2009;**32**(9):749-70, 10.2165/11316500-000000000-00000
677. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schomig A, **Kastrati A**. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. *Eur Heart J* 2009;**30**(8):923-31, 10.1093/eurheartj/ehp044
678. Byrne RA, **Kastrati A**, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schomig A, Mehilli J, Intracoronary S, Angiographic Results: Test

- Efficacy of 3 Limus-Eluting Stents I. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *Eur Heart J* 2009;**30**(20):2441-9, 10.1093/eurheartj/ehp352
679. Byrne RA, Joner M, **Kastrati A**. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. *Minerva Cardioangiologica* 2009;**57**(5):567-84,
680. Byrne RA, Iijima R, Mehilli J, Piniello S, Bruskin O, Schomig A, **Kastrati A**. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. *JACC Cardiovasc Interv* 2009;**2**(4):291-9, 10.1016/j.jcin.2008.11.015
681. Byrne RA, Eberle S, **Kastrati A**, Dibra A, Ndrepepa G, Iijima R, Mehilli J, Schomig A. Distribution of angiographic measures of restenosis after drug-eluting stent implantation. *Heart* 2009;**95**(19):1572-8, 10.1136/hrt.2008.161398
682. Busch G, Steppich B, Sibbing D, Braun SL, Stein A, Groha P, Schomig A, **Kastrati A**, von Beckerath N, Ott I. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. *Thromb Haemost* 2009;**101**(2):340-4,
683. Braun S, von Beckerath N, Ellert J, **Kastrati A**, Schomig A, Vogt W, Sibbing D. Assessment of platelet function in whole blood by multiple electrode aggregometry: transport of samples using a pneumatic tube system. *Am J Clin Pathol* 2009;**132**(5):802-3; author reply 803-4, 10.1309/AJCPYNHXB53AWHDW
684. Bauer A, Mehilli J, Barthel P, Muller A, **Kastrati A**, Ulm K, Schomig A, Malik M, Schmidt G. Impact of myocardial salvage assessed by (99m)Tc-sestamibi scintigraphy on cardiac autonomic function in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *JACC Cardiovasc Imaging* 2009;**2**(4):449-57, 10.1016/j.jcmg.2008.12.018
685. Zohlhofer D, Dibra A, Koppa T, de Waha A, Ripa RS, Kastrup J, Valgimigli M, Schomig A, **Kastrati A**. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. *J Am Coll Cardiol* 2008;**51**(15):1429-37, 10.1016/j.jacc.2007.11.073
686. Vorpahl M, Laugwitz KL, Zrenner B, **Kastrati A**, Schomig A. Unusual use of a standard percutaneous transluminal coronary angioplasty balloon catheter to the rescue. *Eur Heart J* 2008;**29**(22):2732, 10.1093/eurheartj/ehn239
687. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, **Kastrati A**, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Guidelines ESCCfP. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 2008;**29**(23):2909-45, 10.1093/eurheartj/ehn416
688. Stettler C, Allemann S, Wandel S, **Kastrati A**, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Juni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. *BMJ* 2008;**337**:a1331, 10.1136/bmj.a1331
689. Stefanescu A, Braun S, Ndrepepa G, Koppa T, Pavaci H, Mehilli J, Schomig A, **Kastrati A**. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. *Am Heart J* 2008;**155**(2):356-60, 10.1016/j.ahj.2007.10.017
690. Sotgia B, Sciagra R, Parodi G, **Kastrati A**, Antoniucci D, Schomig A, Pupi A. Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischARGE gated SPECT. *Eur J Nucl Med Mol Imaging* 2008;**35**(5):906-11, 10.1007/s00259-007-0663-3
691. Sibbing D, Taubert D, Schomig A, **Kastrati A**, Von Beckerath N. Pharmacokinetics of

- clopidogrel in patients with stent thrombosis. *J Thromb Haemost* 2008;**6**(7):1230-2, 10.1111/j.1538-7836.2008.03004.x
692. Sibbing D, Busch G, Braun S, Jawansky S, Schomig A, **Kastrati A**, Ott I, von Beckerath N. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. *Eur Heart J* 2008;**29**(12):1504-9, 10.1093/eurheartj/ehn195
693. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, **Kastrati A**, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. *Thromb Haemost* 2008;**99**(1):121-6, 10.1160/TH07-07-0478
694. Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J, **Kastrati A**, Schomig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. *J Am Coll Cardiol* 2008;**52**(19):1584-8, 10.1016/j.jacc.2008.05.065
695. Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, **Kastrati A**. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. *J Am Coll Cardiol* 2008;**52**(11):894-904, 10.1016/j.jacc.2008.05.051
696. Sarafoff N, Ndrepepa G, Mehilli J, Dorrlor K, Schulz S, Iijima R, Byrne R, Schomig A, **Kastrati A**. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. *J Intern Med* 2008;**264**(5):472-80, 10.1111/j.1365-2796.2008.01989.x
697. Roos M, Lutz J, Salmhofer H, Lupp P, Knauss A, Braun S, Martinof S, Schomig A, Heemann U, **Kastrati A**, Hausleiter J. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. *Clin Endocrinol (Oxf)* 2008;**68**(4):660-5, 10.1111/j.1365-2265.2007.03074.x
698. Pinkau T, Ndrepepa G, **Kastrati A**, Mann JF, Schulz S, Mehilli J, Schomig A. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. *Cardiology* 2008;**111**(4):247-53, 10.1159/000127446
699. Nuhrenberg TG, Langwieser N, Schwarz JB, Hou Y, Frank P, Sorge F, Matschurat S, Seidl S, **Kastrati A**, Schomig A, Clauss MA, Zohlhofer D. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. *Cardiovasc Res* 2008;**77**(3):580-9, 10.1093/cvr/cvm076
700. Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, Pache J, Seyfarth M, Schomig A, **Kastrati A**. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. *J Am Coll Cardiol* 2008;**52**(7):512-7, 10.1016/j.jacc.2008.05.009
701. Ndrepepa G, **Kastrati A**, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Dirschinger J, Berger PB, Schomig A. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. *Eur Heart J* 2008;**29**(4):455-61, 10.1093/eurheartj/ehm562
702. Ndrepepa G, **Kastrati A**, Braun S, Koch W, Kolling K, Mehilli J, Schomig A. Circulating homocysteine levels in patients with type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis* 2008;**18**(1):66-73, 10.1016/j.numecd.2006.03.007
703. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, **Kastrati A**. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. *Eur J Clin*

- Invest 2008;**38**(2):90-6, 10.1111/j.1365-2362.2007.01908.x
704. Ndrepepa G, Braun S, Mehilli J, Schomig A, **Kastrati A**. Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease. *Cardiology* 2008;**109**(4):249-57, 10.1159/000107788
705. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, **Kastrati A**. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. *J Am Coll Cardiol* 2008;**51**(7):690-7, 10.1016/j.jacc.2007.10.040
706. Mylotte D, Byrne RA, Iijima R, **Kastrati A**. Multivessel percutaneous coronary intervention: a review of the literature and fallacies in its interpretation. *Minerva Cardioangiolog* 2008;**56**(5):493-510,
707. Mehilli J, Byrne RA, Wiecezorek A, Iijima R, Schulz S, Bruskin O, Pache J, Wessely R, Schomig A, **Kastrati A**, Intracoronary S, Angiographic Restenosis Investigators--Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating S. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. *Eur Heart J* 2008;**29**(16):1975-82, 10.1093/eurheartj/ehn253
708. Louvard Y, Thomas M, Dzavik V, Hildick-Smith D, Galassi AR, Pan M, Burzotta F, Zelizko M, Dudek D, Ludman P, Sheiban I, Lassen JF, Darremont O, **Kastrati A**, Ludwig J, Iakovou I, Brunel P, Lansky A, Meerkin D, Legrand V, Medina A, Lefevre T. Classification of coronary artery bifurcation lesions and treatments: time for a consensus! *Catheter Cardiovasc Interv* 2008;**71**(2):175-83, 10.1002/ccd.21314
709. Koch W, Hoppmann P, Schomig A, **Kastrati A**. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. *Int J Cardiol* 2008;**125**(1):116-7, 10.1016/j.ijcard.2007.01.012
710. Koch W, Hoppmann P, Mueller JC, Schomig A, **Kastrati A**. Lack of support for association between common variation in TNFSF4 and myocardial infarction in a German population. *Nat Genet* 2008;**40**(12):1386-7; author reply 1387-8, 10.1038/ng1208-1386
711. Koch W, Hoppmann P, de Waha A, Schomig A, **Kastrati A**. Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. *Hum Mol Genet* 2008;**17**(8):1120-6, 10.1093/hmg/ddn001
712. Koch W, Hoppmann P, Biele J, Mueller JC, Schomig A, **Kastrati A**. Fibrinogen genes and myocardial infarction: a haplotype analysis. *Arterioscler Thromb Vasc Biol* 2008;**28**(4):758-63, 10.1161/ATVBAHA.107.157842
713. **Kastrati A**, Schomig A. Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease? *Nat Clin Pract Cardiovasc Med* 2008;**5**(4):188-9, 10.1038/ncpcardio1120
714. **Kastrati A**, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khatlab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schomig A, Investigators I-RT. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. *N Engl J Med* 2008;**359**(7):688-96, 10.1056/NEJMoa0802944
715. **Kastrati A**. Drug for a while, polymer for life: Is it a good solution? *Catheter Cardiovasc Interv* 2008;**71**(3):340-1, 10.1002/ccd.21491
716. John MC, Wessely R, **Kastrati A**, Schomig A, Joner M, Uchihashi M, Crimins J, Lajoie S, Kolodgie FD, Gold HK, Virmani R, Finn AV. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. *JACC Cardiovasc Interv* 2008;**1**(5):535-44, 10.1016/j.jcin.2008.08.004
717. Iijima R, Ndrepepa G, Mehilli J, Neumann FJ, Schulz S, ten Berg J, Bruskin O, Dotzer F, Dirschinger J, Berger PB, Schomig A, **Kastrati A**. Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. *Clin Res Cardiol* 2008;**97**(3):160-8, 10.1007/s00392-007-0603-z

718. Iijima R, Ndrepepa G, Mehilli J, Dirschinger J, Pache J, Seyfarth M, Schomig A, **Kastrati A**. Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol* 2008;**101**(9):1226-31, 10.1016/j.amjcard.2007.12.019
719. Friedewald VE, Jr., **Kastrati A**, Roberts WC, Vetrovec GW, Windecker S. The editor's roundtable: bare-metal stents versus drug-eluting stents-indications and complications. *Am J Cardiol* 2008;**102**(1):32-9, 10.1016/j.amjcard.2008.03.051
720. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, **Kastrati A**, Chiariello M, Marino P. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. *Int J Cardiol* 2008;**126**(1):37-44, 10.1016/j.ijcard.2007.03.112
721. Byrne RA, **Kastrati A**. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. *Catheter Cardiovasc Interv* 2008;**72**(7):944-9, 10.1002/ccd.21731
722. Byrne R, Iijima R, Mehilli J, Pache J, Schulz S, Schomig A, **Kastrati A**. [Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes]. *Rev Esp Cardiol* 2008;**61**(11):1134-9,
723. Adriaenssens T, Byrne RA, Dibra A, Iijima R, Mehilli J, Bruskina O, Schomig A, **Kastrati A**. Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. *Eur Heart J* 2008;**29**(23):2868-76, 10.1093/eurheartj/ehn512
724. Zohnhofer D, **Kastrati A**, Schomig A. Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: lessons from the REVIVAL-2 trial. *Nat Clin Pract Cardiovasc Med* 2007;**4 Suppl 1**:S106-9, 10.1038/ncpcardio0745
725. Wessely R, **Kastrati A**, Mehilli J, Dibra A, Pache J, Schomig A. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. *Eur Heart J* 2007;**28**(22):2720-5, 10.1093/eurheartj/ehm425
726. Wessely R, Blaich B, Belaiba RS, Merl S, Grolach A, **Kastrati A**, Schomig A. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. *Thromb Haemost* 2007;**97**(6):1003-12,
727. von Beckerath N, **Kastrati A**, Wiczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. *Eur Heart J* 2007;**28**(15):1814-9, 10.1093/eurheartj/ehl489
728. Tiroch K, Koch W, von Beckerath N, **Kastrati A**, Schomig A. Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. *Eur Heart J* 2007;**28**(8):968-73, 10.1093/eurheartj/ehm036
729. Stettler C, Wandel S, Allemann S, **Kastrati A**, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet* 2007;**370**(9591):937-48, 10.1016/S0140-6736(07)61444-5
730. Steinhubl SR, **Kastrati A**, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. *Am Heart J* 2007;**154**(1):3-11, 10.1016/j.ahj.2007.04.009
731. Sibbing D, von Beckerath O, Schomig A, **Kastrati A**, von Beckerath N. Platelet function in clopidogrel-treated patients with acute coronary syndrome. *Blood Coagul Fibrinolysis* 2007;**18**(4):335-9, 10.1097/MBC.0b013e3280d21aed
732. Sibbing D, von Beckerath O, Schomig A, **Kastrati A**, von Beckerath N. Impact of body mass

- index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. *Am J Cardiol* 2007;**100**(2):203-5, 10.1016/j.amjcard.2007.02.081
733. Schomig K, Ndrepepa G, Mehilli J, Pache J, **Kastrati A**, Schomig A. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. *Catheter Cardiovasc Interv* 2007;**70**(3):359-65, 10.1002/ccd.21109
734. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, **Kastrati A**. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. *J Am Coll Cardiol* 2007;**50**(14):1373-80, 10.1016/j.jacc.2007.06.047
735. Ndrepepa G, Schomig A, **Kastrati A**. Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: looking for the reasons. *JAMA* 2007;**297**(15):1711-3, 10.1001/jama.297.15.1711
736. Ndrepepa G, Mehilli J, Martinoff S, Schwaiger M, Schomig A, **Kastrati A**. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. *J Am Coll Cardiol* 2007;**50**(2):149-56, 10.1016/j.jacc.2007.03.034
737. Ndrepepa G, Braun S, Schomig A, **Kastrati A**. Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. *Am J Cardiol* 2007;**100**(4):575-8, 10.1016/j.amjcard.2007.03.064
738. Ndrepepa G, Braun S, Mehilli J, Niemoller K, Schomig A, **Kastrati A**. A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. *Clin Res Cardiol* 2007;**96**(1):30-7, 10.1007/s00392-006-0457-9
739. Ndrepepa G, Braun S, **Kastrati A**, Schomig A. Area under ROC curve, sensitivity, specificity of N-terminal probrain natriuretic peptide in predicting mortality in various subsets of patients with ischemic heart disease. *Clin Res Cardiol* 2007;**96**(10):763-5, 10.1007/s00392-007-0562-4
740. Montalescot G, Antoniucci D, **Kastrati A**, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaud E. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. *Eur Heart J* 2007;**28**(4):443-9, 10.1093/eurheartj/ehl472
741. Meyer TS, Martinoff S, Hadamitzky M, Will A, **Kastrati A**, Schomig A, Hausleiter J. Improved noninvasive assessment of coronary artery bypass grafts with 64-slice computed tomographic angiography in an unselected patient population. *J Am Coll Cardiol* 2007;**49**(9):946-50, 10.1016/j.jacc.2006.10.066
742. Mehilli J, Ndrepepa G, **Kastrati A**, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Kufner S, Dirschinger J, Berger PB, Schomig A. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. *Am Heart J* 2007;**154**(1):158 e1-7, 10.1016/j.ahj.2007.03.050
743. Koch W, Hoppmann P, Mueller JC, Schomig A, **Kastrati A**. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. *Genet Med* 2007;**9**(2):123-9, 10.1097/gim.0b013e318030c9c5
744. Koch W, Hoppmann P, Michou E, Jung V, Pfeufer A, Mueller JC, Gieger C, Wichmann HE, Meitinger T, Schomig A, **Kastrati A**. Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. *Hum Mol Genet* 2007;**16**(15):1821-7, 10.1093/hmg/ddm130
745. **Kastrati A**, Schomig A. Drug-eluting stents is their future as bright as their past? *J Am Coll Cardiol* 2007;**50**(2):146-8, 10.1016/j.jacc.2007.04.028

746. **Kastrati A**, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med* 2007;**356**(10):1030-9, 10.1056/NEJMoa067484
747. **Kastrati A**, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. *Eur Heart J* 2007;**28**(22):2706-13, 10.1093/eurheartj/ehm402
748. Kalyanasundaram A, Berger P, **Kastrati A**. Effects of glycoprotein IIb/IIIa blockers. *Heart* 2007;**93**(10):1293; author reply 1293,
749. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, Ibrahim M, Schomig A, **Kastrati A**. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. *Am Heart J* 2007;**154**(4):688-93, 10.1016/j.ahj.2007.06.005
750. Iijima R, Ndrepepa G, Mehilli J, Bruskina O, Schulz S, Schomig A, **Kastrati A**. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. *Thromb Haemost* 2007;**98**(4):852-7,
751. Hausleiter J, Meyer T, Hadamitzky M, Zankl M, Gerein P, Dorrlor K, **Kastrati A**, Martinoff S, Schomig A. Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. *Eur Heart J* 2007;**28**(24):3034-41, 10.1093/eurheartj/ehm150
752. Dibra A, **Kastrati A**, Alfonso F, Seyfarth M, Perez-Vizcayno MJ, Mehilli J, Schomig A. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. *J Am Coll Cardiol* 2007;**49**(5):616-23, 10.1016/j.jacc.2006.10.049
753. Boettiger C, Koch W, Mehilli J, Schoemig A, **Kastrati A**. Glycoprotein VI polymorphisms and outcome after percutaneous coronary interventions. *Thromb Haemost* 2007;**97**(4):673-4,
754. Adriaenssens T, Mehilli J, Wessely R, Ndrepepa G, Seyfarth M, Wieczorek A, Blach B, Iijima R, Pache J, **Kastrati A**, Schomig A. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. *J Am Coll Cardiol* 2007;**49**(12):1265-71, 10.1016/j.jacc.2007.02.021
755. Adriaenssens T, **Kastrati A**, Schomig A. Successful stenting of bilateral multiple renal arteries in a patient with renovascular hypertension. *J Invasive Cardiol* 2007;**19**(8):E235-7,
756. Zohlhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, **Kastrati A**, Schomig A, Investigators R-. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. *JAMA* 2006;**295**(9):1003-10, 10.1001/jama.295.9.1003
757. Zohlhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, **Kastrati A**, Schomig A, Investigators R-. Stem Cell Therapy after Acute Myocardial Infarction-The Emperor's New Clothes?: Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor in Patients with Acute Myocardial Infarction: A Randomized Controlled Trial. *JAMA* 295: 1003-1010, 2006. *J Am Soc Nephrol* 2006;**17**(5):1207-1217, 10.1681/01.asn.0000926832.82033.c5
758. Wessely R, Schomig A, **Kastrati A**. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. *J Am Coll Cardiol* 2006;**47**(4):708-14, 10.1016/j.jacc.2005.09.047
759. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schomig A, **Kastrati A**. Correlation of a new point-of-care test with conventional optical aggregometry for the

- assessment of clopidogrel responsiveness. *Thromb Haemost* 2006;**95**(5):910-1, 10.1160/th06-01-0046
760. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, **Kastrati A**, Schomig A, Schomig E. Impact of P-glycoprotein on clopidogrel absorption. *Clin Pharmacol Ther* 2006;**80**(5):486-501, 10.1016/j.clpt.2006.07.007
761. Sibbing D, von Beckerath O, Schomig A, **Kastrati A**, von Beckerath N. P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. *J Thromb Haemost* 2006;**4**(4):912-4, 10.1111/j.1538-7836.2006.01869.x
762. Sibbing D, von Beckerath O, Schomig A, **Kastrati A**, von Beckerath N. Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. *J Thromb Haemost* 2006;**4**(12):2566-8, 10.1111/j.1538-7836.2006.02183.x
763. Schulz C, Schomig A, **Kastrati A**. Acute coronary artery stent thrombosis following rapid renewal of functional platelets: implications for intensified antiplatelet therapy. *Thromb Haemost* 2006;**96**(3):384-6, 10.1160/TH06-04-0207
764. Schuhlen H, **Kastrati A**, Mehilli J, Hausleiter J, Dirschinger J, Dotzer F, Bollwein H, Schomig A. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. *Am Heart J* 2006;**151**(6):1248-54, 10.1016/j.ahj.2005.08.002
765. Schomig A, Ndrepepa G, **Kastrati A**. Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. *Eur Heart J* 2006;**27**(16):1900-7, 10.1093/eurheartj/ehl174
766. Parodi G, Ndrepepa G, **Kastrati A**, Conti A, Mehilli J, Sciagra R, Schwaiger M, Antoniucci D, Schomig A. Beyond 12 hours Reperfusion AlternatiVe Evaluation Trial I. Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. *Am Heart J* 2006;**152**(6):1133-9, 10.1016/j.ahj.2006.08.007
767. Pache J, Dibra A, Schaut C, Schuhlen H, Dirschinger J, Mehilli J, **Kastrati A**, Schomig A. Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents. *Catheter Cardiovasc Interv* 2006;**68**(5):690-5, 10.1002/ccd.20814
768. Ndrepepa G, **Kastrati A**, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Dirschinger J, Ulm K, Berger PB, Schomig A. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. *Circulation* 2006;**114**(19):2040-6, 10.1161/CIRCULATIONAHA.106.642306
769. Ndrepepa G, **Kastrati A**, Braun S, Mehilli J, Niemoller K, von Beckerath N, von Beckerath O, Vogt W, Schomig A. N-terminal pro-brain natriuretic peptide and C-reactive protein in stable coronary heart disease. *Am J Med* 2006;**119**(4):355 e1-8, 10.1016/j.amjmed.2005.10.060
770. Ndrepepa G, **Kastrati A**, Braun S, Koch W, Kolling K, Mehilli J, Schomig A. A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. *Clin Chim Acta* 2006;**373**(1-2):70-6, 10.1016/j.cca.2006.05.011
771. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Nekolla S, Vogt W, Schwaiger M, Schomig A, **Kastrati A**. N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. *Am J Cardiol* 2006;**97**(8):1151-6, 10.1016/j.amjcard.2005.11.029
772. Mehilli J, **Kastrati A**, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schomig A, Intracoronary S, Angiographic Restenosis--Test Equivalence Between 2 Drug-Eluting Stents Trial I. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a

- polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. *Circulation* 2006;**113**(2):273-9, 10.1161/CIRCULATIONAHA.105.575977
773. Mehilli J, Dibra A, **Kastrati A**, Pache J, Dirschinger J, Schomig A, Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries Study I. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. *Eur Heart J* 2006;**27**(3):260-6, 10.1093/eurheartj/ehi721
774. Lazar A, Zimmermann T, Koch W, Grundemann D, Schomig A, **Kastrati A**, Schomig E. Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. *Clin Exp Hypertens* 2006;**28**(7):645-53, 10.1080/10641960600946411
775. Koch W, Hoppmann P, Pfeufer A, Schomig A, **Kastrati A**. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. *Eur Heart J* 2006;**27**(21):2524-9, 10.1093/eurheartj/ehl231
776. Koch W, Hoppmann P, Mueller JC, Schomig A, **Kastrati A**. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. *Arterioscler Thromb Vasc Biol* 2006;**26**(5):1114-9, 10.1161/01.ATV.0000217747.66517.11
777. **Kastrati A**, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A, Intracoronary S, Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 Trial I. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. *JAMA* 2006;**295**(13):1531-8, 10.1001/jama.295.13.joc60034
778. **Kastrati A**, Elezi S, Schomig A. [A friend in need is a friend indeed: the case of drug-eluting stents, diabetes and small vessel size]. *Rev Esp Cardiol* 2006;**59**(10):991-3, 10.1157/13093973
779. **Kastrati A**, Dibra A, Mehilli J, Mayer S, Piniack S, Pache J, Dirschinger J, Schomig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. *Circulation* 2006;**113**(19):2293-300, 10.1161/CIRCULATIONAHA.105.601823
780. Iijima R, Mehilli J, Schomig A, **Kastrati A**. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents. *Minerva Cardioangiol* 2006;**54**(5):539-55,
781. Hausleiter J, Meyer T, Hadamitzky M, **Kastrati A**, Martinoff S, Schomig A. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. *J Am Coll Cardiol* 2006;**48**(2):312-8, 10.1016/j.jacc.2006.02.064
782. Hausleiter J, Meyer T, Hadamitzky M, Huber E, Zankl M, Martinoff S, **Kastrati A**, Schomig A. Radiation dose estimates from cardiac multislice computed tomography in daily practice: impact of different scanning protocols on effective dose estimates. *Circulation* 2006;**113**(10):1305-10, 10.1161/CIRCULATIONAHA.105.602490
783. Hausleiter J, **Kastrati A**. Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation? *Nat Clin Pract Cardiovasc Med* 2006;**3**(9):476-7, 10.1038/npcardio0633
784. Elezi S, Dibra A, Schomig A, **Kastrati A**. Current drug-eluting stents in complex patients and lesions. *Minerva Cardioangiol* 2006;**54**(1):5-22,
785. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schomig A, **Kastrati A**. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. *J Am Coll Cardiol* 2006;**48**(7):1304-9, 10.1016/j.jacc.2006.05.068
786. Elezi S, Dibra A, Folkerts U, Mehilli J, Heigl S, Schomig A, **Kastrati A**. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. *J Am Coll Cardiol* 2006;**48**(2):262-7, 10.1016/j.jacc.2006.01.080

787. Zohlhofer D, Hausleiter J, **Kastrati A**, Mehilli J, Goos C, Schuhlen H, Pache J, Pogatsa-Murray G, Heemann U, Dirschinger J, Schomig A. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. *J Am Coll Cardiol* 2005;**46**(11):1999-2003, 10.1016/j.jacc.2005.07.060
788. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T, Wenaweser P, Togni M, Tuller D, Zbinden R, Seiler C, Mehilli J, **Kastrati A**, Meier B, Hess OM. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. *Circulation* 2005;**111**(20):2617-22, 10.1161/CIRCULATIONAHA.104.486647
789. Wessely R, **Kastrati A**, Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. *Ann Intern Med* 2005;**143**(5):392-4, 10.7326/0003-4819-143-5-200509060-00119
790. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, Behnisch B, Schratzenstaller T, Renke-Gluszko M, Stover M, Wintermantel E, **Kastrati A**, Schomig A. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. *Arterioscler Thromb Vasc Biol* 2005;**25**(4):748-53, 10.1161/01.ATV.0000157579.52566.ee
791. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, **Kastrati A**. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. *Blood Coagul Fibrinolysis* 2005;**16**(3):199-204, 10.1097/01.mbc.0000164429.21040.0a
792. von Beckerath N, Taubert D, Pogatsa-Murray G, Wieczorek A, Schomig E, Schomig A, **Kastrati A**. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. *Thromb Haemost* 2005;**93**(4):789-91,
793. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, **Kastrati A**, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. *Circulation* 2005;**112**(19):2946-50, 10.1161/CIRCULATIONAHA.105.559088
794. Unverdorben M, Degenhardt R, Sick P, **Kastrati A**, Desmet W, Colombo A, Garcia E, Klein W, Wagner E, Kohler H, Scholz M, Berthold HK, Vallbracht C. Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). *J Invasive Cardiol* 2005;**17**(4):199-202,
795. Tiroch K, von Beckerath N, Koch W, Lengdobler J, Joost A, Schomig A, **Kastrati A**. Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting. *Atherosclerosis* 2005;**182**(1):145-51, 10.1016/j.atherosclerosis.2005.02.003
796. Steppich B, Mattisek C, Sobczyk D, **Kastrati A**, Schomig A, Ott I. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. *Thromb Haemost* 2005;**93**(1):35-9, 10.1160/TH04-06-0393
797. Sibbing D, von Beckerath O, von Beckerath N, Koch W, Mehilli J, Schwaiger M, Schomig A, **Kastrati A**. Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. *Blood Coagul Fibrinolysis* 2005;**16**(7):511-5, 10.1097/01.mbc.0000186838.16551.ad
798. Schomig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Berger PB, **Kastrati A**, Intracoronary S, Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study I. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. *Eur Heart J* 2005;**26**(14):1379-84, 10.1093/eurheartj/ehi174
799. Schomig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, Nekolla SG, Schlotterbeck K, Schuhlen H, Pache J, Seyfarth M, Martinoff S, Benzer W, Schmitt C, Dirschinger J, Schwaiger M, **Kastrati A**, Beyond 12 hours Reperfusion AlternatiVe

- Evaluation Trial I. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. *JAMA* 2005;**293**(23):2865-72, 10.1001/jama.293.23.2865
800. Schomig A, **Kastrati A**, Wessely R. Prevention of restenosis by systemic drug therapy: back to the future? *Circulation* 2005;**112**(18):2759-61, 10.1161/CIRCULATIONAHA.105.583484
801. Schomig A, **Kastrati A**. Distal embolic protection in patients with acute myocardial infarction: attractive concept but no evidence of benefit. *JAMA* 2005;**293**(9):1116-8, 10.1001/jama.293.9.1116
802. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, **Kastrati A**. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. *Eur Heart J* 2005;**26**(13):1262-8, 10.1093/eurheartj/ehi098
803. Ndrepepa G, **Kastrati A**, Schwaiger M, Mehilli J, Markwardt C, Dibra A, Dirschinger J, Schomig A. Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. *J Nucl Med* 2005;**46**(11):1782-8,
804. Ndrepepa G, Braun S, von Beckerath N, Mehilli J, Gorchakova O, Vogt W, Schomig A, **Kastrati A**. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. *Clin Chim Acta* 2005;**360**(1-2):178-86, 10.1016/j.cccn.2005.04.032
805. Ndrepepa G, Braun S, Niemoller K, Mehilli J, von Beckerath N, von Beckerath O, Vogt W, Schomig A, **Kastrati A**. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. *Circulation* 2005;**112**(14):2102-7, 10.1161/CIRCULATIONAHA.105.550715
806. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Vogt W, Schomig A, **Kastrati A**. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. *Am J Cardiol* 2005;**95**(5):553-7, 10.1016/j.amjcard.2004.10.034
807. Ndrepepa G, Braun S, Dibra A, Mehilli J, Vogt W, Schomig A, **Kastrati A**. Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. *Nutr Metab Cardiovasc Dis* 2005;**15**(6):418-25, 10.1016/j.numecd.2005.02.005
808. Mehilli J, Ndrepepa G, **Kastrati A**, Nekolla SG, Markwardt C, Bollwein H, Pache J, Martinoff S, Dirschinger J, Schwaiger M, Schomig A. Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. *J Am Coll Cardiol* 2005;**45**(6):828-31, 10.1016/j.jacc.2004.11.054
809. Koch W, Latz W, Eichinger M, Ganser C, Schomig A, **Kastrati A**. Genotyping of the angiotensin I-converting enzyme gene insertion/deletion polymorphism by the TaqMan method. *Clin Chem* 2005;**51**(8):1547-9, 10.1373/clinchem.2005.051656
810. Koch W, Hoppmann P, Pfeufer A, Mueller JC, Schomig A, **Kastrati A**. No replication of association between estrogen receptor alpha gene polymorphisms and susceptibility to myocardial infarction in a large sample of patients of European descent. *Circulation* 2005;**112**(14):2138-42, 10.1161/CIRCULATIONAHA.105.545913
811. Koch W, Hoppmann P, Michou E, Jung V, Pfeufer A, Muller J, Meitinger T, Schomig A, **Kastrati A**. TaqMan assays for genotyping of single nucleotide polymorphisms present at a disease susceptibility locus on chromosome 6. *Clin Chem Lab Med* 2005;**43**(2):167-72, 10.1515/CCLM.2005.028
812. **Kastrati A**, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schomig A, Investigators I-DS. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 2005;**293**(2):165-71, 10.1001/jama.293.2.165
813. **Kastrati A**, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease:

- meta-analysis of randomized trials. *JAMA* 2005;**294**(7):819-25, 10.1001/jama.294.7.819
814. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, **Kastrati A**, Schomig A, Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. *Cardiovasc Res* 2005;**68**(3):483-92, 10.1016/j.cardiores.2005.06.029
815. Hausleiter J, **Kastrati A**, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schomig A, investigators of the individualizable drug-eluting Stent System to Abrogate Restenosis P. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. *Eur Heart J* 2005;**26**(15):1475-81, 10.1093/eurheartj/ehi405
816. Finn AV, Palacios IF, **Kastrati A**, Gold HK. Drug-eluting stents for diabetes mellitus: a rush to judgment? *J Am Coll Cardiol* 2005;**45**(4):479-83, 10.1016/j.jacc.2004.10.060
817. Dibra A, Ndrepepa G, Mehilli J, Pineck S, Mayer S, Bollwein H, Hausleiter J, Pache J, Schomig A, **Kastrati A**. Prognostic value of impaired fasting glucose for outcomes of patients with stable angina pectoris treated with percutaneous coronary interventions. *Am J Cardiol* 2005;**96**(8):1113-5, 10.1016/j.amjcard.2005.06.041
818. Dibra A, Ndrepepa G, Mehilli J, Dirschinger J, Pache J, Schuhlen H, Schomig A, **Kastrati A**. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. *Am J Cardiol* 2005;**95**(10):1238-40, 10.1016/j.amjcard.2005.01.055
819. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, Schuhlen H, Schomig A, **Kastrati A**. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. *Am Heart J* 2005;**150**(2):344-50, 10.1016/j.ahj.2004.09.030
820. Dibra A, **Kastrati A**, Schuhlen H, Schomig A. The relationship between hospital or operator volume and outcomes of coronary patients undergoing percutaneous coronary interventions. *Z Kardiol* 2005;**94**(4):231-8, 10.1007/s00392-005-0206-5
821. Dibra A, **Kastrati A**, Mehilli J, Pache J, von Oepen R, Dirschinger J, Schomig A. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial. *Catheter Cardiovasc Interv* 2005;**65**(3):374-80, 10.1002/ccd.20400
822. Dibra A, **Kastrati A**, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A, Investigators I-DS. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *N Engl J Med* 2005;**353**(7):663-70, 10.1056/NEJMoa044372
823. Braun S, Ndrepepa G, von Beckerath N, Mehilli J, Gorchakova O, Vogt W, Schomig A, **Kastrati A**. Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. *Am Heart J* 2005;**150**(3):550-6, 10.1016/j.ahj.2004.10.008
824. von Beckerath N, Koch W, Mehilli J, Gorchakova O, Braun S, Schomig A, **Kastrati A**. ABO locus O1 allele and risk of myocardial infarction. *Blood Coagul Fibrinolysis* 2004;**15**(1):61-7, 10.1097/00001721-200401000-00010
825. Taubert D, **Kastrati A**, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schomig A, Schomig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. *Thromb Haemost* 2004;**92**(2):311-6, 10.1160/TH04-02-0105
826. Schuhlen H, **Kastrati A**, Mehilli J, Hausleiter J, Pache J, Dirschinger J, Schomig A. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. *Am Heart J* 2004;**147**(2):317-22, 10.1016/j.ahj.2003.10.002
827. Schomig A, Ndrepepa G, Mehilli J, Dirschinger J, Nekolla SG, Schmitt C, Martinoff S, Seyfarth M, Schwaiger M, **Kastrati A**, investigators S-s. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in

- patients with acute myocardial infarction. *J Am Coll Cardiol* 2004;**44**(10):2073-9, 10.1016/j.jacc.2004.09.043
828. Pinkau T, Mann JF, Ndrepepa G, Mehilli J, Hadamitzky M, Braun S, **Kastrati A**, Schomig A. Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. *Am J Kidney Dis* 2004;**44**(4):627-35,
829. Pache J, **Kastrati A**, Mehilli J, Bollwein H, Ndrepepa G, Schuhlen H, Martinoff S, Seyfarth M, Nekolla S, Dirschinger J, Schwaiger M, Schomig A. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. *Am Heart J* 2004;**148**(1):e3, 10.1016/j.ahj.2004.01.019
830. Ott I, Koch W, von Beckerath N, de Waha R, Malawaniec A, Mehilli J, Schomig A, **Kastrati A**. Tissue factor promoter polymorphism -603 A/G is associated with myocardial infarction. *Atherosclerosis* 2004;**177**(1):189-91, 10.1016/j.atherosclerosis.2004.07.006
831. Ndrepepa G, Mehilli J, Schwaiger M, Schuhlen H, Nekolla S, Martinoff S, Schmitt C, Dirschinger J, Schomig A, **Kastrati A**. Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. *J Nucl Med* 2004;**45**(5):725-9,
832. Ndrepepa G, Mehilli J, Schwaiger M, Nekolla S, Schmitt C, Dirschinger J, Schomig A, **Kastrati A**. Myocardial salvage after reduced-dose thrombolysis combined with glycoprotein IIb/IIIa blockade versus thrombolysis alone in patients with acute myocardial infarction. *J Thromb Thrombolysis* 2004;**17**(3):191-7, 10.1023/B:THRO.0000040488.26414.9e
833. Ndrepepa G, Mehilli J, Bollwein H, Pache J, Schomig A, **Kastrati A**. Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. *Am J Med* 2004;**117**(11):830-6, 10.1016/j.amjmed.2004.02.036
834. Ndrepepa G, **Kastrati A**, Neumann FJ, Schmitt C, Mehilli J, Schomig A. Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. *Eur Heart J* 2004;**25**(18):1635-40, 10.1016/j.ehj.2004.04.031
835. Mehilli J, **Kastrati A**, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schomig A, Intracoronary S, Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics Study I. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. *Circulation* 2004;**110**(24):3627-35, 10.1161/01.CIR.0000148956.93631.4D
836. Mehilli J, **Kastrati A**, Dirschinger J, Etzel L, Bollwein H, Pache J, Schuhlen H, Von Beckerath N, Seyfarth M, Schmitt C, Schomig A. Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR-DIRECT trial). *Catheter Cardiovasc Interv* 2004;**61**(2):190-5, 10.1002/ccd.10706
837. Kolling K, Ndrepepa G, Koch W, Braun S, Mehilli J, Schomig A, **Kastrati A**. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. *Am J Cardiol* 2004;**93**(10):1201-6, 10.1016/j.amjcard.2004.02.009
838. Koch W, Mehilli J, Pfeufer A, Schomig A, **Kastrati A**. Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting. *J Lipid Res* 2004;**45**(12):2221-6, 10.1194/jlr.M400148-JLR200
839. Koch W, Jung V, von Beckerath N, Schomig A, **Kastrati A**. Peroxisome proliferator-activated receptor gamma gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries. *Diabetologia* 2004;**47**(6):1126-7, 10.1007/s00125-004-1406-7
840. **Kastrati A**, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A.

- Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. *Circulation* 2004;**110**(14):1916-9, 10.1161/01.CIR.0000137972.74120.12
841. **Kastrati A**, Schomig A, Schomig E. Are we making efficient use of clopidogrel? *Eur Heart J* 2004;**25**(6):454-6, 10.1016/j.ehj.2004.02.005
842. **Kastrati A**, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A, Intracoronary S, Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study I. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. *N Engl J Med* 2004;**350**(3):232-8, 10.1056/NEJMoa031859
843. **Kastrati A**, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schomig A, Bavarian Reperfusion Alternatives Evaluation Study I. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2004;**291**(8):947-54, 10.1001/jama.291.8.947
844. **Kastrati A**, Mehilli J, Nekolla S, Bollwein H, Martinoff S, Pache J, Schuhlen H, Seyfarth M, Gawaz M, Neumann FJ, Dirschinger J, Schwaiger M, Schomig A, Investigators S-S. A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. *J Am Coll Cardiol* 2004;**43**(5):734-41, 10.1016/j.jacc.2003.07.054
845. **Kastrati A**. Drug-eluting stents for secondary prevention of restenosis. *Catheter Cardiovasc Interv* 2004;**63**(3):265-6, 10.1002/ccd.20199
846. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, **Kastrati A**, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. *Am Heart J* 2004;**147**(3):457-62, 10.1016/j.ahj.2003.08.011
847. Kandzari DE, Berger PB, **Kastrati A**, Steinhubl SR, Mehilli J, Dotzer F, Ten Berg JM, Neumann FJ, Bollwein H, Dirschinger J, Schomig A, Investigators I-RS. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. *J Am Coll Cardiol* 2004;**44**(11):2133-6, 10.1016/j.jacc.2004.08.060
848. Jaschke B, Milz S, Vogeser M, Michaelis C, Vorpahl M, Schomig A, **Kastrati A**, Wessely R. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. *FASEB J* 2004;**18**(11):1285-7, 10.1096/fj.04-1646fje
849. Hoppmann P, Koch W, Schomig A, **Kastrati A**. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. *Eur Heart J* 2004;**25**(4):335-41, 10.1016/j.ehj.2003.12.004
850. Hausleiter J, **Kastrati A**, Mehilli J, Vogeser M, Zohlhofer D, Schuhlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schomig A, Investigators O. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. *Circulation* 2004;**110**(7):790-5, 10.1161/01.CIR.0000138935.17503.35
851. Hausleiter J, **Kastrati A**, Mehilli J, Schuhlen H, Pache J, Dotzer F, Glatthor C, Siebert S, Dirschinger J, Schomig A, Investigators I-S-. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. *J Intern Med* 2004;**256**(5):388-97, 10.1111/j.1365-2796.2004.01398.x
852. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, **Kastrati A**. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients

- receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. *Eur Heart J* 2004;**25**(21):1898-902, 10.1016/j.ehj.2003.10.039
853. Gorchakova O, Koch W, Mehilli J, von Beckerath N, Schwaiger M, Schomig A, **Kastrati A**. PLA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction. *Thromb Haemost* 2004;**91**(1):141-5, 10.1160/TH03-06-0341
854. Braun S, Ndrepepa G, von Beckerath N, Vogt W, Schomig A, **Kastrati A**. Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. *Atherosclerosis* 2004;**174**(1):105-10, 10.1016/j.atherosclerosis.2004.01.011
855. von Beckerath N, Schusterschitz Y, Koch W, Griesser K, Mehilli J, Gorchakova O, Schomig A, **Kastrati A**. G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. *Atherosclerosis* 2003;**167**(1):135-9, 10.1016/s0021-9150(02)00422-7
856. Schomig A, Ndrepepa G, Mehilli J, Schwaiger M, Schuhlen H, Nekolla S, Pache J, Martinoff S, Bollwein H, **Kastrati A**. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. *Circulation* 2003;**108**(9):1084-8, 10.1161/01.CIR.0000086346.32856.9C
857. Roguin A, Koch W, **Kastrati A**, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. *Diabetes Care* 2003;**26**(9):2628-31, 10.2337/diacare.26.9.2628
858. Pesonen U, Koch W, Schomig A, **Kastrati A**. Leucine 7 to proline 7 polymorphism of the preproneuropeptide Y gene is not associated with restenosis after coronary stenting. *J Endovasc Ther* 2003;**10**(3):566-72, 10.1177/152660280301000323
859. Pache J, **Kastrati A**, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Muller M, Dirschinger J, Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STERO-2) trial. *J Am Coll Cardiol* 2003;**41**(8):1283-8, 10.1016/s0735-1097(03)00119-0
860. Neumann FJ, **Kastrati A**, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, Schmitt C, Seyfarth M, Dirschinger J, Schomig A. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. *JAMA* 2003;**290**(12):1593-9, 10.1001/jama.290.12.1593
861. Mehilli J, **Kastrati A**, Bollwein H, Dibra A, Schuhlen H, Dirschinger J, Schomig A. Gender and restenosis after coronary artery stenting. *Eur Heart J* 2003;**24**(16):1523-30, 10.1016/s0195-668x(03)00320-8
862. Koch W, Tiroch K, von Beckerath N, Schomig A, **Kastrati A**. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. *Cytokine* 2003;**24**(4):161-71, 10.1016/j.cyto.2003.08.004
863. Koch W, Ndrepepa G, Mehilli J, Braun S, Burghartz M, Lengnick H, Kolling K, Schomig A, **Kastrati A**. Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. *Arterioscler Thromb Vasc Biol* 2003;**23**(12):2229-34, 10.1161/01.ATV.0000105055.68038.29
864. Koch W, Mehilli J, von Beckerath N, Bottiger C, Schomig A, **Kastrati A**. Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. *J Am Coll Cardiol* 2003;**41**(11):1957-61, 10.1016/s0735-1097(03)00406-6
865. Koch W, Latz W, Eichinger M, Gschwendner C, Teige B, Schomig A, **Kastrati A**. Haptoglobin gene subtyping by restriction enzyme analysis. *Clin Chem* 2003;**49**(11):1937-40,

- 10.1373/clinchem.2003.022442
866. Hausleiter J, **Kastrati A**, Mehilli J, Schuhlen H, Pache JJ, Dirschinger J, Schricke U, Schwaiger M, Markward C, Schomig A, Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction S. Impact of acute myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction. *Am J Cardiol* 2003;**91**(3):341-3, 10.1016/s0002-9149(02)03165-x
867. Hausleiter J, **Kastrati A**, Mehilli J, Schuhlen H, Pache J, Dotzer F, Sattelberger U, Dirschinger J, Schomig A. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. *Am Heart J* 2003;**146**(5):882-6, 10.1016/S0002-8703(03)00435-6
868. Gorchakova O, Koch W, von Beckerath N, Mehilli J, Schomig A, **Kastrati A**. Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. *Eur Heart J* 2003;**24**(9):820-7, 10.1016/s0195-668x(02)00824-2
869. Dibra A, Mehilli J, Schwaiger M, Schuhlen H, Bollwein H, Braun S, Neverve J, Schomig A, **Kastrati A**. Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. *Eur Heart J* 2003;**24**(12):1128-33, 10.1016/s0195-668x(03)00200-8
870. Dibra A, Mehilli J, Dirschinger J, Pache J, Neverve J, Schwaiger M, Schomig A, **Kastrati A**. Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. *J Am Coll Cardiol* 2003;**41**(6):925-9, 10.1016/s0735-1097(02)02971-6
871. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, Schuhlen H, Schomig A, **Kastrati A**. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. *Am J Med* 2003;**114**(9):715-22, 10.1016/s0002-9343(03)00183-9
872. da Costa CP, Neumann FJ, **Kastrati A**, Stallforth I, Schmid M, Joghetai N, Prebeck S, Wagner H, Miethke T. Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. *Atherosclerosis* 2003;**166**(1):171-6, 10.1016/s0021-9150(02)00326-x
873. Bottiger C, Koch W, Lahn C, Mehilli J, von Beckerath N, Schomig A, **Kastrati A**. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. *Am Heart J* 2003;**146**(5):855-61, 10.1016/S0002-8703(03)00363-6
874. Schomig A, Mehilli J, Holle H, Hosl K, Kastrati D, Pache J, Seyfarth M, Neumann FJ, Dirschinger J, **Kastrati A**. Statin treatment following coronary artery stenting and one-year survival. *J Am Coll Cardiol* 2002;**40**(5):854-61, 10.1016/s0735-1097(02)02053-3
875. Pache J, **Kastrati A**, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, Hall D, Braun S, Dirschinger J, Schomig A. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. *Catheter Cardiovasc Interv* 2002;**55**(4):436-41, 10.1002/ccd.10092
876. Mehilli J, **Kastrati A**, Dirschinger J, Pache J, Seyfarth M, Blasini R, Hall D, Neumann FJ, Schomig A. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. *JAMA* 2002;**287**(2):210-5, 10.1001/jama.287.2.210
877. Mehilli J, **Kastrati A**, Dirschinger J, Dotzer F, Pache J, Hausleiter J, Kramer W, Schuhlen H, Schomig A. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. *Am J Med* 2002;**112**(1):13-8, 10.1016/s0002-9343(01)01010-5
878. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, **Kastrati A**. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. *Clin Chem* 2002;**48**(9):1377-82,

879. Koch W, **Kastrati A**, Mehilli J, von Beckerath N, Schomig A. CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. *Am Heart J* 2002;**143**(6):971-6, 10.1067/mhj.2002.122512
880. Koch W, Ehrenhaft A, Griesser K, Pfeufer A, Muller J, Schomig A, **Kastrati A**. TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. *Clin Chem Lab Med* 2002;**40**(11):1123-31, 10.1515/CCLM.2002.197
881. **Kastrati A**, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, Martinoff S, Neumann FJ, Nekolla S, Blasini R, Seyfarth M, Schwaiger M, Schomig A. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction S. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. *Lancet* 2002;**359**(9310):920-5, 10.1016/S0140-6736(02)08022-4
882. Hausleiter J, **Kastrati A**, Mehilli J, Schuhlen H, Pache J, Dotzer F, Dirschinger J, Schomig A. Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. *J Am Coll Cardiol* 2002;**40**(5):882-9, 10.1016/s0735-1097(02)02043-0
883. Hausleiter J, **Kastrati A**, Mehilli J, Dotzer F, Schuhlen H, Dirschinger J, Schomig A, investigators I-ST. Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial). *Am J Cardiol* 2002;**89**(1):58-60, 10.1016/s0002-9149(01)02164-6
884. Dong J, Ndrepepa G, Schmitt C, Mehilli J, Schmieder S, Schwaiger M, Schomig A, **Kastrati A**. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. *Circulation* 2002;**105**(25):2946-9, 10.1161/01.cir.0000022604.56986.ff
885. von Beckerath N, Koch W, Mehilli J, Bottiger C, Braun S, Schomig A, **Kastrati A**. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. *Atherosclerosis* 2001;**156**(2):463-8, 10.1016/s0021-9150(00)00686-9
886. Schuhlen H, **Kastrati A**, Schomig A. Images in cardiology: Structural failure of a coronary stent. *Heart* 2001;**86**(1):26, 10.1136/heart.86.1.26
887. Schuhlen H, **Kastrati A**, Pache J, Dirschinger J, Schomig A. Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. *Intracoronary Stenting and Antithrombotic Regimen. Am J Cardiol* 2001;**87**(4):397-400, 10.1016/s0002-9149(00)01390-4
888. Schuhlen H, **Kastrati A**, Pache J, Dirschinger J, Schomig A. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. *J Am Coll Cardiol* 2001;**37**(8):2066-73, 10.1016/s0735-1097(01)01285-2
889. Schuhlen H, Eigler N, Whiting JS, Haubner R, Hausleiter J, Dirschinger J, **Kastrati A**, Schwaiger M, Schomig A. Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re liquid-filled balloon. *Am J Cardiol* 2001;**87**(4):463-6, A7, 10.1016/s0002-9149(00)01406-5
890. Neumann FJ, **Kastrati A**, Miethke T, Mehilli J, Pogatsa-Murray G, Koch W, Seyfarth M, Schomig A. Previous cytomegalovirus infection and restenosis after coronary stent placement. *Circulation* 2001;**104**(10):1135-9, 10.1161/hc3501.095479
891. Neumann F, **Kastrati A**, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, Joethaei N, da Costa CP, Wagner H, Schomig A. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. *Lancet* 2001;**357**(9274):2085-9, 10.1016/s0140-6736(00)05181-3

892. Mehilli J, **Kastrati A**, Dirschinger J, Dotzer F, Schuhlen H, Fleckenstein M, Neumann FJ, Schomig A. A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with coronary artery disease. *Catheter Cardiovasc Interv* 2001;**54**(4):414-9, 10.1002/ccd.2003
893. Koch W, **Kastrati A**, Bottiger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. *Atherosclerosis* 2001;**159**(1):137-44, 10.1016/s0021-9150(01)00467-1
894. Koch W, Bottiger C, Mehilli J, von Beckerath N, Neumann FJ, Schomig A, **Kastrati A**. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. *Am J Cardiol* 2001;**88**(10):1120-4, 10.1016/s0002-9149(01)02045-8
895. **Kastrati A**, Schuhlen H, Schomig A. Stenting for small coronary vessels: a contestable winner. *J Am Coll Cardiol* 2001;**38**(6):1604-7, 10.1016/s0735-1097(01)01589-3
896. **Kastrati A**, Schomig A. Good medicines for bad genes. *Eur Heart J* 2001;**22**(7):523-5, 10.1053/euhj.2000.2448
897. **Kastrati A**, Mehilli J, Dirschinger J, Pache J, Ulm K, Schuhlen H, Seyfarth M, Schmitt C, Blasini R, Neumann FJ, Schomig A. Restenosis after coronary placement of various stent types. *Am J Cardiol* 2001;**87**(1):34-9, 10.1016/s0002-9149(00)01268-6
898. **Kastrati A**, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. *Circulation* 2001;**103**(23):2816-21, 10.1161/01.cir.103.23.2816
899. **Kastrati A**, Dirschinger J, Schomig A. Restenosis in one lesion in patients with multilesion stenting occurs even when the companion lesion is free of restenosis. *Catheter Cardiovasc Interv* 2001;**53**(2):287-8, 10.1002/ccd.1167
900. von Beckerath N, Koch W, Mehilli J, Bottiger C, Schomig A, **Kastrati A**. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. *Blood* 2000;**95**(11):3297-301,
901. von Beckerath N, **Kastrati A**, Koch W, Bottiger C, Mehilli J, Seyfarth M, Schomig A. G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. *Atherosclerosis* 2000;**149**(1):151-5, 10.1016/s0021-9150(99)00317-2
902. Schomig A, **Kastrati A**, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. *N Engl J Med* 2000;**343**(6):385-91, 10.1056/NEJM200008103430602
903. Neumann FJ, **Kastrati A**, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schlee M, Seyfarth M, Dirschinger J, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. *J Am Coll Cardiol* 2000;**35**(4):915-21, 10.1016/s0735-1097(99)00635-x
904. Neumann FJ, **Kastrati A**, Miethke T, Pogatsa-Murray G, Seyfarth M, Schomig A. Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. *Circulation* 2000;**101**(1):11-3, 10.1161/01.cir.101.1.11
905. Mehilli J, **Kastrati A**, Dirschinger J, Bollwein H, Neumann FJ, Schomig A. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. *JAMA* 2000;**284**(14):1799-805, 10.1001/jama.284.14.1799
906. Koch W, **Kastrati A**, Mehilli J, Bottiger C, von Beckerath N, Schomig A. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. *Circulation* 2000;**102**(2):197-202, 10.1161/01.cir.102.2.197
907. **Kastrati A**, Schomig A, Dirschinger J, Mehilli J, von Welser N, Pache J, Schuhlen H, Schilling T, Schmitt C, Neumann FJ. Increased risk of restenosis after placement of

- gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. *Circulation* 2000;**101**(21):2478-83, 10.1161/01.cir.101.21.2478
908. **Kastrati A**, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann FJ. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. *Circulation* 2000;**102**(21):2593-8, 10.1161/01.cir.102.21.2593
909. **Kastrati A**, Pache J, Dirschinger J, Neumann FJ, Walter H, Schmitt C, Schomig A. Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis. *Am Heart J* 2000;**139**(2 Pt 1):208-16, 10.1067/mhj.2000.102198
910. **Kastrati A**, Koch W, Gawaz M, Mehilli J, Bottiger C, Schomig K, von Beckerath N, Schomig A. PIA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. *J Am Coll Cardiol* 2000;**36**(1):84-9, 10.1016/s0735-1097(00)00709-9
911. **Kastrati A**, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann FJ, von Beckerath N, Bottiger C, Duff GW, Schomig A. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. *J Am Coll Cardiol* 2000;**36**(7):2168-73, 10.1016/s0735-1097(00)01014-7
912. **Kastrati A**, Hall D, Schomig A. Long-term outcome after coronary stenting. *Curr Control Trials Cardiovasc Med* 2000;**1**(1):48-54, 10.1186/cvm-1-1-048
913. **Kastrati A**, Dirschinger J, Schomig A. Genetic risk factors and restenosis after percutaneous coronary interventions. *Herz* 2000;**25**(1):34-46, 10.1007/BF03044122
914. **Kastrati A**, Dirschinger J, Boekstegers P, Elezi S, Schuhlen H, Pache J, Steinbeck G, Schmitt C, Ulm K, Neumann FJ, Schomig A. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. *Catheter Cardiovasc Interv* 2000;**50**(3):290-7, 10.1002/1522-726x(200007)50:3<290::aid-ccd5>3.0.co;2-w
915. Bottiger C, **Kastrati A**, Koch W, Mehilli J, Seidl H, Schomig K, von Beckerath N, Schomig A. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. *Thromb Haemost* 2000;**83**(4):559-62,
916. Wehinger A, **Kastrati A**, Elezi S, Baum H, Braun S, Neumann FJ, Schomig A. Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. *J Am Coll Cardiol* 1999;**33**(4):1005-12, 10.1016/s0735-1097(98)00684-6
917. Schomig A, **Kastrati A**. Long lesions, long stents and the long process of stent optimization. *J Am Coll Cardiol* 1999;**34**(3):660-2, 10.1016/s0735-1097(99)00302-2
918. **Kastrati A**, Schomig A, Seyfarth M, Koch W, Elezi S, Bottiger C, Mehilli J, Schomig K, von Beckerath N. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. *Circulation* 1999;**99**(8):1005-10, 10.1161/01.cir.99.8.1005
919. **Kastrati A**, Schomig A, Elezi S, Dirschinger J, Mehilli J, Schuhlen H, Blasini R, Neumann FJ. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. *Circulation* 1999;**100**(12):1285-90, 10.1161/01.cir.100.12.1285
920. **Kastrati A**, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. *Am J Cardiol* 1999;**83**(12):1617-22, 10.1016/s0002-9149(99)00165-4
921. Elezi S, **Kastrati A**, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. *Catheter Cardiovasc Interv* 1999;**48**(2):151-6, 10.1002/(sici)1522-726x(199910)48:2<151::aid-ccd6>3.0.co;2-c

922. Dirschinger J, **Kastrati A**, Neumann FJ, Boekstegers P, Elezi S, Mehilli J, Schuhlen H, Pache J, Alt E, Blasini R, Steinbeck G, Schomig A. Influence of balloon pressure during stent placement in native coronary arteries on early and late angiographic and clinical outcome: A randomized evaluation of high-pressure inflation. *Circulation* 1999;**100**(9):918-23, 10.1161/01.cir.100.9.918
923. Bottiger C, **Kastrati A**, Koch W, Mehilli J, von Beckerath N, Dirschinger J, Gawaz M, Schomig A. Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. *Am J Cardiol* 1999;**84**(9):987-91, 10.1016/s0002-9149(99)00485-3
924. Schuhlen H, **Kastrati A**, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schomig A. Intracoronary stenting and risk for major adverse cardiac events during the first month. *Circulation* 1998;**98**(2):104-11, 10.1161/01.cir.98.2.104
925. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, **Kastrati A**, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. *Circulation* 1998;**98**(24):2695-701, 10.1161/01.cir.98.24.2695
926. Ndrepepa G, Cina P, Gjini V, Kondili A, Balla I, **Kastrati A**. The influence of pacing rate and autonomic blockade on human primary and secondary atrial pacemakers. *Cardiologia* 1998;**43**(3):287-93,
927. **Kastrati A**, Schomig A, Elezi S, Schuhlen H, Wilhelm M, Dirschinger J. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. *Circulation* 1998;**97**(24):2396-401, 10.1161/01.cir.97.24.2396
928. **Kastrati A**, Neumann FJ, Schomig A. Operator volume and outcome of patients undergoing coronary stent placement. *J Am Coll Cardiol* 1998;**32**(4):970-6, 10.1016/s0735-1097(98)00334-9
929. Elezi S, **Kastrati A**, Wehinger A, Walter H, Schuhlen H, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Clinical and angiographic outcome after stent placement for chronic coronary occlusion. *Am J Cardiol* 1998;**82**(6):803-6, A9, 10.1016/s0002-9149(98)00440-8
930. Elezi S, **Kastrati A**, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. *J Am Coll Cardiol* 1998;**32**(7):1866-73, 10.1016/s0735-1097(98)00467-7
931. Elezi S, **Kastrati A**, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. *Circulation* 1998;**98**(18):1875-80, 10.1161/01.cir.98.18.1875
932. Schomig A, Neumann FJ, Walter H, Schuhlen H, Hadamitzky M, Zitzmann-Roth EM, Dirschinger J, Hausleiter J, Blasini R, Schmitt C, Alt E, **Kastrati A**. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. *J Am Coll Cardiol* 1997;**29**(1):28-34, 10.1016/s0735-1097(96)00450-0
933. Schomig A, **Kastrati A**, Elezi S, Schuhlen H, Dirschinger J, Dannegger F, Wilhelm M, Ulm K. Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. *Circulation* 1997;**96**(11):3880-7, 10.1161/01.cir.96.11.3880
934. **Kastrati A**, Schuhlen H, Hausleiter J, Walter H, Zitzmann-Roth E, Hadamitzky M, Elezi S, Ulm K, Dirschinger J, Neumann FJ, Schomig A. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. *Circulation* 1997;**96**(2):462-7,
935. **Kastrati A**, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. *J Am Coll Cardiol* 1997;**30**(6):1428-36, 10.1016/s0735-1097(97)00334-3

936. Hausleiter J, Jost S, Nolte CW, Dirschinger J, **Kastrati A**, Stiel GM, Wunderlich W, Fischer F, Linderer T, Hausmann D, Schomig A. Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems. *Coron Artery Dis* 1997;**8**(2):83-90, 10.1097/00019501-199702000-00003
937. Schomig A, Neumann FJ, **Kastrati A**, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996;**334**(17):1084-9, 10.1056/NEJM199604253341702
938. von Hoch F, Neumann FJ, Theiss W, **Kastrati A**, Schomig A. Efficacy and safety of collagen implants for haemostasis of the vascular access site after coronary balloon angioplasty and coronary stent implantation. A randomized study. *Eur Heart J* 1995;**16**(5):640-6, 10.1093/oxfordjournals.eurheartj.a060967
939. Schomig A, **Kastrati A**, Mudra H, Blasini R, Schuhlen H, Klauss V, Richardt G, Neumann FJ. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. *Circulation* 1994;**90**(6):2716-24, 10.1161/01.cir.90.6.2716
940. Schomig A, **Kastrati A**, Dietz R, Rauch B, Neumann FJ, Katus HH, Busch U. Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment. *J Am Coll Cardiol* 1994;**23**(5):1053-60, 10.1016/0735-1097(94)90589-4
941. Schomig A, Seyfarth M, **Kastrati A**. [New intervention procedures: lasers, atherectomy, stents]. *Z Kardiol* 1993;**82 Suppl 5**:127-31,
942. **Kastrati A**, Schomig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. *Circulation* 1993;**87**(5):1498-505, 10.1161/01.cir.87.5.1498
943. Kondili A, **Kastrati A**, Popa Y. Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. *Wien Klin Wochenschr* 1990;**102**(17):510-3,
944. Berisha S, **Kastrati A**, Goda A, Popa Y. Optimal value of filling pressure in the right side of the heart in acute right ventricular infarction. *Br Heart J* 1990;**63**(2):98-102, 10.1136/hrt.63.2.98
945. Berisha S, Goda A, **Kastrati A**, Frasherli A, Popa Y. Acute haemodynamic effects of nifedipine in patients with ventricular septal defect. *Br Heart J* 1988;**60**(2):149-55, 10.1136/hrt.60.2.149